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ABSTRACT
This dissertation focuses on the capabilities of a novel public health data system - the Sentinel
System - to supplement existing postmarket surveillance systems of the U.S. Food and Drug
Administration (FDA). The Sentinel System is designed to identify and assess safety risks
associated with drugs, therapeutic biologics, vaccines, and medical devices that emerge
postlicensure. Per the initiating legislation, the FDA must complete a priori evaluations of the
Sentinel System's technical capabilities to support regulatory decision-making.
This research develops qualitative and quantitative tools to aid the FDA in such evaluations,
particularly with regard to the Sentinel System's novel sequential database surveillance
capabilities. Sequential database surveillance is a "near real-time" sequential statistical method to
evaluate pre-specified exposure-outcome pairs. A "signal" is detected when the data suggest an
excess risk that is statistically significant. The qualitative tool - the Sentinel System Pre-
Screening Checklist - is designed to determine whether the Sentinel System is well suited, on its
face, to evaluate a pre-specified exposure-outcome pair. The quantitative tool - the Sequential
Database Surveillance Simulator - allows the user to explore virtually whether sequential
database surveillance of a particular exposure-outcome pair is likely to generate evidence to
identify and assess safety risks in a timely manner to support regulatory decision-making.
Particular attention is paid to accounting for uncertainties including medical product adoption and
utilization, misclassification error, and the unknown true excess risk in the environment.
Using vaccine examples and the simulator to illustrate, this dissertation first demonstrates the
tradeoffs associated with sample size calculations in sequential statistical analysis, particularly the
tradeoff between statistical power and median sample size. Second, it demonstrates differences in
performance between various surveillance configurations when using distributed database
systems. Third, it demonstrates the effects of misclassification error on sequential database
surveillance, and specifically how such errors may be accounted for in the design of surveillance.
Fourth, it considers the complexities of modeling new medical product adoption, and specifically,
the existence of a "dual market" phenomenon for these new medical products. This finding raises
non-trivial generalizability concerns regarding evidence generated via sequential database
surveillance when performed immediately post-licensure.
Thesis Co-Chairman: Deborah J. Nightingale
Title: Professor of the Practice of Aeronautics and Astronautics and Engineering Systems
Thesis Co-Chairman: Roy Welsch
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1 MOTIVATION AND OUTLINE OF THE DISSERTATION
In the mid 2000s, the U.S. Food and Drug Administration (FDA) came under heavy
criticism after several high-profile regulatory failures to act on postmarket' drug safety
risks in a timely manner that minimized public harm.2 These failures prompted a
landmark Institute of Medicine (IOM) study on the FDA's postmarket drug safety
systems and authorities, including "the sum of all activities conducted by FDA and other
stakeholders to monitor, evaluate, improve, and ensure drug safety." 3 This dissertation
focuses on one of the IOM's recommendations that became a legislative mandate - the
creation and use of a novel public health data system to supplement existing postmarket
systems. Specifically, the IOM found the "[FDA's] ability to test drug safety hypotheses
is limited," and consequently recommended:
"that in order to facilitate the formulation and testing of drug safety hypotheses, [the FDA]
(a) increase their intramural and extramural programs that access and study data from
large automated healthcare databases and (b) include in these programs studies on drug
utilization patterns and background incidence rates for adverse events of interest, and (c)
develop and implement active surveillance of specific drugs and diseases as needed in a
variety of settings." 4
Congress responded by directing the FDA to establish a novel public health data system5
to supplement existing systems to identify and assess safety risks6 associated with drugs,
' The "postmarket" period is the period after licensure of a product by the U.S. Food and Drug
Administration. Once licensed, the product is approved to be marketed to the general public, albeit perhaps
with restrictions on access that will be discussed herein. Throughout this dissertation, the descriptors
"postmarket," "postlicensure," and "postapproval" are used interchangeably to refer to this period,
consistent with source material.
2 See U.S. House Committee on Energy and Commerce and Subcommittee on Oversight and
Investigations, FDA 's Role in Protecting the Public Health: Examining FDA 's Review of Safety and
Efficacy Concerns in Anti-depressant Use by Children (U.S. G.P.O., 2005).; U.S. Senate Committee on
Finance and U.S. Senate Committee on Finance, FDA, Merck, and Vioxx: Putting Patient Safety First?
(U.S. G.P.O., 2005).
3 Institute of Medicine (IOM), The Future ofDrug Safety: Promoting and Protecting the Health of the
Public (Washington, DC: National Academies Press, 2007), 2, http://www.nap.edu/catalog/11750.html.
4 Ibid., 7.
5 § 905 in Food and Drug Administration Amendments Act of 2007, Public Law 110-85, 2007, codified at
21 U.S.C. § 355(k)(3).
6 § 901 in Food and Drug Administration Amendments Act of 2007, Public Law 110-85, 2007, codified at
21 U.S.C. § 355-1(b) defines the scope of safety risks of concern as follows: "The term 'serious risk' means
a risk of a serious adverse drug experience" and "The term 'serious adverse drug experience' is an adverse
drug experience that (A) results in-(i) death; (ii) an adverse drug experience that places the patient at
immediate risk of death[... ];(iii) inpatient hospitalization or prolongation of existing hospitalization; (iv) a
persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions;
or (v) a congenital anomaly or birth defect; or (B) based on appropriate medical judgment, may jeopardize
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therapeutic biologics, and vaccines 7 that emerge after licensure when the product is more
widely used in the general population (i.e., as opposed to a carefully controlled clinical
trial)8 . Specifically, the FDA was to:
"(i) develop methods to obtain access to disparate data sources including the data sources
specified in subparagraph (C);
[Subparagraph C specifies:
(aa) federal health-related electronic data (such as data from the Medicare program
and the health systems of the Department of Veterans Affairs);
(bb) private sector health-related electronic data (such as pharmaceutical purchase
data and health insurance claims data); and
(cc) other data as the Secretary deems necessary to create a robust system to identify
adverse events and potential drug safety signals;]
(ii) develop validated methods for the establishment of a postmarket risk identification
and analysis system to link and analyze safety data from multiple sources with the goals
of including, in aggregate.. .at least 100,000,000 patients by July 1, 2012."9 (emphasis
added)
The FDA's implementation of this legislation - the Sentinel Initiative'0 - will enable
users to systematically query distinct databases of patient-level data and return
aggregated query results to gain knowledge on the postmarket risks and benefits of
the patient and may require a medical or surgical intervention to prevent an outcome described under
subparagraph (A)."
7 § 905(a)(3) in Food and Drug Administration Amendments Act of 2007, Public Law 110-85, 2007,
codified at 21 U.S.C. § 355(k)(3)(A) clarifies that the system contains "information with respect to a drug
approved under this section [section 355] or under section 351 of the Public Health Service Act." This
scope technically covers blood/blood products and tissue/tissue products, but I limit this dissertation to
drugs, therapeutic biologics (i.e., those regulated within the FDA's Center for Drug Evaluation and
Research) and vaccines. As of July 9, 2012, the scope of the system was expanded to include medical
devices, although I do not address this use in this dissertation. See § 615 in Food and Drug Administration
Safety and Innovation Act, Public Law 112-144, 2012.
8 Institute of Medicine (IOM), The Future ofDrug Safety: Promoting and Protecting the Health of the
Public, 38., The IOM noted that medical product approval systems are characterized by an inherent
"delayed availability of important safety data until a drug is used in larger and more diverse populations."
Most, but not all, postmarket safety data arises from postmarket clinical experiences (as opposed to a
clinical trial setting), and prior to the widespread availability of electronic healthcare data, was contained in
individual case reports. See T. Brewer and G. A. Colditz, "Postmarketing Surveillance and Adverse Drug
Reactions: Current Perspectives and Future Needs," Journal of the American Medical Association 281, no.
9 (1999): 824-829.
9 § 905 in Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355(k)(3)(B)(i-ii) and 21 U.S.C. § 355(k)(3)(C)(i)(III).
10 M. A. Robb et al., "The US Food and Drug Administration's Sentinel Initiative: Expanding the Horizons
of Medical Product Safety," Pharmacoepidemiology and Drug Safety 21 Suppl 1 (2012): 9-11; R. E.
Behrman et al., "Developing the Sentinel System - A National Resource for Evidence Development," The
New England Journal of Medicine (2011); Food and Drug Administration U.S. Department of Health and
Human Services, "The Sentinel Initiative" (FDA, 2010),
http://www.fda.gov/downloads/Safety/FDAsSentinellnitiative/UCM233360.pdf.
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medical products". The FDA created a five-year pilot program - the Mini-Sentinel
System - to build initial infrastructure, develop capabilities, test methods, and conduct
pilot assessments.' 2 It is important to understand that as of this writing, the Mini-Sentinel
System is considered a "laboratory"' 3 and its capabilities are at various stages of
development. As a system, it is not yet routinely employed in postmarket safety
assessments being conducted at the FDA.
First, a key feature of the Mini-Sentinel System is the secondary use, or repurposing,
of electronic healthcare data in order to identify and/or assess postmarket safety signals.
These data are currently administrative/claims data with some clinical data such as
laboratory tests.' 4 Second, the sizable scale and distributed architecture of this effort is
another unique feature, with data that comprise nearly one-third of the privately insured
U.S. population.' 5 Third, the system's reusable data infrastructure facilitates the
execution of conventional multi-site pharmacoepidemiologic studies16
Specifically, the Mini-Sentinel System eliminates the need to constitute a study
database de novo to assess hypotheses with respect to postmarket safety signal(s) of
interest. Instead, these data are continually maintained in a common, interoperable
format' 7 across multiple sites resulting in less time spent harmonizing data sources for
each postmarket safety activity. Also, the use of these data has been designated as a
" Congress did not specify medical devices for inclusion in the active postmarket risk identification and
analysis system until just recently. See § 615 of Food and Drug Administration Safety and Innovation Act,
Public Law 112-144.
12 R. Platt et al., "The U.S. Food and Drug Administration's Mini-Sentinel Program: Status and Direction,"
Pharmacoepidemiology and Drug Safety 21 Suppl 1 (2012): 1--8; Robb et al., "The US Food and Drug
Administration's Sentinel Initiative: Expanding the Horizons of Medical Product Safety."
13 Platt et al., "The U.S. Food and Drug Administration's Mini-Sentinel Program: Status and Direction."
14 Ibid. Healthcare providers use administrative/claims data to charge health insurance companies for their
services.
1s See infra at note 113-114 for more details.
16 Multi-site studies typically combine patient data, which requires data use agreements among the multiple
sites as well as privacy and human subjects reviews at each site. For a general description of the conduct of
pharmacoepidemiologic studies using databases, see U.S. Department of Health and Human Services et al.,
"Guidance for Industry and FDA Staff: Best Practices for Conducting and Reporting
Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets (Draft)", February 16, 2011,
http://www.fda.gov/downoads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM 2 4 35 3
7.pdf.
"7 L. H. Curtis et al., "Design Considerations, Architecture, and Use of the Mini-Sentinel Distributed Data
System," Pharmacoepidemiology and Drug Safety 21 Suppl 1 (2012): 23-31.
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public health activity as opposed to "research," which means that the Common Rule' 8
does not apply to these activities and review by Institutional Review Boards is not
required.19 Practically, many front-end time delays and administrative requirements
associated with testing drug safety hypotheses have been eliminated or reduced.
Consequently, the system provides an efficient environment for the conduct of
conventional pharmacoepidemiologic studies using administrative data.
More importantly, and perhaps Congress's principal intent, this data infrastructure
also allows for new routine postmarket monitoring capabilities including 1) the retrieval
of population-wide descriptive statistics on medical product usage2 0 , diagnoses, and
outcomes; 2) the performance of statistical surveillance methods for the automated
generation of new safety signals (e.g., data-mining and syndromic surveillance); and 3)
the performance of sequential statistical analyses on pre-specified postmarket drug safety
hypotheses (i.e., safety signals). As of this writing, some of these capabilities are in
embryonic stages of development. However, I include them here to give the reader a
broad understanding of the potential of the system. These capabilities are novel
supplements to the FDA's existing systems because the data infrastructure makes data
available in "near real-time,"2' allowing for more timely evidence generation to support
regulatory decision-making.
It is important to understand that "near real-time" is a relative concept. That is,
relative to a conventional observational study with a singular end-of-study analysis,
18 The Common Rule refers to federal regulations that protect the rights of human subjects involved in
biomedical and behavioral research. It can be found in numerous instances within the entire Code of
Federal Regulations but is classically located at 45 CFR § 46 in its entirety. Department of Health and
Human Services, "Code of Federal Regulations Title 45 Part 46, Protection of Human Subjects", July 14,
2009, http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html.
19 D. McGraw, K. Rosati, and B. Evans, "A Policy Framework for Public Health Uses of Electronic Health
Data," Pharmacoepidemiology and Drug Safety 21 Suppl 1 (2012): 18-22.
2 For many years, the FDA has had access to proprietary, nationally projected medical product utilization
data. See Institute of Medicine (IOM), The Future ofDrug Safety: Promoting and Protecting the Health of
the Public, 112. This capability is new because it will be possible to link data on medical product
utilization to diagnoses and outcomes. For example, one might be able to assess "channeling" behavior, or
the tendencies for certain types of patients to be prescribed particular products.
21 "Near real-time" data refer to data on clinical experiences that arrive with a variable delay from when the
experience occurred. There are two sources of delay. First, there is a processing delay, which is the time
that elapses between when the experience occurs, and when it is recorded and available for analysis.
Second, there is a refresh delay, which is associated with the frequency with which an originating data
source renews their dataset and makes it available for analysis. These concepts will be explained in greater
detail in subsection 6.2.2.
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which might analyze data years after the outcomes occurred in time2 2, "near real-time"
data make analyses possible on the order of months2 3. This "near real-time" data stream
allows regulators and public health investigators to analyze data as they accumulate,
thereby generating population-wide incidence rates and risk estimates sooner than
conventional observational studies. Yet, these gains in speed in a surveillance setting
come with a price. They are offset by data that may be "unsettled" and later corrected,
analyses performed with limited confounding control25, analyses performed without full
26
adjudication of exposures and outcomes , or analyses that rely on previous validation
studies. Implementing more refined confounding control and/or adjudicating data
increase time-to-results and cost because these activities move further away from
automated analyses. However, these activities increase the quality of analyses by
reducing the biases associated with the results2 7 , and may substantially affect regulatory
decision-making. It remains to be seen whether regulators will favor speed over quality
and how they will trade such quantities off for particular safety questions.
Still, if reasonable but imperfect information is available sooner, and it leads to
regulatory action(s) that prevent adverse events, improve clinical care decisions, and
conserve surveillance or research resources for other public health needs, then these gains
22 For example, in a FDA-funded large retrospective observational study, the study period ended in 2005, a
full five years prior to preliminary analyses. See L. A. Habel et al., "ADHD Medications and Risk of
Serious Cardiovascular Events in Young and Middle-aged Adults," JAMA : the Journal of the American
Medical Association 306, no. 24 (2011): 2673-2683; W. 0. Cooper et al., "ADHD Drugs and Serious
Cardiovascular Events in Children and Young Adults," The New England Journal of Medicine 365, no. 20
(2011): 1896-1904.
23 While the Mini-Sentinel System's current data structure involves monthly data refreshes, older and
similar distributed database networks like the Vaccine Safety Datalink collect and analyze data in weekly
increments. See generally W. K. Yih et al., "Active Surveillance for Adverse Events: The Experience of the
Vaccine Safety Datalink Project," Pediatrics 127 Suppl 1 (2011): S54-64.
24 Recall that these data have a primary purpose - reimbursement of medical services - that may subject
them to adjustments, rejections, corrections, re-submissions, and other changes for some period of time
after their chronological occurrence.
25 The degree of confounding control associated with the new capabilities of the Mini-Sentinel System will
be discussed in greater detail in 4.2.1.1.
26 Adjudication refers to procedures that are performed to validate the data, i.e. to ensure that the electronic
record actually reflects patient experiences. It often involves medical chart abstraction and confirmation of
the exposures, outcomes, and covariates of interest.
27 For example, sequential database surveillance performed for HINI influenza vaccination-Guillain-Barre
Syndrome (GBS) found that electronic identification of GBS had a positive predictive value of 53.3%. The
resultant differences between risk estimates with chart-confirmed GBS vs. electronically identified GBS are
substantial. See Appendix B in Grace M. Lee et al., "H IN1 and Seasonal Influenza Vaccine Safety in the
Vaccine Safety Datalink Project," American Journal of Preventive Medicine 41, no. 2 (August 2011): 121-
128. Biases will be described in greater detail in section 4.2.
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must be weighed against the cost of operating and maintaining the Sentinel System at the
scale specified by Congress28 . Quantifying the value of this system first requires mapping
the needs of the FDA in the postmarket to an analysis of the optimal use(s) of this system
for each of its capabilities, and then determining the appropriate demand for such use(s).
Examining the proper, efficient, and routine incorporation of some of these novel
capabilities into the existing postmarket surveillance systems of the FDA is the
subject of this dissertation. This research develops qualitative and quantitative tools to
aid the FDA in evaluating the Mini-Sentinel System's capabilities with regard to
generating postmarket evidence to support regulatory decision-making. I consider drugs,
therapeutic biologics, and vaccines as the exposures 29 of interest. The unit of analysis that
30I examine, and take as an input to my models, is a pre-specified exposure-outcome pair .
Thus, this dissertation does not address the optimal use of the Mini-Sentinel System for
signal detection activities, which involve searching the data for new safety signals
without pre-specified hypotheses of interest.
Like any technical system, the Mini-Sentinel System has design-based limitations and
cannot fulfill all of the FDA's postmarket needs. These design-based limitations are
summarized in a qualitative tool that the FDA can employ to determine whether the Mini-
Sentinel System is well suited, on its face, to evaluate a pre-specified exposure-outcome
pair. I call this qualitative tool the Mini-Sentinel System Pre-Screening Checklist and
describe it herein in Section 4. Once an initial qualitative assessment is complete,
quantitative tools may further be used to determine the Mini-Sentinel System's likelihood
of meeting the FDA's needs for assessment. The quantitative tool I describe herein in
Section 6 is the Sequential Database Surveillance Simulator. The simulator allows the
FDA to explore the surveillance possibilities for a particular pre-specified exposure-
28 Congress specified coverage of 100,000,000 persons by 2012 in Food and Drug Administration
Amendments Act of 2007, Public Law 110-85. It is unclear if a needs assessment was performed to justify
this particular size.
29 Rothman et al. define exposure as follows: "In epidemiology, it is customary to refer to potential causal
characteristics as exposures. Thus, exposure can refer to a behavior (e.g., needle sharing), a treatment or
other intervention (e.g., an educational program about hazards of needle sharing), a trait (e.g., a genotype),
an exposure in the ordinary sense (e.g., an injection of contaminated blood), or even a disease (e.g.,
diabetes as the cause of death)." Kenneth J. Rothman, Sander Greenland, and Timothy L. Lash, Modern
Epidemiology, Third. (Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008), 52.
3 Outcomes are health outcomes of interest, and safety surveillance particularly focuses on adverse events
as health outcomes of interest. An exposure-outcome pair is a hypothesized relationship between the
exposure and outcome of interest, e.g., oral anti-diabetic medications and acute myocardial infarctions.
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outcome pair under a variety of potential real-world circumstances in a virtual, low-cost
way. Using this tool, the FDA may begin to make assessments of the Mini-Sentinel
System's sequential database surveillance capabilities for individual pairs. As the FDA
considers the larger scope of exposure-outcome pairs that it needs to evaluate and uses
the tool repeatedly, the FDA can begin to draw conclusions with regard to overall
demand for this capability. I comment on, but do not fully examine questions of overall
demand, which requires consideration of the entire scope of exposure-outcome pairs that
might exist, an n-dimensional space.
A primary motivation to examine this topic is the public investment required to
maintain the infrastructure in the long term. First, although the infrastructure is not
explicitly funded beyond the pilot Mini-Sentinel System, the incorporation of this system
into routine postmarket surveillance activities requires non-trivial annual maintenance
and operation costs. These costs simply keep the data up-to-date and capable of being
accessed. Second, each request to access these data has some processing costs that clearly
vary with the number and size of the data requests in addition to how efficiently the
requests can be coded, tested, and distributed to the individual sites who access their
proprietary databases. Third, as the system is used for more protocol-oriented (i.e., ad
hoc) analyses, senior scientific support (e.g., epidemiologists, clinicians, and
biostatisticians) will be necessary for each of these assessments. Fourth, the FDA must
scale its regulatory efforts (i.e., full-time trained staff) to process the output assessments
of this system. Taken together, continued funding of this resource requires budgeting for
both fixed and variable costs that are not yet well-defined.
Another motivation is the public health effects of the legal coupling3 I of the Mini-
Sentinel System's capabilities to the FDA's ability to require industry-funded postmarket
studies or clinical trials, known as postmarket requirements (PMRs) 3 2 . Specifically, when
identifying or assessing a particular postmarket safety signal, the FDA must make a
3 § 901 in Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at U.S.C.
§ 355(o)(3)(D).
32 A postmarketing requirement is a mandate from the FDA to the manufacturer/sponsor of a particular
product to perform a study of various types. See Department of Health and Human Services et al.,
"Guidance for Industry: Postmarketing Studies and Clinical Trials - Implementation of Section 505(o)(3) of
the Federal Food, Drug, and Cosmetic Act (Final)", March 31, 2011,
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM 17200
1.pdf.
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determination on whether its publicly-funded postmarket safety systems (including the
Mini-Sentinel System) generate sufficient knowledge on postmarket safety risks to make
a regulatory decision, or whether additional privately-funded (i.e. manufacturer-funded)
studies are necessary. These decisions clearly hold significant implications for the FDA,
manufacturers/sponsors, healthcare providers, and patients. Such decisions are likely to
be scrutinized and perhaps contested, and depend on a clear scientific demonstration of
suitable use of the system. The ethical implications of this decision were the subject of a
recent IOM committee report, which noted,
"When the FDA imposes a postmarketing requirement, it is expressing... a judgment that
the public health interests served by requiring additional research outweigh the burdens
placed on pharmaceutical manufacturers and - more important from an ethical standpoint
-any risk of harm or burdens on research participants." 33
In this dissertation, Section 2 reviews the FDA's routinely operating postmarket
systems (i.e., the existing postmarket systems), and the addition of the "pilot" Mini-
Sentinel System. Specifically, the Mini-Sentinel System's data infrastructure, and risk
identification and analysis capabilities are reviewed. Section 3 establishes the legal/policy
context in which the FDA's postmarket systems are now embedded and more thoroughly
explains the aforementioned legal coupling of the Mini-Sentinel System's technical
capabilities to the FDA's regulatory ability to require privately-funded postmarket
studies. That is, it examines the legal requirements with regard to the scientific quality of
the evidence needed to support various regulatory actions. Additionally, Section 3
outlines the FDA's postmarket regulatory decision-making process and potential
regulatory actions that may result following identification and analysis of new safety
information. Section 4 presents the Mini-Sentinel System Pre-Screening Checklist, a
qualitative tool designed to aid the decision-maker in evaluating whether the Mini-
Sentinel System is likely to be suited, on itsface, to evaluate particular exposure-outcome
pairs. Specifically, Section 4 addresses situations when the Mini-Sentinel System may be
ill-suited as an evidence generation system of interest due to its inability to overcome
various biases in an observational setting, issues of sample size, or issues of
generalizability to broader populations.
3 Institute of Medicine (1OM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs
(Washington, D.C.: National Academies Press, 2012), 4, http://books.nap.edu/catalog/13219.html.
24
Section 5 reviews the scientific and technical state-of-the-art with respect to
prospective sequential database surveillance. Section 6 describes the Sequential Database
Surveillance Simulator in detail. Section 7 illustrates the use of the Sequential Database
Surveillance Simulator with a vaccine-based example. Particularly, Section 7 establishes
the important tradeoffs associated with sample size calculations in sequential statistical
analyses, particularly the tradeoff between statistical power and median sample size. It
draws attention to the performance characteristics of various surveillance configurations
with respect to timeliness and accuracy of signal detection. Section 8 adds complexity to
the vaccine example by examining the effects of misclassification on sequential database
surveillance performance. It also establishes a way to use the simulator to investigate the
performance of different algorithms for detecting outcomes of interest. This simulated
example is particularly important because it addresses inherent differences in the Mini-
Sentinel System's component databases, particularly the existence of a small subset of
databases with access to richer laboratory data. Sequential database surveillance
performance is compared between this small subset with high quality data to the larger
database configuration with claims-only data.
Section 9 addresses complications related to modeling medical product adoption and
utilization, specifically the uptake of new molecular entities. A cohort of 40 new
molecular entities is examined. A subset of this cohort is then investigated by fitting
Mini-Sentinel System data to classical diffusion models. An important finding that results
is that many new molecular entities are better described by "dual market" adoption
patterns. In other words, the market for these medical products consists of two distinct
sets of adopters. This finding raises a non-trivial generalizability concern when sequential
database surveillance is performed immediately post-licensure. Section 10 is a summary
of the findings of the dissertation and a discussion on future work. Appendices A-C
contain supporting data and Appendix D is a glossary of terms to assist the reader.
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2 The FDA'S POSTMARKET SYSTEMS
2.1 The FDA's Routinely Operating Postmarket Systems
The Institute of Medicine (IOM)'s overview of the U.S. Food and Drug
Administration (FDA)'s postmarket systems and their contribution to identifying and
assessing medical product-associated risks is briefly reviewed herein. As stated earlier,
because the FDA has not yet deployed the Mini-Sentinel System in routine postmarket
assessment, the overview presented in this subsection still reflects the current state at the
FDA.
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Figure 1. Identification and Adjudication of a Signal of Serious Risk in the U.S. Food and Drug
Administration's Postmarket Surveillance Systems
Adapted from the Institute of Medicine. 34
*In the original Institute of Medicine report, this stage was referred to as "signal strengthening or testing."
The wording was changed to reflect a more neutral stance.
**In the original Institute of Medicine report, this stage was referred to as "signal confirmation." The
wording was changed to reflect a more neutral stance.
Abbreviations: AERS, Adverse Event Reporting System; VAERS, Vaccine Adverse Event Reporting
System.
Figure 1 shows the three-stage process for identification and adjudication of medical
product-associated postmarket safety risks, often referred to as safety signals3 5 .
34 This figure is generated from descriptions contained in Institute of Medicine (IOM), The Future of Drug
Saftty: Promoting and Protecting the Health of the Public, 105-119.
3 Two well-accepted definitions of "signal" are as follows: 1) "Information that arises from one or multiple
sources (including observations and experiments) which suggests a new potentially causal association, or a
new aspect of a known association, between an intervention and an event or set of related events, either
adverse or beneficial, that is judged to be of sufficient likelihood to justify verificatory action." Council for
International Organizations of Medical Sciences. Working Group VIII, Practical aspects ofsignal
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2.1.1 Signal Detection
Signal detection 36 is the generation of a hypothesis with respect to a signal of serious
risk3 7 associated with a medical product. It is usually based on the discovery of new data
and subsequent analyses of those data. In this first stage in the lifecycle of a safety signal,
the FDA's spontaneous reporting systems - the Adverse Event Reporting System 38 and
Vaccine Adverse Event Reporting System 39 - generate the bulk of hypotheses regarding
potential associations 0 between medical products (i.e., exposures) and adverse events
(i.e., outcomes). 4 1 Disproportionality analyses are used to identify exposure-outcome
pairs that are reported in excess of what would be expected if these pairs were
detection in pharmacovigilance : report of CIOMS Working Group VIII. (Geneva: CIOMS, 2010). 2)
"Reported information on a possible causal relationship between an adverse event and a drug, the
relationship being unknown or incompletely documented previously. Usually more than a single report is
required to generate a signal, depending upon the seriousness of the event and the quality of the
information." World Health Organization, The Importance of Pharmacovigilance - Safety Monitoring of
Medicinal Products (Geneva, Switzerland: World Health Organization, 2002), 42,
http://apps.who.int/medicinedocs/en/d/Js4893e/. See also Manfred Hauben and Jeffrey K Aronson,
"Defining 'Signal' and Its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous
Definitions," Drug Safety 32, no. 2 (2009): 99-110.
36 The FDA has also used the following definition of signal generation (which is generally an
interchangeable term with signal detection): "an approach that uses statistical methods to identify medical
product-adverse outcome associations that may be safety signals; no particular medical product exposure
or adverse outcome is pre-specified." See Robb et al., "The US Food and Drug Administration's Sentinel
Initiative: Expanding the Horizons of Medical Product Safety," 10.§7 901 in Food and Drug Administration Amendments Act of 2007, Public Law 110-85,.codified at 21
U.S.C. § 355-1(b)(6), gives the legislative definition: "The term 'signal of a serious risk' means
information related to a serious adverse drug experience associated with use of a drug."
38 See generally, Gerald J. Dal Pan, Marie Lindquist, and Kate Gelperin, "Postmarketing Spontaneous
Pharmacovigilance Reporting Systems," in Pharmacoepidemiology, ed. Brian L. Strom, Stephen E.
Kimmel, and Sean Hennessy, Fifth. (John Wiley & Sons, 2011), 137-157; S. R. Ahmad, "Adverse Drug
Event Monitoring at the Food and Drug Administration," Journal of General Internal Medicine 18, no. 1
(2003): 57-60.
39 See generally, R. Ball et al., "Statistical, Epidemiological, and Risk-assessment Approaches to
Evaluating Safety of Vaccines Throughout the Life Cycle at the Food and Drug Administration," Pediatrics
127 Suppl 1 (2011): S31-8.
44 Associations in epidemiology are referred to as correlations in other fields of study. Strom defines an
association as a statistically significant inference regarding a population. He further defines types of
associations, one of which is causal when a biological inference establishes causation and all confounding
is eliminated. See Brian L. Strom, "Basic Principles of Clinical Epidemiology Relevant to
Pharmacoepidemiologic Studies," in Pharmacoepidemiology, ed. Brian L. Strom, Stephen E. Kimmel, and
Sean Hennessy, Fifth. (John Wiley & Sons, 2011), 38-43; C. H. Hennekens and D. DeMets, "Statistical
Association and Causation: Contributions of Different Types of Evidence," JAMA : the Journal of the
American Medical Association 305, no. 11 (2011): 1134-1135.
4' Thomas J Moore, Sonal Singh, and Curt D Furberg, "The FDA and New Safety Warnings," Archives of
Internal Medicine 172, no. 1 (January 9, 2012): 78-80; D. K. Wysowski and L. Swartz, "Adverse Drug
Event Surveillance and Drug Withdrawals in the United States, 1969-2002: The Importance of Reporting
Suspected Reactions," Archives of Internal Medicine 165, no. 12 (2005): 1363-1369.
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independently distributed in the database. 4 2 Under certain conditions, it is also possible to
identify a signal based on a single case report. For example, the FDA recently identified a
single potentially medical product-associated death as a signal4 3, and other outcomes may
require only a few cases to generate a signal.4 4
Spontaneous reporting systems provide effective and inexpensive signal detection,
particularly for rare or very rare4 5 outcomes that are not detectable in clinical trials and
that are unlikely to be related to the disease being treated. These types of signals are
sometimes categorized as "Type B" adverse events, meaning they are considered to be
idiosyncratic events that occur in patients with some (typically) unknown hypersensitivity
46
or predisposing condition. However, spontaneous reporting systems are a) known to
have data quality problems; b) be subject to significant underreporting with regard to
common outcomes (e.g., acute myocardial infarctions); c) be subject to significant
underreporting when the outcomes are unlikely to trigger suspicion of being medical
product-related; and d) be ineffective at calculating incidence or prevalence of an event in
the population.4 7 In summary, these systems provide a useful but limited function (i.e.,
they perform well for Type B signal detection).
42 J S Almenoff et al., "Novel Statistical Tools for Monitoring the Safety of Marketed Drugs," Clinical
Pharmacology and Therapeutics 82, no. 2 (August 2007): 157-166.
43 In this case, there was a labeled, known risk regarding fingolimod-associated bradycardia, which may
lead to death. To manage the risk, the label recommended increased monitoring for the first six hours
following the initial dose. This death occurred in a 24-hour period following the initial dose despite
compliance with the prescribed 6-hour monitoring period, suggesting an unexpected increase in the severity
of risk. This increased severity was the important factor in identifying a new signal. See Center for Drug
Evaluation and Research, "Drug Safety and Availability - FDA Drug Safety Communication: Safety
Review of a Reported Death After the First Dose of Multiple Sclerosis Drug Gilenya (fingolimod),"
WebContent, December 20, 2011, http://www.fda.gov/Drugs/DrugSafety/ucm284240.htm.
44 Institute of Medicine (IOM), The Future of Drug Saftty: Promoting and Protecting the Health of the
Public, 108-109. "Even a small number of reports of events that are commonly caused by drug exposure,
such as liver or kidney failure, aplastic anemia, anaphylaxis, Stevens-Johnson syndrome, and so on, can
constitute an important safety signal."
45 The Council for International Organizations of Medical Sciences (CIOMS) Working Group III,
Guidelines fbr Preparing Core Clinical Safety Information on Drugs. (Geneva: World Health Organization
(WHO), 1995)."Rare" outcomes refer to those that occur with a frequency of greater than 1 event per
10,000 person-years, but less than I event per 1,000 person years. "Very Rare" outcomes occur with a
frequency less than 1 event per 10,000 person-years but greater than I event per 100,000 person-years.
46 R H Meyboom, M Lindquist, and A C Egberts, "An ABC of Drug-related Problems," Drug Safety: An
International Journal of Medical Toxicology and Drug Experience 22, no. 6 (June 2000): 415-423.
47 B. L. Strom, "Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: a
Counterpoint," Journal of the American Medical Association 292, no. 21 (2004): 2643-2646; U.S. General
Accounting Office, Adverse Events: The Magnitude of Health Risk Is Uncertain Because ofLimited
Incidence Data, vol. GAO/HEHS-00-21 (Washington, DC: GPO, 2000); T. J. Moore, B. M. Psaty, and C.
D. Furberg, "Time to Act on Drug Safety," Journal of the American Medical Association 279, no. 19
29
Signal detection with regard to more common outcomes, or those that may be related
to the natural history of the disease, are typically detected from safety data in a
prelicensure or postlicensure clinical trial 48, or meta-analyses of randomized clinical trial
data49. These data may be underpowered statistically to suggest an association, but be
biologically plausible and concerning enough to generate a signal. These types of signals
have been referred to as "Type C" adverse effects or "statistical effects."50 In the absence
of large sample sizes, they are difficult to detect because of the high background
frequency of the adverse event in the unexposed population. Notably, the Mini-Sentinel
System enables such large sample sizes, implying a potential improvement to the FDA's
signal detection capabilities for Type C signals once the Mini-Sentinel System is
incorporated into routine operations. Signal detection in the Mini-Sentinel System is an
active area of ongoing research that will be described briefly in section 2.2.2.2.
Once a safety signal has been detected, the FDA must determine whether the
available evidence requires it to take immediate regulatory action, to gather more
information (e.g., conduct postmarket studies51), or to do both simultaneously.52
2.1.2 Signal Refinement
The IOM identified two follow-on stages for signal adjudication after a signal has
been detected. It differentiated these stages based on the type of postmarket study that
was used to test the hypothesis of a medical product-associated risk. The IOM identified
the second stage as a "signal strengthening and testing" stage, which is now known as
(1998): 1571-1573; Brewer and Colditz, "Postmarketing Surveillance and Adverse Drug Reactions:
Current Perspectives and Future Needs."
48 For example, cardiovascular safety signals for Vioxx@ (rofecoxib) were identified by the FDA's Medical
Officer in prelicensure clinical trials. See B. M. Psaty and C. D. Furberg, "COX-2 Inhibitors--lessons in
Drug Safety," The New England Journal of Medicine 352, no. 11 (2005): 1133-1135.
49 For example, a published meta-analysis of Avandia@ (rosiglitazone) prompted unplanned interim
analyses of trial data. See D. M. Nathan, "Rosiglitazone and Cardiotoxicity--weighing the Evidence," The
New England Journal of Medicine 357, no. 1 (2007): 64-66; B. M. Psaty and C. D. Furberg, "The Record
on Rosiglitazone and the Risk of Myocardial Infarction," The New England Journal ofMedicine 357, no. 1
(2007): 67-69; S. E. Nissen and K. Wolski, "Effect of Rosiglitazone on the Risk of Myocardial Infarction
and Death from Cardiovascular Causes," The New England Journal of Medicine 356, no. 24 (2007): 2457-
2471.
so Meyboom, Lindquist, and Egberts, "An ABC of Drug-related Problems."
5 Postmarket studies may include laboratory studies, animal studies, or clinical investigations. For
examples, see Department of Health and Human Services et al., "Guidance for Industry: Postmarketing
Studies and Clinical Trials - Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic
Act (Final)."
5 The FDA's decision algorithm is discussed more thoroughly herein in section 3.
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signal refinement5 3 . The postmarket studies used to support evidence development in this
stage include conventional pharmacoepidemiologic research using administrative
databases and active surveillance of emergency rooms for adverse drug events.
Generally, pharmacoepidemiologic research using administrative databases can refer
to descriptive studies that report drug utilization54 or physician prescribing behavior55 , or
to analytical studies designed to produce information on comparative drug safety56 or
effectiveness 57. Administrative database studies can also evaluate the changes in health
outcomes produced by changes in health policy such as the effect of changing insurance
copayment requirements.58 These studies sample electronic healthcare data, which can be
either administrative/claims data or electronic health records. Within the drug safety
realm, much has been written on the strengths and limitations of these studies. 9
Advantages include the ability to study large sample sizes inexpensively and the potential
for greater generalizability than results from more exclusive randomized experiments.
Disadvantages include the potential for biased results from poor quality and missing
53 The FDA has used the following definition of signal refinement: "a process by which an identified
potential safety signal is further investigated to determine whether evidence exists to support a relationship
between the medical product exposure and the outcome." See Robb et al., "The US Food and Drug
Administration's Sentinel Initiative: Expanding the Horizons of Medical Product Safety," 10.
54 See, for example, Paul N Pfeiffer et al., "Depression Care Following Psychiatric Hospitalization in the
Veterans Health Administration," The American Journal of Managed Care 17, no. 9 (September 2011):
e358-364.
55 See for example, Paul N Pfeiffer et al., "Trends in Antidepressant Prescribing for New Episodes of
Depression and Implications for Health System Quality Measures," Medical Care 50, no. 1 (January 2012):
86-90.
56 See, for example, Habel et al., "ADHD Medications and Risk of Serious Cardiovascular Events in Young
and Middle-aged Adults"; Cooper et al., "ADHD Drugs and Serious Cardiovascular Events in Children and
Young Adults."
" See, for example, Seo Young Kim and Daniel H Solomon, "Use of Administrative Claims Data for
Comparative Effectiveness Research of Rheumatoid Arthritis Treatments," Arthritis Research & Therapy
13, no. 5 (2011): 129.
5 See, for example, Sujha Subramanian, "Impact of Medicaid Copayments on Patients with Cancer:
Lessons for Medicaid Expansion Under Health Reform," Medical Care 49, no. 9 (September 2011): 842-
847.
59 W. A. Ray, "Improving Automated Database Studies," Epidemiology (Cambridge, Mass.) 22, no. 3
(2011): 302-304; B. L. Strom, "Methodologic Challenges to Studying Patient Safety and Comparative
Effectiveness," Medical Care 45, no. 10 Supl 2 (2007): S 13-5; S. Schneeweiss and J. Avorn, "A Review of
Uses of Health Care Utilization Databases for Epidemiologic Research on Therapeutics," Journal of
Clinical Epidemiology 58, no. 4 (2005): 323-337; R. Temple, "Meta-analysis and Epidemiologic Studies in
Drug Development and Postmarketing Surveillance," JAMA : the Journal of the American Medical
Association 281, no. 9 (1999): 841-844.
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data.60 As the IOM states, "precise but biased estimates of risk are not generally
useful."6 '
Consequently, it is not unusual for independently conducted pharmacoepidemiologic
studies to produce variation in their estimates of risk62, and although the same possibility
exists with randomized studies 63, there is more skepticism of pharmacoepidemiologic
studies.64 Some attribute these problems to growing pains of the discipline.65 On that
note, there have been efforts to increase the internal validity and repeatability of these
studies.66 Despite these potential shortcomings, the FDA funds a limited number of
67pharmacoepidemiologic studies via contract. Manufacturers also conduct these studies
60 Biases associated with observational data are discussed extensively herein in section 4.2.
61 Institute of Medicine (IOM), The Future of Drug Safety: Promoting and Protecting the Health of the
Public, 114.
62 See, for example, the FDA's struggle to interpret the results of seven observational studies studying the
risks of venous thromboembolism associated with drospirenone-containing contraceptives. See Center for
Drug Evaluation and Research, "Drug Safety and Availability - FDA Drug Safety Communication:
Updated Information About the Risk of Blood Clots in Women Taking Birth Control Pills Containing
Drospirenone," WebContent, April 10, 2012, http://www.fda.gov/Drugs/DrugSafety/ucm299305.htm;
Center for Drug Evaluation and Research, "Reproductive Health Drugs Advisory Committee - Briefing
Information for the December 9, 2011 Joint Meeting of the Advisory Committee for Reproductive Health
Drugs and the Drug Safety and Risk Management Advisory Committee," WebContent, December 9, 2011,
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsA
dvisoryCommittee/ucm28263 .htm.
63 D. Jane-wit, R. I. Horwitz, and J. Concato, "Variation in Results from Randomized, Controlled Trials:
Stochastic or Systematic?," Journal of Clinical Epidemiology 63, no. 1 (2010): 56-63.
64 D. A. Lawlor et al., "Those Confounded Vitamins: What Can We Learn from the Differences Between
Observational Versus Randomised Trial Evidence?," Lancet 363, no. 9422 (2004): 1724-1727; S. J.
Pocock and D. R. Elbourne, "Randomized Trials or Observational Tribulations?," The New England
Journal of Medicine 342, no. 25 (2000): 1907-1909.
65 J. Avorn, "In Defense of Pharmacoepidemiology--embracing the Yin and Yang of Drug Research," The
New England Journal of Medicine 357, no. 22 (2007): 2219-2221; E. von Elm and M. Egger, "The Scandal
of Poor Epidemiological Research," BMJ (Clinical Research Ed.) 329, no. 7471 (2004): 868-869.
66 E. von Elm et al., "The Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) Statement: Guidelines for Reporting Observational Studies," Annals of Internal Medicine 147,
no. 8 (2007): 573-577; G. C. Hall et al., "Guidelines for Good Database Selection and Use in
Pharmacoepidemiology Research," Pharmacoepidemiology and Drug Safety 21, no. 1 (2012): 1-10; U.S.
Department of Health and Human Services et al., "Guidance for Industry and FDA Staff: Best Practices for
Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets
(Draft)."
67 U.S. Government Accountability Office, FDA Has Begun Efforts to Enhance Postmarket Saftty, but
Additional Actions Are Needed, vol. GAO-1 0-68 (Washington, DC: GPO, 2009), 28-30,
http://www.gao.gov/products/GAO-10-68."Since FDA initially awarded about $5.4 million in total to these
companies in fiscal year 2005, these contracts have yielded five completed epidemiologic studies on drug
safety, including a study on how antidepressant use in pregnancy affects the health of newborns. In fiscal
year 2008, FDA added about $9 million in total to the four contracts."
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to fulfill postmarket study commitments or requirements to assess particular safety
signals.68
Active surveillance of emergency rooms via the National Electronic Injury
Surveillance System Cooperative Adverse Drug Event Surveillance program is another
means of generating descriptive statistics with respect to physician-identified adverse
drug experiences. Implemented as a joint venture of the FDA, the Centers for Disease
Control and Prevention and the Consumer Products Safety Commission, this program
employs trained personnel to routinely review patient records to document physician-
identified adverse drug experiences in a nationally representative sample of emergency
departments. 69 This type of active surveillance establishes incidence and prevalence data,
particularly among medical products with a "narrow therapeutic range" that cause easily-
recognized serious adverse events when used at improperly high dosages (i.e.,
overdoses). 70 These medical product-associated adverse events - also designated
commonly as "Type A" adverse effects 71 - are predictable, and normally resolve or do not
recur when the dose is reduced. Generally, there is no question of causality, and these
statistics may contribute to the FDA's efforts to manage known risks associated with
supratherapeutic effects.
Overall, the IOM described the output of the signal refinement stage as:
"provid[ing] guidance for the development of further studies or provid[ing] sufficient
information to narrow the uncertainty about drug-related risks and benefits and guide
regulatory actions and the decisions of patients and providers."72
68 For example, see D. D. Dore et al., "A Cohort Study of Acute Pancreatitis in Relation to Exenatide Use,"
Diabetes, Obesity & Metabolism 13, no. 6 (2011): 559-566; D. D. Dore, J. D. Seeger, and K. Arnold Chan,
"Use of a Claims-based Active Drug Safety Surveillance System to Assess the Risk of Acute Pancreatitis
with Exenatide or Sitagliptin Compared to Metformin or Glyburide," Current Medical Research and
Opinion 25, no. 4 (2009): 1019-1027. These studies were used to fulfill postmarket commitments. See
commitment IDs 221528-221541 in Center for Drug Evaluation and Research, "Postmarket Requirements
and Commitments Database", n.d., http://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm.
69 D. S. Budnitz et al., "National Surveillance of Emergency Department Visits for Outpatient Adverse
Drug Events," Journal of the American Medical Association 296, no. 15 (2006): 1858-1866.
70 For example, "insulin or warfarin was implicated in more than one quarter of all estimated
hospitalizations." In Ibid., 1863. The denominator refers to all emergency department visits with
identifiable adverse drug events that then resulted in hospitalizations.
7' Meyboom, Lindquist, and Egberts, "An ABC of Drug-related Problems."
72 Institute of Medicine (IOM), The Future ofDrug Safety: Promoting and Protecting the Health of the
Public, 115.
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In other words, the outputs of the signal refinement stage can simply precede further
investigation or can terminate in regulatory action.
2.1.3 Signal Evaluation
The IOM identified "signal confirmation" as the third stage, which is now termed
signal evaluation73. During signal evaluation, evidence development is generated with the
conduct of "full-scale observational studies and clinical trials." 74 The intent of such
studies is to establish causal relationships as opposed to statistical associations.7 5 It is
unclear exactly what the IOM meant when describing "full-scale" observational studies.76
Moreover, the committee then references two randomized comparative safety and
effectiveness studies as exemplars of this stage. These two National Institutes of Health-
funded studies77 are noteworthy for their comparison of multiple therapeutic options,
their wide exploration of both safety/effectiveness endpoints78, and their cost, at $125
million and $725 million. In general, the costs and operational feasibility of these
7 The FDA has used the following definition: "Signal evaluation consists of the implementation of a full
epidemiological analysis to more thoroughly evaluate the causal relationship between exposure to the
medical product and the adverse outcome of interest." Robb et al., "The US Food and Drug
Administration's Sentinel Initiative: Expanding the Horizons of Medical Product Safety," 10.
7 Institute of Medicine (IOM), The Future ofDrug Safety: Promoting and Protecting the Health of the
Public, 115.
7 For a definition of association, see supra at note 40.
76 While the IOM is not clear on these distinctions, they did segregate "full-scale" observational studies
from retrospective studies in administrative databases. This designation is unsettled and the subject of
consternation among many epidemiologists who believe that properly executed database studies with
significant validation and confounding control can be used for causal inference. See supra at note 73,
implying that database studies can support causal inference. I hypothesize that the IOM's idea of full-scale
observational studies likely involved primary data collection, but there is little supporting evidence to
confirm or refute this conjecture.
77 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, "Major Outcomes in High-
risk Hypertensive Patients Randomized to Angiotensin-converting Enzyme Inhibitor or Calcium Channel
Blocker Vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT)," Journal of the American Medical Association 288, no. 23 (2002): 2981-2997; J. E. Rossouw
et al., "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal
Results From the Women's Health Initiative Randomized Controlled Trial," Journal of the American
Medical Association 288, no. 3 (2002): 321-333.
7' Dual safety/effectiveness endpoints occur when considering therapeutics that are licensed to lower
cardiovascular risk. These study endpoints are, by nature, both related to safety and effectiveness. In
comparison, Vioxx@ (rofecoxib) was licensed to treat osteoarthritis and so cardiovascular risk associated
with it is a more strictly safety-related endpoint.
79 Institute of Medicine (IOM), The Future ofDrug Safety: Promoting and Protecting the Health of the
Public, 115.
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studies result in their undersupply. 80 However, therapeutics approved with surrogate
endpoints8 1 under the FDA's accelerated approval process require such trials, which are
primarily focused on demonstrating efficacy as opposed to safety.
Absent the accelerated approval mechanism or other special program, prior to the
2007 Food and Drug Administration Amendments Act (FDAAA), the FDA had no legal
authority to mandate postmarket studies - either database studies, "full-scale"
observational studies or randomized clinical trials - and relied on voluntary commitments
from sponsors.82 For example, if a therapeutic was approved with a surrogate endpoint
under the traditional approval process, then the FDA secured a non-enforceable
postmarket commitment to complete follow-up studies.83 Many of these studies were
never initiated or completed. 84 The IOM attributed this low completion rate to
inadequately and hastily designed studies that were not practical. 85 The FDAAA
broadened the FDA's authority to mandate these studies8 6 and required the FDA to
investigate the backlog of postmarket commitments annually.87 Since then, the FDA has
80 R. F. Reynolds et al., "Is the Large Simple Trial Design Used for Comparative, Post-approval Safety
Research? A Review of a Clinical Trials Registry and the Published Literature," Drug Safety: an
International Journal of Medical Toxicology and Drug Experience 34, no. 10 (2011): 799-820; D.
Carpenter, "A Proposal for Financing Postmarketing Drug Safety Studies by Augmenting FDA User Fees,"
Health Affairs (Project Hope) Suppl Web Exclusives (2005): W5-469-80; S. R. Tunis, D. B. Stryer, and C.
M. Clancy, "Practical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in
Clinical and Health Policy," Journal of the American Medical Association 290, no. 12 (2003): 1624-1632.
8 A surrogate endpoint is hypothesized to be a proxy measure of a clinical endpoint that defines the
therapeutic's benefit. For example, progression-free survival is an oft used surrogate endpoint for
morbidity/mortality associated with cancer. See U.S. Government Accountability Office, FDA Needs to
Enhance Its Oversight of Drugs Approved the Basis of Surrogate Endpoints, GAO-09-866 (Washington,
DC: GPO, 2009), http://www.gao.gov/products/GAO-09-866.
82 Institute of Medicine (IOM), The Future ofDrug Safety: Promoting and Protecting the Health of the
Public, 155-157; Department of Health and Human Services et al., "Guidance for Industry: Postmarketing
Studies and Clinical Trials - Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic
Act (Final)."
83 U.S. Government Accountability Office, FDA Needs to Enhance Its Oversight of Drugs Approved the
Basis of Surrogate Endpoints.
84 Department of Health and Human Services Office of the Inspector General, FDA 's Monitoring of
Postmarket Study Commitments, vol. OEI-01-04-00390 (Washington, DC: OIG, 2006).
85 Institute of Medicine (IOM), The Future of Drug Safety: Promoting and Protecting the Health of the
Public, 111 116.
86 § 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355(o)(3).
87 § 921 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355(k)(5)(C).
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substantially changed their tracking system for these studies88 and many commitments
have been fulfilled or cancelled after further review.89
In general, signal evaluation studies designed explicitly for safety endpoints, as
opposed to following up surrogate endpoints, are rare. 90 There is active debate about
whether randomized controlled trials are the most appropriate ethical and scientific
approach to address safety issues in the postmarket.9 ' Concerns include the equipoise
among participants when the purpose of the study is to establish proof of harm, the
deviations from the ideal randomized controlled trial design that change statistical
inferences, and the appropriateness of particular analyses (e.g., intention-to-treat 92).
While randomized controlled trials are commonly accepted as the gold standard for proof
of efficacy, internal disagreements at the FDA regarding the type of evidence required to
adjudicate the rosiglitazone-cardiovascular outcomes safety signal prompted the FDA to
reach out to the IOM for guidance on the matter.93 Essentially, the IOM found legitimate
ethical and scientific arguments on both sides, and stressed the needs both to reach out to
advisory committees and the public for guidance and to act transparently regarding these
more contentious decisions on a case-by-case basis.
The FDA has taken this case-by-case approach. With respect to rosiglitazone, the
FDA canceled an ongoing randomized controlled trial and issued a risk evaluation and
88 See Center for Drug Evaluation and Research, "Postmarket Requirements and Commitments Database."
89 See Center for Drug Evaluation and Research, "Postmarketing Requirements and Commitments:
Reports," WebContent, n.d., http://www.fda.gov/Drugs/GuidanceComplianceRegulatorylnformation/Post-
marketingPhaselVCommitments/ucm064436.htm; U.S. Government Accountability Office, FDA Needs to
Enhance Its Oversight of Drugs Approved the Basis of Surrogate Endpoints.
90 Reynolds et al., "Is the Large Simple Trial Design Used for Comparative, Post-approval Safety
Research? A Review of a Clinical Trials Registry and the Published Literature." Many phase IV
randomized controlled trials or large simple trials are designed with the primary purpose of the study being
to assess an efficacy or effectiveness endpoint but where data on the general safety profile were also
collected.
91 See Institute of Medicine (IOM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs;
J. P. Vandenbroucke, "Why Do the Results of Randomised and Observational Studies Differ?," BMJ
(Clinical Research Ed.) 343 (2011): d7020; P. N. Papanikolaou, G. D. Christidi, and J. P. loannidis,
"Comparison of Evidence on Harms of Medical Interventions in Randomized and Nonrandomized
Studies," CMAJ: Canadian Medical Association Journal 174, no. 5 (2006): 635-641; J. P.
Vandenbroucke, "What Is the Best Evidence for Determining Harms of Medical Treatment?," CMAJ:
Canadian Medical Association Journal 174, no. 5 (2006): 645-646.;
92 See Miguel A Hemin and Sonia Hernnndez-Diaz, "Beyond the Intention-to-treat in Comparative
Effectiveness Research," Clinical Trials (London, England) 9, no. 1 (February 2012): 48-55.
93 See Institute of Medicine (IOM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs,
xvii.
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mitigation strategy, which significantly limits utilization of rosiglitazone. 94 More
recently, the FDA held several advisory committee meetings to address the type of signal
evaluation study that would be required to evaluate a long-acting beta agonist-death
signal in children.95 In this case, the FDA required four manufacturers to conduct
randomized controlled trials, and to collect data in a way that makes the results amenable
to future meta-analysis. 96 In general, both Congress and the IOM have placed a heavy
justification burden on the FDA regarding engaging in signal evaluation studies.
2.1.4 Other Studies
Notably, the IOM does not describe how the results of meta-analyses 97 should be
regarded in its three-phase structure. Attention to meta-analyses has increased following
publication of results that identified the rosiglitazone-cardiovascular outcomes safety
signal. 98 Concerns about meta-analyses relate to the heterogeneity of contributing studies
and specifically, how exposures, outcomes, and covariates are classified; and what types
of patients are included/excluded. 99 Essentially, combining potentially dissimilar data
requires many judgments from investigators with little established guidance regarding
how to pool data. In a recent study, Golder et al. found no comparable difference in risk
estimates derived from meta-analyses of randomized controlled trials as opposed to meta-
94 Center for Drug Evaluation and Research, "Postmarket Drug Safety Information for Patients and
Providers - HHS FDA: Briefing on Avandia," WebContent, September 23, 2010,
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/ucm227
934.htm.
95 Center for Drug Evaluation and Research, "Pulmonary-Allergy Drugs Advisory Committee - Briefing
Information for the March 10-11, 2010 Joint Meeting of the Pulmonary-Allergy Drugs Advisory
Committee and Drug Safety and Risk Management Committee," WebContent, March 10, 2010,
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-
AllergyDrugsAdvisoryCommittee/ucm202692.htm.
96 Food and Drug Administration and Center for Drug Evaluation and Research, "FDA Drug Safety
Communication: FDA Requires Post-market Safety Trials for Long-Acting Beta-Agonists (LABAs),"
WebContent, April 15, 2011, http://www.fda.gov/Drugs/DrugSafety/ucm251512.htm.
9' Berlin et al. define meta-analysis as "the statistical analysis of a collection of analytic results for the
purpose of integrating the findings." Jesse A. Berlin, M. Soledad Cepeda, and Carin J. Kim, "The Use of
Meta-analysis in Pharmacoepidemiology," in Pharmacoepidemiology, ed. Brian L. Strom, Stephen E.
Kimmel, and Sean Hennessy, Fifth. (John Wiley & Sons, 2011), 723.
9 Nissen and Wolski, "Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from
Cardiovascular Causes."
99 Institute of Medicine (IOM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs,
128-131.
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analyses of observational studies.100 However, the FDA published findings particularly
noting the difficulties in using meta-analyses of randomized controlled trials to study
drug safety questions. 10' As part of performance goals in the Prescription Drug and User
Fee Amendments of 2012 (PDUFA V), the FDA has agreed to develop guidance on the
role of meta-analyses in regulatory decision-making. 102
2.2 Mini-Sentinel System: Active Postmarket Risk Identification and Analysis
In general, Congress chose to focus its public health resources in the signal detection
and refinement stages. Recall that the legislatively mandated addition of the Mini-
Sentinel System to the FDA's armamentarium of postmarket safety systems is a direct
response to the IOM's recommendation regarding strengthening the FDA's ability to test
drug safety hypotheses. Essentially, the data structure of the Mini-Sentinel System both
facilitates, and significantly scales, the FDA's existing capacity to perform
pharmacoepidemiologic studies using administrative databases. Figure 2 shows a
hypothesized placement of the Mini-Sentinel System and its potential capabilities within
the safety signal adjudication framework. In comparison to Figure 1, the Mini-Sentinel
System now enlarges the FDA's signal refinement capabilities and, in the future, may add
to the FDA's signal detection capabilities. This next subsection describes the Mini-
Sentinel System's data infrastructure and proposed capabilities that will supplement the
FDA's existing postmarket safety systems.
100 Su Golder, Yoon K Loke, and Martin Bland, "Meta-analyses of Adverse Effects Data Derived from
Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview," PLoS
Medicine 8, no. 5 (May 2011): e1001026. See also Jan P Vandenbroucke and Bruce M Psaty, "Benefits and
Risks of Drug Treatments: How to Combine the Best Evidence on Benefits with the Best Data About
Adverse Effects," JAMA: The Journal of the American Medical Association 300, no. 20 (November 26,
2008): 2417-2419.
101 Tarek A Hammad, Simone P Pinheiro, and George A Neyarapally, "Secondary Use of Randomized
Controlled Trials to Evaluate Drug Safety: a Review of Methodological Considerations," Clinical Trials
(London, England) 8, no. 5 (October 2011): 559-570.
102 Food and Drug Administration and Center for Drug Evaluation and Research, "Prescription Drug User
Fee Act (PDUFA) V: Reauthorization Performance Goals and Procedures; Fiscal Years 2013 Through
2017," WebContent, July 19, 2012,
http://www.fda.gov/downloads/Forlndustry/UserFees/PrescriptionDrugUserFee/UCM270412.pdf.
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Figure 2. Hypothesized Identification and Adjudication of a Signal of Serious Risk in the U.S. Food
and Drug Administration's Postmarket Surveillance Systems Including the Mini-Sentinel System
Adapted from Figure 1 based on material elsewhere. 103
Abbreviations: AERS, Adverse Event Reporting System; VAERS, Vaccine Adverse Event Reporting
System.
2.2.1 Mini-Sentinel System Data Infrastructure
At the outset, Congress's mandate - "to link and analyze safety data from multiple
sources with the goals of including, in aggregate.. .at least 100,000,000 patients by July 1,
2012"v104 - necessitated the cooperation of multiple data partners with access to sensitive
and legally protected health data. To facilitate their participation, the Mini-Sentinel
System was envisioned as a distributed data environment as opposed to a centralized data
repository.105 The advantages of a distributed data environment are discussed
elsewhere' 06 , but the main advantage is that it allows data partners to maintain control
over their data and its uses. It also mitigates many legal, proprietary, privacy, and security
concerns with respect to dealing with privately held, protected, and identifiable patient
data.
103 Platt et al., "The U.S. Food and Drug Administration's Mini-Sentinel Program: Status and Direction."
104 Food and Drug Administration Amendments Act of 2007, Public Law 110-85.
1o R. Platt et al., "The New Sentinel Network--improving the Evidence of Medical-product Safety," The
New England Journal of Medicine 361, no. 7 (2009): 645-647.
106 J. C. Maro et al., "Design of a National Distributed Health Data Network," Annals ofInternal Medicine
151, no. 5 (2009): 341-344.
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There were few existing distributed data models to rely on to guide development of
the proposed infrastructure. The most prominent was the Centers for Disease Control and
Prevention's Vaccine Safety Datalink (VSD), which performs vaccine safety research and
surveillance, using administrative and claims data from participating health plans
covering approximately 8.8 millions persons.'0 7 Other health data infrastructures that had
utilized a distributed data environment included the HMO Research Network
(HMORN)' 08, the Meningococcal Vaccine Study'0 9, and the concurrently developed
Post-licensure Immunization Safety Monitoring (PRISM) project'10 . All of these projects
employ similar data architectures that are generically depicted in Figure 3 below.
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Figure 3. Generic Depiction of a Distributed Data Network Architecture
In a distributed data environment, participating data partners/sites periodically use an
extract, transfer, and load procedure to generate copies of data and store them in a
separate, firewalled location onsite. The frequency of dataset refreshes varies by data
107 J. Baggs et al., "The Vaccine Safety Datalink: a Model for Monitoring Immunization Safety," Pediatrics
127 Suppi 1 (2011): S45-53.
108 R. Platt et al., "Multicenter Epidemiologic and Health Services Research on Therapeutics in the HMO
Research Network Center for Education and Research on Therapeutics," Pharmacoepidemiology and Drug
Safety 10, no. 5 (2001): 373-377.
10 P. Velentgas et al., "A Distributed Research Network Model for Post-marketing Safety Studies: The
Meningococcal Vaccine Study," Pharmacoepidemiology and Drug Safety 17, no. 12 (2008): 1226-1234.
"1o M. Nguyen et al., "The Food and Drug Administration's Post-Licensure Rapid Immunization Safety
Monitoring Program: Strengthening the Federal Vaccine Safety Enterprise," Pharmacoepidemiology and
Drug Safety 21 Suppl 1 (2012): 291-297.
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partner, but is generally quarterly and may be annual."' These datasets have been
transformed in order to adhere to a common data model, thereby ensuring identical file
structures, data fields, and coding systems. Important elements of the common data
model include demographic data, enrollment data, outpatient pharmacy dispensing data,
and healthcare encounter information including diagnoses and medical procedures (e.g.,
results from inpatient, outpatient, and emergency department visits). The Mini-Sentinel
System's common data model is described in detail elsewhere.12 As of July 2011, it
contains data from 17 partners covering over 300 million person-years of observation
time, 2.4 billion unique encounters including 38 million acute inpatient stays, and 2.9
billion dispensings of prescriptions.11 3 Further, the FDA reported that it met the 100
million persons requirement in the initiating legislation in December 2011.114
For the most part, the Mini-Sentinel System and the antecedent distributed data
networks primarily rely on administrative claims data as opposed to clinical data obtained
via electronic health records (EHRs). Others 1 5 have noted the relative strengths and
weaknesses associated with each type of data and I review them here. Administrative
claims data are advantageous because their primary purpose - billing for the utilization of
health services - ensures that common coding conventions and interoperable systems are
available for large sample sizes. Additionally, healthcare providers have strong incentives
to submit claims for all care provided and health insurers record nearly all medical
activities associated with their enrollees. Consequently, such records may provide more
complete capture than data contained in stand-alone EHRs originating in individual
physician practices or hospitals.
" Curtis et al., "Design Considerations, Architecture, and Use of the Mini-Sentinel Distributed Data
System."
112 Ibid.
" Platt et al., "The U.S. Food and Drug Administration's Mini-Sentinel Program: Status and Direction."
114 Melissa Robb, "FDA's Mini-Sentinel Exceeds 100 Million Lives (and Counting)... A Major Milestone
in Developing a Nationwide Rapid-response Electronic Medical Product Safety Surveillance Program,"
FDA Voice, June 29, 2012, http://blogs.fda.gov/fdavoice/index.php/201 2/06/fdas-mini-sentinel-exceeds-
100-million-lives-and-counting-a-major-milestone-in-developing-a-nationwide-rapid-response-electronic-
medical-product-safety-surveillance-program/.
15 Brian L. Strom, "Overview of Automated Databases in Pharmacoepidemiology," in
Pharmacoepidemiology, ed. Brian L. Strom, Stephen E. Kimmel, and Sean Hennessy, Fifth. (John Wiley &
Sons, 2011), 158-162; John Seeger and Gregory W. Daniel, "Commercial Insurance Databases," in
Pharmacoepidemiology, ed. Brian L. Strom, Stephen E. Kimmel, and Sean Hennessy, Fifth. (John Wiley &
Sons, 2011), 189-208; Schneeweiss and Avorn, "A Review of Uses of Health Care Utilization Databases
for Epidemiologic Research on Therapeutics."
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Some principal disadvantages of administrative claims data are the lack of clinical
richness (e.g., clinical notes) that may be found in EHRs and the potential lack of
generalizability since uninsured populations simply are not captured. Given the slow
adoption of EHRs in the United States" 6 (particularly ones that are interoperable) and the
need for additional technologies to effectively capture data in EHRs (e.g., natural
language processing), the routine inclusion of these data is still far off. H However, some
participating data partners that act as integrated delivery systems - i.e., those that both
insure patients and deliver their care - have supplemental data arising from laboratory
results and EHRs. Additionally, claims data may suffer from data quality issues due to
attempts to manipulate the payment system to secure more favorable reimbursement,
known as "upcoding." 8
Finally, the PRISM project within the Mini-Sentinel System linked data from
Immunization Information Systems (e.g., registries) that cover 14 million persons in eight
states.' This linkage was designed to capture immunizations received outside the
medical home (e.g., in a retail setting). In the future, attempts to link disease-based
registries, birth indices, death indices, and other sources of data are planned. 2 0
2.2.2 Mini-Sentinel System Capabilities
As shown in Figure 2, there are five capabilities of the Mini-Sentinel System, some
currently unrealized, which will be discussed in turn: 1) the development of population-
wide descriptive statistics with regard to treatments, medical conditions, and outcomes
via use of rapid retrieval queries; 2) the retrospective identification of new potential
signals of serious risk via data-mining; 3) the prospective identification of new potential
signals of serious risk via syndromic surveillance; 4) the retrospective assessment of pre-
specified safety signals using a singular analysis, or "one-time protocol-based
116 A. K. Jha et al., "Use of Electronic Health Records in U.S. Hospitals," The New England Journal of
Medicine 360, no. 16 (2009): 1628-1638.
117 However, new "meaningful use" regulations may hasten adoption. See Chun-Ju Hsiao et al., "Electronic
Health Record Systems and Intent to Apply for Meaningful Use Incentives Among Office-based Physician
Practices: United States, 2001-2011," NCHS Data Brief, no. 79 (November 2011): 1-8.
"1 Christopher S Brunt, "CPT Fee Differentials and Visit Upcoding Under Medicare Part B," Health
Economics 20, no. 7 (July 2011): 831-841.
119 D. A. Salmon et al., "Immunization-safety Monitoring Systems for the 2009 HINI Monovalent
Influenza Vaccination Program," Pediatrics 127 Suppl 1 (2011): S78-86.
120 Platt et al., "The U.S. Food and Drug Administration's Mini-Sentinel Program: Status and Direction."
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assessment"; and 5) the prospective assessment of pre-specified safety signals using
sequential database surveillance.
2.2.2.1 Rapid Retrieval Queries (Summary Tables and Modular Programs)
Rapid retrieval queries are standardized executable computer programs that are
distributed to Mini-Sentinel System data partners via the Mini-Sentinel Operations Center
(MSOC). These queries generate descriptive statistics regarding medical product usage,
diagnoses, and procedures. The data partners may execute these programs onsite and send
results back (via the MSOC) to the initiator for analysis, or may opt out of particular
queries. Only authorized users with appropriate credentials may distribute queries.
The simplest of these queries run against "summary tables" that are annual prevalence
counts of enrollment, diagnoses, procedures, and drug utilization.12 ' The prevalence
counts are stratified by year, sex, and age group. These queries are broad and describe
simple phenomena, e.g., how many females had acute myocardial infarctions in the years
2005-2008.122 They can be used for rapid feasibility checks12 3 and as part of sample size
calculations. They typically can be completed within a week of the initiating request from
the FDA. The MSOC reported that over 50 summary table queries were performed in
June and July 2011.124 The MSOC has posted the results'2 5 of some of these summary
tables including hip implant procedures, diagnoses of progressive multifocal
leukoencephalopathy, and asthma.
More complex queries are referred to as "modular programs" and these queries
operate in the same fashion but run against patient-level data as opposed to summary
tables. A key feature of modular programs is the parameterized nature of the code,
121 Mini-Sentinel Operations Center, "Distributed Query Tool - Summary Tables", August 10, 2011,
http://mini-sentinel.org/dataactivities/details.aspx?ID=117.
122 Mini-Sentinel Operations Center, "Assessments of Diagnoses and Medical Procedures I Acute
Myocardial Infarctions", April 27, 2012, http://mini-
sentinel.org/assessments/diagnosesand_ medical_procedures/details.aspx?ID=132.
123 A feasibility check generally considers whether a database contains sufficient exposures or outcomes in
appropriate populations to answer the study question.
124 Curtis et al., "Design Considerations, Architecture, and Use of the Mini-Sentinel Distributed Data
System."
125 Mini-Sentinel Operations Center, "Assessments of Diagnoses and Medical Procedures", n.d.,
http://mini-sentinel.org/assessments/diagnosesandmedical_procedures/default.aspx.
126 For a brief summary, see Table 3, in Curtis et al., "Design Considerations, Architecture, and Use of the
Mini-Sentinel Distributed Data System."
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meaning it can be used repeatedly with modifications to the input information. They
allow for more complicated questions, e.g., how many females prescribed new/incident
oral anti-diabetic medications had acute myocardial infarctions? There are four
established modular programs: 1) describes incident/prevalent medication use or
procedures; 2 7 2) describes incident/prevalent medication use or procedures among
individuals with particular diagnoses; 2 8 3) describes outcomes among incident users of
medications with/without particular diagnoses; 2 9 4) describes concomitant medication
use among incident/prevalent users of another medication with/without particular
diagnoses.13 0 The current capacity for modular program requests is one per week as part
'3'of a service agreement with data partners and the FDA. Modular program requests can
typically be completed within a few weeks of the initiating request from the FDA.
Modular programs 1, 2, and 4 most closely mirror previous studies of medical
product utilization. They can be useful for understanding prescribing patterns or
"channeling" behaviors, or for observing usage patterns related to specific subgroups.
Modular program 3 (MP3) is a more unique and powerful program for safety signal
assessment because it describes crude (i.e., mostly unadjusted) potentially medical
product-associated adverse event rates. The results of modular program 3 could be used
to develop crude risk estimates. The MSOC has posted the results of two MP3 queries
evaluating smoking cessation drugs and cardiovascular outcomes 3 2 , and angiotensin-II
receptor blockers and celiac disease'm. Several new modular programs are actively being
developed as well as enhancements to MP3.
127 Mini-Sentinel Operations Center, "Module 1: Drug Use - General Characterization", August 17, 2011,
1, http://www.mini-sentinel.org/workproducts/DataActivities/Mini-SentinelModular-Program-
_v1 .0.pdf.
128 Mini-Sentinel Operations Center, "Module 2: Drug Use - By Medical Condition", August 17, 2011, 2,
http://www.mini-sentinel.org/workproducts/Data 
_Activities/Mini-SentinelModular-Program-2 vI .0.pdf.
129Mini-Sentinel Operations Center, "Module 3: Drug Use - Incident Outcomes", August 17, 2011, 3,
http://www.mini-sentinel.org/workproducts/DataActivities/Mini-Sentinel Modular-Program-3_v1.0.pdf.
130 Mini-Sentinel Operations Center, "Module 4: Drug Use - Concomitant Use", August 17, 2011, 4,
http://www.mini-sentinel.org/work_products/Data Activities/Mini-Sentinel Modular-Program-4_vi .0.pdf.
131 Brown, J.S., Personal communication, March 5, 2012.
132 Mini-Sentinel Operations Center, "Smoking Cessation Drugs & Cardiovascular Outcomes", January 17,
2012, http://www.mini-sentinel.org/work_products/Assessments/Mini-Sentine Smoking-Cessation-Drugs-
and-Selected-Cardiovascular-Outcomes.pdf.
33 Mini-Sentinel Operations Center, "Angiotensin II Receptor Blockers & Celiac Disease", January 17,
2012, http://www.mini-sentinel.org/work_products/Assessments/Mini-Sentinel 
_Angiotensin-II-Receptor-
Blockers-and-Celiac-Disease.pdf.
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2.2.2.2 Data-mining and Syndromic Surveillance
Data-mining and syndromic surveillance are both signal detection methods, which are
performed without a priori specification of a hypothesized medical product-associated
risk. Table 1 is a convenient way to classify these activities based on 1) their temporal
perspective (i.e., when the data are sampled relative to when the sampling design is
specified) and 2) the existence of a pre-specified hypothesis of medical product-
associated risk, implying the existence of supporting data that suggest a potential risk.
Temporal Perspective
Retrospective Prospective
Exposure- Pre-Specified Protocol based one-time Sequential Database
Outcome assmnsSurveillance
IPair of Non pre-specified Data-mining ydro
Table 1. Types of Active Postmarket Risk Identification and Analysis 3 4
Data-mining is a retrospective assessment of an existing database, and might likely
employ disproportionality analyses similar to techniques currently used to analyze data in
the spontaneous reporting system.135 Syndromic surveillance is prospective monitoring
for certain outcomes, irrespective of medication usage, that are present beyond some
baseline level. In the past, the Centers for Disease Control and Prevention and other local
public health agencies have monitored less serious outcomes, e.g., fever and influenza-
like symptoms, to track infectious disease outbreaks.136 Regulatory authorities might
adapt this technique, by generating a list of known medical product-associated outcomes
such as aplastic anemia or Stevens Johnson Syndrome, and create an alerting system
triggered by the arrival of new data, i.e. a data refresh.
134 Sebastian Schneeweiss and Jennifer Nelson, "Mini-Sentinel Methods Core: Accomplishments and
Lessons Learned" (presented at the International Society of Pharmacoepidemiology (ISPE), Chicago, IL,
August 17, 2011).
135 Almenoff et al., "Novel Statistical Tools for Monitoring the Safety of Marketed Drugs."
136 W Katherine Yih et al., "Evaluating Real-time Syndromic Surveillance Signals from Ambulatory Care
Data in Four States," Public Health Reports (Washington, D.C.: 1974) 125, no. 1 (February 2010): 111-
120; Jian Xing, Howard Burkom, and Jerome Tokars, "Method Selection and Adaptation for Distributed
Monitoring of Infectious Diseases for Syndromic Surveillance," Journal ofBiomedical Informatics 44, no.
6 (December 2011): 1093-1101.
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Both data-mining and syndromic surveillance are in the very earliest stages of
development in Mini-Sentinel System, and have not been piloted. 7 They are shown
grayed in Figure 2 and Table 1 to reflect their embryonic development. However, once
these capabilities are developed, they could serve as a technical solution to another of the
IOM's recommendations: "systematically implement statistical-surveillance methods on
a regular and routine basis for the automated generation of new safety signals."138 For the
purpose of analyzing the optimal use of the Mini-Sentinel System, this dissertation
presumes safety signals have been detected and thus, will not further address these
capabilities. However, when considering questions regarding the appropriate size of the
future Sentinel System and the value of this system in fulfilling the FDA's
responsibilities, the speed and thoroughness of safety signal detection beyond the existing
passive spontaneous reporting systems merits more research.
2.2.2.3 Protocol-Based One-Time Assessments
Protocol-based one-time assessments refer to retrospective studies to assess particular
exposure-outcome pairs using a singular end-of-study analysis. These assessments use
customized protocols that adjust for confounding beyond age and sex using more
advanced techniques' 39; use a variety of epidemiologic study designs'4 0 ; and generate
analytic results. These assessments may include medical chart adjudication of exposure,
137 Davis, R. and Kulldorff, M., "Statistical Methods Development Details I Vaccine Safety Monitoring -
Adverse Events", November 16, 2010, http://mini-
sentinel.org/methods/methodsdevelopment/details.aspx?ID=1028.
138 Institute of Medicine (IOM), The Future of Drug Safety: Promoting and Protecting the Health of the
Public, 7.
139 J. A. Rassen and S. Schneeweiss, "Using High-dimensional Propensity Scores to Automate
Confounding Control in a Distributed Medical Product Safety Surveillance System,"
Pharmacoepidemiology and Drug Saftty 21 Suppl 1 (2012): 41-49; J. A. Rassen, J. Avorn, and S.
Schneeweiss, "Multivariate-adjusted Pharmacoepidemiologic Analyses of Confidential Information Pooled
from Multiple Health Care Utilization Databases," Pharmacoepidemiology and Drug Safety 19, no. 8
(2010): 848-857; R. J. Glynn, J. J. Gagne, and S. Schneeweiss, "Role of Disease Risk Scores in
Comparative Effectiveness Research with Emerging Therapies," Pharmacoepidemiology andDrug Safety
21 Suppl 2 (2012): 138-147; J. A. Rassen et al., "Privacy-maintaining Propensity Score-based Pooling of
Multiple Databases Applied to a Study of Biologics," Medical Care 48, no. 6 Suppl (2010): S83-9.
140 J. J. Gagne et al., "Design Considerations in an Active Medical Product Safety Monitoring System,"
Pharmacoepidemiology and Drug Safety 21 Suppl 1 (2012): 32-40.
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outcomes, or covariates.14' In short, these assessments have much in common with
traditional multi-site pharmacoepidemiologic studies using administrative databases. One
difference is that the distributed database model may limit typical multi-variate
regression-based analyses on patient-level data, which would require pooling of patient-
level data across data partners.14 2 However, development of distributed regression
techniques, i.e., regression that can be performed on non-pooled data, is on the
horizon1 4 3, and some Mini-Sentinel System investigators are actively researching more
sophisticated distributed approaches. In the interim, propensity scores and other summary
statistics are used to allow for a greater inclusion of potential confounding variables.14 4
Three protocol-based one-time assessments have been initiated as pilots: 1) venous
thromboembolism following quadrivalent human papilloma virus vaccine;' 4 5 and 2)
angioedemia following administration of particular anti-hypertensives;14 6 and 3)
intussusception following rotavirus vaccine.'47
2.2.2.4 Sequential Database Surveillance
Sequential database surveillance is another means of assessing evidence regarding a
statistical association with respect to a pre-specified exposure-outcome pair. It differs
from protocol-based one-time assessments in that it is performed prospectively with
multiple, repeated assessments or hypothesis tests. Generally, to conduct a sequential
database surveillance evaluation, one prospectively gathers data from multiple databases
(e.g., population-based health data) to monitor the incidence rate of a medical product-
141 See, for example, Michael D. Nguyen et al., "Monitoring for Venous Thromboembolism After Gardasil
Vaccination," Mini-Sentinel, March 6, 2012, http://www.mini-sentinel.org/workproducts/PRISM/Mini-
Sentinel PRISMGardasil-and-Venous-Thromboembolism-Protocol.pdf.
142 See Darren Toh et al., "Protocol for Signal Refinement of Angioedema Events in Association with Use
of Drugs That Act on the Renin-Angiotensin-Aldosterone System," Mini-Sentinel, July 18, 2011,
http://www.mini-sentinel.org/workproducts/Assessments/Mini-Sentinel Angioedema-and-
RAASProtocol.pdf.... "Performing a centralized, conventional multivariable-adjusted analysis to obtain
[Mini-Sentinel System]-wide estimates [of risk] may not be the preferred approach because it requires
transferring of potentially identifiable individual-level information."
143 Alan F. Karr et al., "Privacy-Preserving Analysis of Vertically Partitioned Data Using Secure Matrix
Products," Journal of Official Statistics 25, no. 1 (2009): 125-138.
144 M. A. Brookhart et al., "Confounding Control in Healthcare Database Research: Challenges and
Potential Approaches," Medical Care 48, no. 6 Suppl (2010): S 114-20.
"5 Nguyen et al., "Monitoring for Venous Thromboembolism After Gardasil Vaccination."
146 Toh et al., "Protocol for Signal Refinement of Angioedema Events in Association with Use of Drugs
That Act on the Renin-Angiotensin-Aldosterone System."
147 Greene, Sharon K. Personal communication. June 14, 2012.
47
adverse event pair under surveillance. One then compares the observed incidence rate to
an expected rate, which is calculated based on either a concurrent-, historical-, or self-
controlled group. Comparisons are made at regular intervals as data accrue using
sequential statistical tests with pre-specified signaling thresholds. If the test statistic
exceeds the threshold, then a statistical signal of excess risk is identified, the
hypothesized exposure-outcome association is strengthened, and the null hypothesis of no
excess risk is rejected. This signal is ordinarily followed by confirmatory assessments
and review to validate or refute the finding.
Sequential database surveillance is not a new technique in medical product
surveillance although it has largely been performed to study vaccines14 that are
administered to healthy people and where there is less potential confounding. One
sequential database surveillance protocol is being tested in the Mini-Sentinel System: the
risk of acute myocardial infarction associated with oral anti-diabetic agents. 49 Another
protocol is in development for sequential analyses related to influenza vaccine safety. 50
The literature on prospective sequential database surveillance is reviewed herein in
Section 5.
This dissertation is focused on developing qualitative and quantitative tools to aid
regulators in utilizing the sequential database surveillance capabilities in the Mini-
Sentinel System. However, prior to engaging in the specifics of using the Mini-Sentinel
System for these purposes, it is necessary to first examine how the FDA uses postmarket
evidence to support regulatory decision-making. I turn to that topic next.
141 Yih et al., "Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink
Project."
149 B. Fireman et al., "A Protocol for Active Surveillance of Acute Myocardial Infarction in Association
with the Use of a New Antidiabetic Pharmaceutical Agent," Pharmacoepidemiology and Drug Safety 21
Suppl 1 (2012): 282-290.
50)Greene, Sharon K. Personal communication, June 14, 2012.
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3 FDA REGULATORY DECISION-MAKING
This section connects the U.S. Food and Drug Administration (FDA)'s evidence-
generation activities 15 via its postmarket systems (as generally discussed in the previous
section) to regulatory decision-making while embedding both of these activities in the
new legal framework enacted in the Food and Drug Administration Amendments Act. As
will be explained next, the emergence of new safety information 5 2 in the postmarket
compels the FDA to re-evaluate a medical product's benefit-risk profile and make a
regulatory decision. Such a decision may involve a) taking regulatory actions to influence
medical product utilization or a deliberate decision to forego such actions, or b) taking
regulatory actions to generate new knowledge on a product's benefits and risks. It can
also pursue these two courses simultaneously (and often does) when a safety signal
cannot be fully resolved based on the existing evidence, but interim regulatory actions are
taken while awaiting additional analyses.
It is important to distinguish the pursuit of evidence generation for the sake of science
and the pursuit of evidence generation for the sake of regulatory decision-making. With
regard to the former, the Institute of Medicine has said that:
"The science of drug safety concerns questions of causal, not just statistical, relationships.
That is, the important drug-safety question is whether drug exposure actually causes an
adverse outcome, not simply whether such an outcome occurs more frequently in people
who choose to take the drug."
153
Yet, safety signals of pressing public health importance may necessitate regulatory
action, and time and ethical constraints may rule out research more conducive to strict
causal inference. 54 This mismatch between the need for action and the lack of ideal
evidence to support it has led many public health policymaking entities - e.g., the
Environmental Protection Agency, the Agency for Healthcare Research and Quality - to
151 There are additional evidence generation activities that have not been explicitly discussed herein such as
clinical pharmacology activities, pharmacogenomic activities, and other animal and laboratory studies.
These studies also support regulatory decision-making, but are beyond the scope of this dissertation.
152 "New safety information" is a regulatory term which is explained infra at note 216.
s5 Institute of Medicine (IOM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs,
115.
154 Causal inference is discussed in greater detail herein in subsection 3.4.
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establish frameworks15 5 designed to systematically grade the strength of a body of
evidence and make determinations about causal inference. 15 6 The FDA, as of yet, has not
systematically adopted one of these frameworks for postmarket evidence. 5 7 Interestingly,
these frameworks are used to assess evidence that has already been developed and draw
conclusions regarding its strength. Congress has directed the FDA to proceed in the
reverse order: to set a goal or standard of sufficient evidence, and then assess the ability
of evidence-generating systems to attain that goal.
155 For example, see U.S. EPA, Guidelinesfor Carcinogen Risk Assessment (Washington, D. C.: U.S.
Environmental Protection Agency, 2005), http://www.epa.gov/cancerguidelines/; D. K. Owens et al.,
Methods Guide for Effectiveness and Comparative Effectiveness Reviews, AHRQ Methods for Effective
Health Care (Rockville (MD): Agency for Healthcare Research and Quality (US), 2008),
http://www.ncbi.nlm.nih.gov/pubmed/21433399.
156 Complete coverage of this literature is beyond the scope of this dissertation. What is important is that
the reader understands the potential outcomes that result after this grading exercise. For example, the
Institute of Medicine has proposed "the following categorization of the strength of the overall evidence for
or against a causal relationship from exposure to disease:
1. Sufficient: The evidence is sufficient to conclude that a causal relationship exists.
2. Equipoise andAbove: The evidence is sufficient to conclude that a causal relationship is at least as
likely as not, but not sufficient to conclude that a causal relationship exists.
3. Below Equipoise: The evidence is not sufficient to conclude that a causal relationship is at least as
likely as not, or is not sufficient to make a scientifically informed judgment.
4. Against: The evidence suggests the lack of a causal relationship."
For more, see Institute of Medicine (IOM), Improving the Presumptive Disability Decision-Making Process
for Veterans, ed. Catherine C. Bodurow and Jonathan M. Samet (The National Academies Press, 2008),
189, http://www.nap.edu/openbook.php?recordid=l 1908; Institute of Medicine (IOM), Adverse Efftcts of
Vaccines: Evidence and Causality (Washington, D.C.: The National Academies Press, 2012); Neal A
Halsey et al., "Algorithm to Assess Causality After Individual Adverse Events Following Immunizations,"
Vaccine 30, no. 39 (August 24, 2012): 5791-5798.
m For initial (and continued) licensure of products, the FDA does set the minimum standard to be
"substantial evidence." Substantial evidence is defined as "evidence consisting of adequate and well-
controlled investigations, including clinical investigations, by experts qualified by scientific training and
experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and
responsibly be concluded by such experts that the drug will have the effect it purports or is represented to
have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed
labeling thereof. If the Secretary determines, based on relevant science, that data from one adequate and
well-controlled clinical investigation and confirmatory evidence (obtained prior to or after such
investigation) are sufficient to establish effectiveness, the Secretary may consider such data and evidence to
constitute substantial evidence for purposes of the preceding sentence." Codified at 21 U.S.C. § 355(d).
Additionally, with regard to therapies for diabetes mellitus and cardiovascular events, the FDA is quite
specific: "If the premarketing application contains clinical data that show that the upper bound of the two-
sided 95 percent confidence interval for the estimated increased risk (i.e., risk ratio) is between 1.3 and 1.8,
and the overall risk-benefit analysis supports approval, a postmarketing trial generally will be necessary to
definitively show that the upper bound of the two-sided 95 percent confidence interval for the estimated
risk ratio is less than 1.3." See U.S. Department of Health and Human Services, Food and Drug
Administration, and Center for Drug Evaluation and Research, "Guidance for Industry: Diabetes Mellitus:
Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes (Final)",
December 17, 2008,
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM07162
7.pdf.
50
Recall that per the Food and Drug Administration Amendments Act, when the FDA is
confronted with new safety information in the postmarket, it must make a determination
on whether its publicly-funded postmarket safety systems (including the Mini-Sentinel
System) will generate sufficient knowledge to make a regulatory decision, or whether
additional privately-funded (i.e. manufacturer-funded) studies are necessary. 5 8 As of this
writing, the FDA has not yet stated the basis on which determinations of sufficiency will
be made. Presumably, the Mini-Sentinel System's "laboratory" status has allowed the
FDA to defer construction of a sufficiency standard on the grounds that the capabilities of
the Mini-Sentinel System as an evidence-generating system are unknown at this time.
Still, the legislation directs the FDA to anticipate the strength of evidence needed to
support particular regulatory actions (or deliberate choices not to take such actions), and
then to choose appropriate systems to generate that evidence. The Mini-Sentinel System
is just one of such systems.
In this section, I draw the reader's attention to the statutes, regulations, and guidance
that inform and govern the FDA's options for regulatory action, and specifically, what
these texts require with respect to findings of causality and the strength of the evidence.
As the reader will discover, with the exception of one particular regulatory action, the law
is unclear on this issue, leaving much to the judgment of the FDA. 159 In general, as will
be discussed more thoroughly in subsection 3.4, the ability to infer causal relationships
from observational data - e.g., the data available in the Mini-Sentinel System - is
challenging at best.' 60 However, if the FDA determines that robust findings on causality
(either affirmation or rejection) are necessary precedents to particular regulatory actions,
then the FDA's postmarket systems (including the Mini-Sentinel System) must be
158 § 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355(o)(3)(B).
159 This ambiguity leads to scientific and policy disagreements within the FDA. See, for example, a
summary of discordant views with respect to the rosiglitazone-cardiovascular outcomes safety signal in
Institute of Medicine (IOM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs, 131-
133. Incidentally, the Agency for Healthcare Research and Quality found similar disagreements among
their experts even when using a common framework. See Nancy D N D Berkman et al., Reliability Testing
of the AHRQ EPC Approach to Grading the Strength of Evidence in Comparative Effectiveness Reviews,
AHRQ Methods for Effective Health Care (Rockville (MD): Agency for Healthcare Research and Quality
(US), 2012), http://www.ncbi.nlm.nih.gov/pubmed/22764383.
160 See generally Miguel Hern6n and Jamie Robins, Causal Inference, v1. 10.17 ed. (Chapman & Hall/CRC,
2012), 25-40, http://www.hsph.harvard.edu/faculty/miguel-hernan/causal-inference-book/; Institute of
Medicine (IOM), Improving the Presumptive Disability Decision-Making Process for Veterans, Chapter 7
and Appendix J.
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evaluated with respect to their ability to generate evidence to support such findings. In
other words, the legal standards to support particular regulatory decision-making factor
into whether the Mini-Sentinel System will be deemed a sufficient evidence-generation
system.
3.1 Pre-requisites to Sufficiency: New Safety Information and Purpose
Per the Food and Drug Administration Amendments Act, two necessary precursors
to the FDA's sufficiency decision are the establishment of new safety information' and
the designation of a purpose (i.e., a goal) for evidence generation:
"(i) To assess a known serious risk related to the use of the drug involved.
(ii) To assess signals of serious risk related to the use of the drug.
(iii) To identify an unexpected serious risk when available data indicates the potential for
a serious risk."162
The determination of sufficiency will logically be different for the three
aforementioned purposes in the legislation. These three purposes each imply a differing
"maturity" to the existing evidence regarding the pre-specified exposure-outcome pair.
The first purpose, assessing known serious risks, implies a causal relationship is
known and the risk is likely included in the FDA-approved product labeling. Examples of
known serious risks that might still require regulatory action include an increased
incidence of supratherapeutic effects, e.g., insulins-hypoglycemia, that change the
benefit-risk profile of the product.
The second purpose - to assess signals of serious risk - implies that a signal has been
detected, but has not yet been adequately quantified and a determination of causality, if
attempted, has not been conclusive. Examples of potential signals of serious risk are
161 New safety information is defined as "information derived from a clinical trial, an adverse event report,
a postapproval study (including a study under section 505(o)(3)), or peer-reviewed biomedical literature;
data derived from the postmarket risk identification and analysis system under section 505(k); or other
scientific data deemed appropriate by the Secretary about- (A) a serious risk or an unexpected serious risk
associated with use of the drug that the Secretary has become aware of (that may be based on a new
analysis of existing information) since the drug was approved, since the risk evaluation and mitigation
strategy was required, or since the last assessment of the approved risk evaluation and mitigation strategy
for the drug; or (B) the effectiveness of the approved risk evaluation and mitigation strategy for the drug
obtained since the last assessment of such strategy." Codified at 21 U.S.C. § 355-1(b)(3).
162 § 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355(o)(3)(B).
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published quarterly by the FDA on its website.'63 These signals may or may not be
included in the product's label, but often result in regulatory action in the form of safety-
related label changes.1 64
The third purpose - identifying an unexpected serious risk' 65 when available data
indicates the potential for a serious risk - implies that some pre-specification of an
exposure-outcome pair has occurred, that this outcome is not (fully) indicated in the
labeling166 , and that signal detection (i.e., identification) is ongoing. A good example is
referenced herein167 regarding a fingolimod-bradycardia signal, which was more severe
than first anticipated. Other examples might be medical products presumed to cause
teratogenic effects that were not directly observed (e.g., perhaps based on evidence from
animal studies), or medical products that are part of a class when class-wide risks have
been detected.
Typically, these three purposes are associated with traditional safety issues, i.e., the
emergence of adverse events. Also, a manufacturing quality issue in which the active
pharmaceutical ingredient is omitted or undersupplied might be generally regarded as a
safety issue. However, Evans168 goes further and concludes that the FDA may require a
postmarket requirement in accordance with the three purposes above based on data
suggesting a lack of benefit (i.e., what she refers to as "non-response" or "efficacy
failure"' 69). She grounds her argument in the legislation's definition of adverse drug
163 Center for Drug Evaluation and Research, "Adverse Events Reporting System (AERS) - Potential
Signals of Serious Risks/New Safety Information Identified from the Adverse Event Reporting System
(AERS)," WebContent, n.d.,
http://www.fda.gov/drugs/guidanceComplianceRegulatorylnformation/Surveillance/AdverseDrugEffects/u
cm082196.htm.
64 Abbey Powers and G Elliott Cook, "Potential Safety Signals and Their Significance," Archives of
Internal Medicine 172, no. 1 (January 9, 2012): 72-73.
165 § 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85. "The term
'unexpected serious risk' means a serious adverse drug experience that is not listed in the labeling of a
drug, or that may be symptomatically and pathophysiologically related to an adverse drug experience
identified in the labeling, but differs from such adverse drug experience because of greater severity,
specificity, or prevalence." Codified at 21 U.S.C. § 355-1(b)(8).
166 The legislative language on this point is difficult to parse since it allows for the outcome to be unlabeled
or perhaps "under-labeled" in a sense that the severity, specificity or prevalence is not well-defined.
167 See supra at note 43. This example might also legitimately be an example of the first purpose: assessing
a known serious risk.
168 B. J. Evans, "Seven Pillars of a New Evidentiary Paradigm: The Food, Drug, and Cosmetic Act Enters
the Genomic Era," Notre Dame Law Review 85, no. 2 (2010): 480,498-500.
169 To be clear, non-response or efficacy failure referenced in Evans is not associated with manufacturing
problems. Rather, efficacy failure varies by the individual and is likely attributable to unknown scientific
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experience"7 , which includes, in part, "any failure of expected pharmacological action of
the drug." She argues that a lack of benefit would meet the requirements of one of the
three purposes above if the lack of benefit resulted in serious harm 1 . The IOM has
endorsed this interpretation172 and is particularly concerned with therapeutics approved
based on surrogate endpoints in this regard.
Herein, I do not explicitly consider the use of the FDA's postmarket safety systems
(including the Mini-Sentinel System) as an evidence generation system to support
regulatory decision-making when the precipitating issue is a lack of benefit. Others have
suggested that systems like the Mini-Sentinel System - large-scale administrative
database networks - could support such evidence generation. 7 3
3.2 FDA Guidance: Tracked Safety Issues
Given new safety information, the FDA can generate a tracked safety issue, which is
a management tool that is a convenient operational unit of analysis for this dissertation. 7 4
The FDA has stated that a tracked safety issue will be established if the identified safety
issue has the potential to lead to any of the following actions:
* "Withdrawal of FDA approval of a drug
- Withdrawal of an approved indication
* Limitations on a use in a specific population or subpopulation
factors involving an individual's genetic makeup. The serious harm that may result is not the harm caused
by the drug itself, but the harm caused because the patient has foregone other therapeutic options. Evans
refers to this as a "lost-chance" injury, based on "lost-chance" doctrine, which, in some states, allows
lawsuits from patients who have suffered irreversible disease progression as a result of a delay in treating or
diagnosing their disease. Evans, "Seven Pillars of a New Evidentiary Paradigm," 499.
"0 § 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85. "The term
'adverse drug experience' means any adverse event associated with the use of a drug in humans, whether or
not considered drug related, including-(A) an adverse event occurring in the course of the use of the drug
in professional practice; (B) an adverse event occurring from an overdose of the drug, whether accidental or
intentional;(C) an adverse event occurring from abuse of the drug; (D) an adverse event occurring from
withdrawal of the drug; and (E) any failure of expected pharmacological action of the drug." Codified at 21
U.S.C. § 355-1(b)(1).
171 See supra at note 6.
Institute of Medicine (IOM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs, 31.
"The present committee considers providing FDA with that authority [to investigate any failure of the
expected pharmacological action of the drug] to be in the interest of the public's health. When questions
arise about the health benefits of a drug, studies to document a drug's effectiveness may be as critical for
ensuring that the benefit-risk profile of a drug remains favorable as studies that investigate its risks."
173 S. Toh et al., "Comparative-effectiveness Research in Distributed Health Data Networks," Clinical
Pharmacology and Therapeutics 90, no. 6 (2011): 883-887.
174 A tracked safety issue implies that some degree of signal detection is complete, which is important in
this dissertation since I am primarily concerned with FDA decision-making after signal detection has
suggested an exposure-outcome pair to monitor.
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- Additions or modifications to the Warnings and Precautions, or Contraindications sections of
the labeling, or the Medication Guide or other required Patient Package Insert, including
safety labeling changes required under the Food and Drug Administration Amendments Act
(FDAAA)
- Establishment of or changes to the proprietary name/container label/labeling/packaging to
reduce the likelihood of medication errors
- Establishment or modification of a risk evaluation and mitigation strategy (REMS)
- A requirement that a sponsor conduct a safety-related postmarketing trial or study
- The conduct of a safety-related observational epidemiological study by FDA."' 75
A tracked safety issue relates to a particular exposure-outcome pair and is classified as
emergency, priority, or standard based on a number of characteristics that define the
safety issue.76 Once classified, the FDA examines the existing evidence, re-evaluates the
risk-benefit profile for the drug, and determines whether regulatory action is necessary.
Figure 4 illustrates the series of decisions the FDA must make once a tracked safety issue
is evaluated.
The FDA's first decision (marked in Figure 4 as Decision 1) concerns initial
regulatory actions. To be clear, a regulatory action can encompass a) actions intended to
inform/influence patient and prescriber behavior (e.g., labeling changes, restriction of
access to particular therapies), b) deliberate choices to maintain the status quo, which is
routine monitoring, or c) actions that generate additional evidence (e.g., issuance of a
postmarket requirement). Additionally, the FDA can pursue the first and third courses
simultaneously. Should Decision 1 involve an evidence-generating regulatory action and
there is a desire to pursue privately-funded postmarket requirements, the FDA is required
to make a sufficiency finding as discussed previously (shown in Figure 4 as Decision 2).
175 U.S. Department of Health and Human Services, Food and Drug Administration, and Center for Drug
Evaluation and Research, "Guidance: Classifying Significant Postmarketing Drug Safety Issues (Draft)",
March 8, 2012, 3,
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM29521
1.pdf.
176 U.S. Department of Health and Human Services, Food and Drug Administration, and Center for Drug
Evaluation and Research, "Guidance: Classifying Significant Postmarketing Drug Safety Issues (Draft)."
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Regulatory Actions to Influence Utilization Outcomes
Figure 4. FDA Decision Process Following Identification and Evaluation of a Tracked Safety Issue
Abbreviations: TSI, tracked safety issue; FDA, Food and Drug Administration; PMR, postmarket
requirement; CDER, Center for Drug Evaluation and Research; AERS, Adverse Event Reporting System;
SDS, sequential database surveillance.
3.3 Plausible Regulatory Actions
Of the potential regulatory actions described in the tracked safety issue guidance, I do
not consider issues related to medication error management. For the remaining actions, I
review the legal and regulatory standards for evidence to support such actions. To be
clear, I review these standards because a statutorily required sufficiency determination on
the evidence generation capabilities of the FDA's postmarket systems depends on
consideration of the strength of evidence necessary to support particular regulatory
actions. For example, if regulators determine that a strong finding (either affirmation or
rejection) of causality is needed to support a particular regulatory action, then the FDA's
postmarket systems (including the Mini-Sentinel System) must be evaluated with respect
to their likelihood of generating that finding.
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3.3.1 Safety-Related Labeling Changes
The most common regulatory action performed by the FDA is to make changes to the
product's FDA-approved labeling. This labeling is the FDA's principal means of
communicating benefits and risks associated with a medical product. In general, changes
to a product's label are normal and expected. These changes reflect the evolving nature of
the benefit-risk profile of a medication as it is used in larger and more diverse
populations. However, because a label is intended to influence a medication's adoption
and use, historically, its contents have been a source of conflict between the FDA and
manufacturers. 7 7 In 2007, Congress eliminated many potential conflicts by expanding
the FDA's authority to mandate safety-related labeling changes given emergent safety
information.17 8 The FDA has issued guidance with respect to how it will use this new
authority' 79, but the evidence bar for certain safety-related label changes was already
established in FDA regulations.
Specifically, the Warnings and Precautions section of the label is intended to
document serious, or otherwise clinically significant, adverse drug reactions'8 0 , and:
"the labeling must be revised to include a warning about a clinically significant hazard as
soon as there is reasonable evidence of a causal association with a drug; a causal
relationship need not have been definitely established."' 8 '
The reader should note that this regulatory action is the only regulatory action with
explicit statements with regard to causality. The FDA's guidance on this section also
directs the manufacturer to include "anticipated" adverse drug reactions that have not yet
been observed but might be reasonably suspected to occur based on a) known
pharmacologic effects, chemical effects, or class-based effects; or b) animal studies (e.g.,
177 See, for example, a summary of the FDA's negotiations with Merck regarding the Vioxx@ (rofecoxib)
label in David A. Kessler and David C. Vladeck, "A Critical Examination of the FDA's Efforts To Preempt
Failure-To-Warn Claims," Georgetown Law Journal 96 (2008): n82.
178 § 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355(o)(4).
179 Department of Health and Human Services et al., "Guidance for Industry: Safety Labeling Changes -
Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act (Draft)", April 12, 2011,
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM25078
3.pdf.
180 U.S. Department of Health and Human Services et al., "Guidance for Industry: Warnings and
Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and
Biological Products - Content and Format (Final)", October 11, 2011,
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM07509
6.pdf.
18 21 CFR § 201.57(c)(6) and 21 CFR § 201.80(e), April 1, 2012 edition.
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studies that might indicate teratogenicity).s 2 The "anticipated" language bears a
similarity to the definition of "unexpected serious risk" in the FDAAA. Both imply that
prior knowledge makes the outcome likely even if it is not yet observed. Also, the FDA
directs the manufacturer to include adverse drug reactions that may be associated with
unapproved (i.e., off-label) uses.'s3
In contrast, the Contraindications section of the label requires that "known hazards
and not theoretical possibilities must be listed" and is intended to describe situations
when "the drug should not be used because the risk of use (e.g., certain potentially fatal
adverse reactions) clearly outweighs any possible therapeutic benefit."1 84 The FDA
guidance contains similar language regarding "anticipated adverse drug reactions" in the
Contraindications section.' 85 To distinguish the Warnings and Precautions section from
the Contraindications section, information in the former is intended to qualify/moderate
use of a medical product (e.g., certain subpopulations may be at higher risk for certain
adverse events) whereas information in the latter is intended to eliminate particular uses
(e.g., certain subpopulations should never use this product). The Boxed Warnings section
of the label is a subset of information already included in the either the Warnings and
Precautions or the Contraindications section.
For completeness, the Adverse Reactions section of the label is required to list the
adverse reactions that occur with the drug and with drugs in the same pharmacologically
active and chemically related class.'8 6 This list is limited to "adverse events for which
there is some basis to believe there is a causal relationship between the drug and the
occurrence of the adverse event."' 87 Despite FDA's guidance to the contrary8 8 , this
182 U.S. Department of Health and Human Services et al., "Guidance for Industry: Warnings and
Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and
Biological Products - Content and Format (Final)."
183 Ibid.
184
"8 21 CFR § 201.57(c)(5) and 21 CFR § 201.80(d), April 1, 2012 edition.
185 U.S. Department of Health and Human Services et al., "Guidance for Industry: Warnings and
Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and
Biological Products - Content and Format (Final)."
18 21 CFR 201.57(c)(7)(i), April 1, 2012 edition.
187 21 CFR §201.57(c)(7), April 1, 2012 edition.
188 U.S. Department of Health and Human Services et al., "Guidance for Industry: Adverse Reactions
Section of Labeling for Human Prescription Drug and Biological Products-Content and Format (Final)",
January 18, 2006,
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM07505
7.pdf.
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section is more a laundry list of documented adverse reactions. The FDA also indicates in
guidance that it does not believe that changes to the Adverse Reactions section alone
would normally trigger a "safety-related label change" action per the 2007 legislation.' 89
Powers et al. documented the percentage of potential signals of serious risk identified
by the Adverse Event Reporting System (AERS) that resulted in safety-related labeling
changes, and a majority of these changes were in the Warnings and Precautions
section. In her study of AERS-identified signals, only two resulted in changes to the
Contraindications section: Exjade@ (deferasirox) and Saphris@ (asenapine). It is unclear
whether evidence beyond the AERS signal was required to generate changes to the
Contraindications section. Others' 9' have taken a different approach by examining safety-
related labeling changes and working backward to identify the evidence used to initiate
them. Both confirm changes to the Warnings and Precautions section to be a more
prevalent regulatory action than to the Contraindications section.
In general, while the medication's label is a comprehensive summary of a
medication's risks and benefits, it includes technical language that may seem confusing
to patients. "Patient labeling" - in the form of Medication Guides and Patient Package
Inserts - are benefit-risk communications written explicitly for patients (as opposed to
healthcare providers or pharmacists). Medication Guides are required in one or more of
the following circumstances:
"(1) The drug product is one for which patient labeling could help prevent serious adverse
effects. (2) The drug product is one that has serious risk(s) (relative to benefits) of which
patients should be made aware because information concerning the risk(s) could affect
patients' decision to use, or to continue to use, the product. (3) The drug product is
important to health and patient adherence to directions for use is crucial to the drug's
effectiveness." 19 2
Patient Package Inserts are required for all oral contraceptives' 93 and estrogen-containing
189 Department of Health and Human Services et al., "Guidance for Industry: Safety Labeling Changes -
Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act (Draft)," 4. "FDA
expects that information that results in changes made only to the ADVERSE REACTIONS section, but
does not warrant inclusion in other sections of labeling (such as WARNINGS AND PRECAUTIONS),
would not normally trigger required safety labeling changes under section 505(o)(4)."
190 Powers and Cook, "Potential Safety Signals and Their Significance."
191 Moore, Singh, and Furberg, "The FDA and New Safety Warnings"; Jean Lester et al., "Evaluation of
FDA Safety-Related Drug Label Changes in 2010", unpublished manuscript, May 5, 2012.
192 21 CFR § 208.1(c), April 1, 2012 edition.
193 21 CFR § 310.501, April 1, 2012 edition.
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therapeutics.194 Patient Package Inserts can also be voluntary components of labeling.
Both Medication Guides and mandatory Patient Package Inserts have distribution
requirements.1 95 The FDA maintains a list of active products that require a Medication
Guide.' 96 Whether Medication Guides can be required on the basis of causal associations
(i.e., as Warning and Precautions changes are) as opposed to known risks (i.e., as
Contraindications changes are) seems an open question, but it appears that either could
form the evidence base for a Medication Guide.
The FDA has begun tracking its safety-related label changes (including Medication
Guides/Patient Package Inserts) in a monthly database, and these changes are delineated
by section.' 97 More significant interrogation of this dataset could be used to more closely
link evidentiary standards with resultant safety-related label changes.
3.3.2 Changes to Risk Evaluation and Mitigation Strategies
Another type of regulatory action available to the FDA is the issuance or revision of a
risk evaluation and mitigation strategy (REMS). A REMS may consist of up to five
related elements that contain individual requirements. Those elements are: a Medication
Guide/Patient Package Insert; a communication plan; elements to assure safe use
(ETASU) provisions; an implementation system; and a timetable for assessments.198 I
focus on the first three elements because an implementation system is not independent of
ETASU provisions. REMS assessments are designed to evaluate the degree to which the
strategy is meeting its goals.199
The evidentiary standard for issuance of REMS in the postapproval period is broad:
194 21 CFR § 310.515, April 1, 2012 edition.
195 21 CFR § 208.24, April 1, 2012 edition.
1 Center for Drug Evaluation and Research, "Medication Guides," WebContent, n.d.,
http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm.
197 Center for Drug Evaluation and Research, "Drug Safety Labeling Changes," WebContent, n.d.,
http://www.fda.gov/Safety/MedWatch/Safetylnformation/Safety-
RelatedDrugLabelingChanges/default.htm.
198 § 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355-1(e).
199 Department of Health and Human Services et al., "Guidance for Industry: Format and Content of
Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and REMS
Modifications (Draft)", October 1, 2009,
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM 18412
8.pdf.
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"if the Secretary becomes aware of new safety information and makes a determination that
such a [risk evaluation and mitigation] strategy is necessary to ensure that the benefits of
the drug outweigh the risks of the drug." 200
In general, the statute provides flexibility to the FDA, but makes it difficult to
interpret what type of data or analyses would be required to make a showing that the
REMS (and its subsequent assessments) assures that a drug's benefit outweighs its risk.
First, Medication Guide/Patient Package Inserts are described above. While
Medication Guides can be entirely managed via the existing regulatory structure, a
Medication Guide mandated as a part of a REMS ensures that an assessment of the
strategy will be performed. The FDA has stated in guidance that it does not intend to
issue Medication Guide-only REMS unless a "Medication Guide without a REMS will
not be sufficient to ensure that the benefits of the drug outweigh the risks." 2 0 1 Further, it
has stated its intention to include a Medication Guide as part of a REMS when the REMS
202
already includes an ETASU provision. As of March 2012, 125 REMS were issued as
Medication Guide-only REMS, and 105 of these were later released (i.e., the REMS
requirement was fulfilled/canceled).2 03 To be clear, these Medication Guides still exist;
they are just no longer governed by the REMS regulatory structure, which requires
mandatory assessments.
Second, while Medication Guides mandate particular manufacturer-patient
communications, a communication plan refers to communications between manufacturers
and healthcare providers or pharmacists. Historically, these communications have been
"Dear Healthcare Provider" letters sent for one or more of the following three purposes:
1) new medical product information related to a significant hazard to health; 2) new
medical product information related to important changes to the product's labeling; and
200 § 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355-1(a)(2).
201 U.S. Department of Health and Human Services et at., "Guidance: Medication Guides - Distribution
Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) (Final)", November 17,
2011,8,
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryinformation/Guidances/UCM24457
0.pdf.
202 U.S. Department of Health and Human Services et al., "Guidance: Medication Guides - Distribution
Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) (Final)."
203 Center for Drug Evaluation and Research, "News & Events - Slides for the June 7, 2012 Risk Evaluation
and Mitigation Strategy (REMS) Assessments Public Workshop," WebContent, n.d.,
http://www.fda.gov/Drugs/NewsEvents/ucm307675.htm.
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3) correction of advertising or labeling information related to the medical product. 20 4
However, the FDAAA also references communications related to explaining REMS
provisions20s (i.e., specifically ETASU and implementation plans), and "disseminating
information to health care providers through professional societies about any serious risks
of the drug and any protocol to assure safe use." 206 As of March 2012, 40 REMS have
been established with communication plans as the primary element and 7 of those have
been released.207
The ETASU provisions and accompanying implementation systems are regulatory
actions that serve to restrict access to particular medications, and thus might include the
separately noted regulatory action in the tracked safety issue guidance related to
"limitations on a use in a specific population or subpopulation." 208 To be clear, safety-
related changes to the labeling - particularly the Contraindications section - may also
accomplish this goal in a less burdensome fashion. The FDA has implemented restricted
distribution programs in a variety of circumstances in the past 209, albeit with uncertain
legal authority to do so except under certain conditions. Specifically, these ETASU
provisions pertain to known serious risks and restrict utilization in one of the following
ways:
"(A) health care providers who prescribe the drug have particular training or experience,
or are specially certified (the opportunity to obtain such training or certification with
respect to the drug shall be available to any willing provider from a frontier area in a
widely available training or certification method (including an on-line course or via mail)
as approved by the Secretary at reasonable cost to the provider); (B) pharmacies,
practitioners, or health care settings that dispense the drug are specially certified (the
opportunity to obtain such certification shall be available to any willing provider from a
frontier area); (C) the drug be dispensed to patients only in certain health care settings,
such as hospitals; (D) the drug be dispensed to patients with evidence or other
204 21 CFR § 200.5 See also K Uhl and P Honig, "Risk Management of Marketed Drugs: FDA and the
Interface with the Practice of Medicine," Pharmacoepidemiology and Drug Safety 10, no. 3 (May 2001):
205-208.
2 § 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355-1(e)(2)... "disseminating information about the elements of the risk evaluation and mitigation
strategy to encourage implementation by health care providers of components that apply to such health care
providers, or to explain certain safety protocols (such as medical monitoring by periodic laboratory tests);"
206 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355-1(e)(3).
207 Center for Drug Evaluation and Research, "News & Events - Slides for the June 7, 2012 Risk Evaluation
and Mitigation Strategy (REMS) Assessments Public Workshop."
208 U.S. Department of Health and Human Services, Food and Drug Administration, and Center for Drug
Evaluation and Research, "Guidance: Classifying Significant Postmarketing Drug Safety Issues (Draft)."
209 Judith C. Maro, "Development of a public health information infrastructure for postmarket evidence"
(Thesis, Massachusetts Institute of Technology, 2009), 58-61, http://dspace.mit.edu/handle/1721.1/53058.
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documentation of safe-use conditions, such as laboratory test results; (E) each patient
using the drug be subject to certain monitoring; or (F) each patient using the drug be
enrolled in a registry." 2 10
The evidentiary standard to issue a REMS with an ETASU provision specifically states
that:
"(A) the drug, which has been shown to be effective, but is associated with a serious
adverse drug experience, can be approved only if, or would be withdrawn unless, such
elements are required as part of such strategy to mitigate a specific serious risk listed in
the labeling of the drug; and (B) for a drug initially approved without elements to assure
safe use, other elements under subsections (c), (d), and (e) are not sufficient to mitigate
such serious risk." 21I
As of April 2012, the FDA reports that 64 medical products are subject to ETASU
provisions.m Among these, rosiglitazone-containing medications, long acting/extended
release opioids, and transmucosal immediate-release fentanyl products are examples of
products for which REMS were created postapproval to manage risks.2 13 The latter two
are class-wide REMS for opioid-containing medications, in which the known risks to be
mitigated are supratherapeutic or "Type A" effects: addiction, abuse, misuse, overdose,
and death. The REMS for rosiglitazone is notable in that continually refers to the
"potential increased risk of myocardial infarction,"2 14 (emphasis added) despite the
legislative language requiring known serious risks.
3.3.3 Issuance of a Postmarket Requirement and the conduct of a study by FDA
In the Food and Drug Administration Amendments Act, Congress also granted the
FDA new legal authorities to require manufacturers to conduct postmarket studies.
210 § 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355-1(f)(3).
211 § 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355-1(f)(1).
212 Center for Drug Evaluation and Research, Food and Drug Administration, and U.S. Department of
Health and Human Services, "Advances in FDA's Safety Program for Marketed Drugs" (FDA, April
2012), 10, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM300946.pdf.
213 See Center for Drug Evaluation and Research, "Postmarket Drug Safety Information for Patients and
Providers - Approved Risk Evaluation and Mitigation Strategies (REMS)," WebContent, n.d.,
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/ucm 111
350.htm.
214 point to this example to demonstrate the difficulty in reaching consensus on causality. Center for Drug
Evaluation and Research, "Approved Risk Evaluation and Mitigation Strategies (REMS): Avandia
(rosiglitazone)," WebContent, n.d.,
http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProvide
rs/UCM255624.pdf.
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However, it did not do so unconditionally. First, the FDA can exercise these new legal
authorities either at the time of approval (i.e., licensure)21 , or in the postmarket period. In
the latter case, the legal authority can be exercised "only if the Secretary [of Health and
Human Services] becomes aware of new safety information." 216 Second, the FDA is not
permitted to require a manufacturer to perform new postmarket requirements in the form
of postapproval studies or postapproval clinical trials:
"unless the Secretary [of Health and Human Services] makes a determination that the
reports under subsection (k)(1) [i.e., spontaneous reporting systems] and the active
postmarket risk identification and analysis system as available under subsection (k)(3)
will not be sufficient to meet the purposes set forth in subparagraph (B)" 217
(emphasis added)
To summarize, the FDA has three supporting assertions to make prior to generating a
postmarket requirement: a) the data (either the scientific data available pre-licensure or
new safety information) support the postmarket requirement's generation; b) the purpose
of the postmarket requirement satisfies one of the three purposes discussed in subsection
3.1 and c) the findings of sufficiency regarding the spontaneous reporting systems and
active postmarket risk identification and analysis system. 2 18 For postmarket requirements
generated at the time of approval, sufficiency determinations have been made
independent of actual use of the system.219 Letters informing manufacturers of
postmarket requirements generated postapproval are not public, and therefore it is unclear
how these sufficiency determinations have been made.
§ 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355(o)(3)(A). At the time of licensure, the FDA can require a postmarket requirement "on the
basis of scientific data deemed appropriate by the Secretary, including information regarding chemically-
related or pharmacologically-related drugs."
2 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355(o)(3)(C). For the definition of new safety information, see supra at note 152.
2 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355(o)(3)(D). For the language with respect to the purposes, see supra at note 162.
218 For example of these three assertions, see the "Postmarketing Requirements under 505(o) section of the
FDA's recent approval letter for Myrbetriq (mirabegron). Search the FDA's approved drugs database at
"Drugs@FDA: FDA Approved Drug Products", n.d.,
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
219 The FDA has stated the results of such determinations in letters to manufacturers at the time of approval.
The language in these letters has generally stated, "The new pharmacovigilance system that FDA is
required to establish under section 505(k)(3) of the FDCA will not be sufficient to assess this serious risk."
To find these letters, one must search the FDA database for newly approved drugs:
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
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There are no known legal standards indicating what might trigger "the conduct of a
safety-related observational epidemiological study by FDA."220 Further, it is unclear
whether a safety-related observational epidemiological study by FDA would be
performed within the Mini-Sentinel System as either a protocol-based one-time
assessment or a sequential database surveillance assessment, or whether it would be
221performed under the existing pharmacoepidemiology contract.
3.3.4 Withdrawal
The most stringent regulatory action is withdrawal of a medical product, or removal
of its licensure for use. The legal standard for withdrawal of a medical product or a
particular indication uses similar broad language to the REMS provisions. Specifically,
withdrawal is permitted if new data:
"show that such drug is unsafe for use under the conditions of use upon the basis of which
the application was approved... [or] that there is a lack of substantial evidence that the
drug will have the effect it purports or is represented to have under the conditions of use
prescribed, recommended, or suggested in the labeling thereof."2 2 2
The first part of the above rationale addresses safety issues whereas the latter addresses
efficacy. In the past, varying sources of evidence have supported safety-related
withdrawals. Some drugs, e.g., levomethadyl acetate and oral bromfenac sodium, were
withdrawn on the basis of risks identified in the spontaneous reporting systems and
assessed by creating a case-series analysis (i.e., an in-depth study of particular cases)
whereas others, e.g., rofecoxib, were withdrawn on the basis of postmarket clinical trial
data.2 23
3.4 Causal Inference - How Necessary for Regulatory Action?
In summary, with the exception of changes to the Warnings and Precautions section
of a product's label, the law is ambiguous on the strength of causal inference needed to
220 U.S. Department of Health and Human Services, Food and Drug Administration, and Center for Drug
Evaluation and Research, "Guidance: Classifying Significant Postmarketing Drug Safety Issues (Draft)."
221 See supra at note 67.
222 21 U.S.C. § 355(e). To be clear, this is not a full quotation of the legislative language. Although they are
valid grounds for withdrawal, I am excluding issues related to fraud or falsification, or a sponsor's lack of
compliance with regard to required reports, inspections, and other assessments.
223 See Zaina P Qureshi et al., "Market Withdrawal of New Molecular Entities Approved in the United
States from 1980 to 2009," Pharmacoepidemiology and Drug Safety 20, no. 7 (July 2011): 772-777; Dal
Pan, Lindquist, and Gelperin, "Postmarketing Spontaneous Pharmacovigilance Reporting Systems."
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support various regulatory actions, leaving much to the discretion of the FDA. While the
FDA might prefer to regulate with robust causal evidence to support its action(s), time
and ethical constraints may rule out study designs that are likely to generate such
evidence (let us assume said designs are well-executed). To that end, Hernin and Robins
describe a study design that guarantees robust causal inference: the ideal randomized
experiment. It is characterized by "no loss to follow-up, full adherence to the assigned
treatment over the duration of the study, a single version of treatment, and double blind
assignment."224 Such conditions are improbable even in a double blind randomized
controlled trial.22 s Generally, choosing a study design likely to draw the most robust
conclusions of causality comes at a price: longer timeframes and higher costs to generate
the evidence.2 26
To that end, randomized controlled trials may be reasonably ruled out as evidence-
generating systems from the outset when the outcome is so rare that the costs of such a
trial would be prohibitive. 2 2 7 Second, they may be ethically questionable when morbidity
or mortality associated with the outcome is high and a premium is placed on earlier rather
than later regulatory decision-making. Third, the existence of safe substitute products
may also favor earlier rather than later regulatory decision-making. 228 Finally,
randomized controlled trials may start too late since the Food and Drug Administration
Amendments Act stages them as a study design of last resort.2 29 At that point, it is
difficult to maintain clinical equipoise, which is an ethical requirement for investigator-
230
assigned treatments.
224 Hernin and Robins, Causal Inference, 14-15.
m Hernin and Hemandez-Diaz, "Beyond the Intention-to-treat in Comparative Effectiveness Research."
226 Randomized controlled trials were discussed earlier in subsection 2.1.3.
m See, for example, FDA advisory committee discussion on potential new studies that may clarify
conflicting observational studies showing an association between venous thromboembolism and
drospirenone-containing contraceptives. The advisory committee discusses the infeasibility of randomized
clinical trials because of the rareness of the outcome. See Center for Drug Evaluation and Research,
"Reproductive Health Drugs Advisory Committee - Briefing Information for the December 9, 2011 Joint
Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk
Management Advisory Committee."
228 See for example, arguments that the availability of Actos@ (pioglitazone) favored regulatory action on
Avandia@ (rosiglitazone) without necessitating completion of a randomized controlled trial. Institute of
Medicine (IOM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs, 62.
22 901 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85, codified at 21
U.S.C. § 355(o)(3)(D)(ii).
230 Institute of Medicine (IOM), Ethical and Scientific Issues in Studying the Safety ofApproved Drugs,
187.
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In general, the circumstances of the particular exposure-outcome pair, as Hemn and
Robins point out, require one to assess whether conclusions of causation are really
necessary, or whether prediction (i.e., associational measures) will suffice? 23 ' Similarly,
the IOM has stated:
"Passive surveillance, epidemiologic research with administrative databases, and
active surveillance can be used to answer many drug safety questions. When they do
not provide definitive answers, they can sometimes provide guidance for the development
of further studies or provide sufficient information to narrow the uncertainty about drug-
related risks and benefits and guide regulatory actions and the decisions of patients
and providers. In some instances, full-scale observational studies or clinical trials will be
required to answer key questions, particularly if the outcome of interest is common in the
patients taking a drug."232 (emphasis added)
When a randomized controlled trial is ruled out for time or ethical reasons as
discussed above and when robust findings of causality are still desired, it is possible that
observational data may still support such findings. Essentially, the observational data
must be transformed to emulate a randomized trial.233 Specifically, observational studies
may support causal inference when three criteria are met that allow investigators to
conclude that association is equivalent to causation. These three criteria are:
"1. the values of treatment under comparison correspond to well-defined interventions
2. the conditional probability of receiving every value of treatment, though not decided
by the investigators, depends only on the measured covariates
3. the conditional probability of receiving every value of treatment is greater than zero,
234
i.e., positive."
In general, most pharmacoepidemiologic studies easily can satisfy conditions 1 and 3.
Condition 2 essentially requires the elimination of bias - selection bias, measurement
bias, or confounding bias - that may be responsible for explaining the relationship
between the exposure and outcome. Specific discussions of these biases and the ability to
eliminate them using data in the Mini-Sentinel System are described next.
23! Hernan and Robins, Causal Inference, 38.
232 Institute of Medicine (IOM), The Future ofDrug Safety: Promoting and Protecting the Health of the
Public, 115.
233 Hernan and Robins, Causal Inference, 26. "For each causal question that we intend to answer using
observational data, we will need to carefully describe (i) the randomized experiment that we would like to,
but cannot, conduct, and (ii) how the observational study emulates that randomized experiment." See also
Miguel A Hernin et al., "Observational Studies Analyzed Like Randomized Experiments: An Application
to Postmenopausal Hormone Therapy and Coronary Heart Disease," Epidemiology (Cambridge, Mass.) 19,
no. 6 (November 2008): 766-779.
234 Hernan and Robins, Causal Inference, 26.
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It is sometimes possible to make causal inferences even in the presence of bias when
the effect size and direction together are of such a magnitude that the impact of the bias is
inconsequential.2 3 ' For example, some drugs are withdrawn on the basis of a case-series
analysis 236 and these data do not emulate a randomized experiment. In short, for these
circumstances, no amount of bias could explain the effect size 237 observed. Thus, it may
be possible to conclude causality with the following criteria:
"the suspected [adverse event]: i) is rare in the population when the medication is not used,
ii) is not a manifestation of the underlying disease, iii) has a strong temporal association
with drug administration, and iv) is biologically plausible as a drug reaction or is
generally the result of a drug reaction based on other clinical experience."238
In the next section, I address potential circumstances that limit causal inference in the
Mini-Sentinel System, and develop a qualitative tool by which the FDA might make an
initial sufficiency decision: The Mini-Sentinel System Pre-screening Checklist.
23s Institute of Medicine (IOM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs,
150.
236 See supra at note 223.
237 The effect size is the quantitative strength of an association, which is usually a point estimate of the
effect. See Strom, "Basic Principles of Clinical Epidemiology Relevant to Pharmacoepidemiologic
Studies." Some epidemiologist use the phrase "effect" only to denote casual relationships as opposed to
associations. That is not how I use it here. Typically, epidemiologic effect sizes are given in absolute terms
as risk differences or rate differences, or are given in relative terms as risk ratios, rate ratios, or odds ratios.
See Rothman, Greenland, and Lash, Modern Epidemiology, 51-70.
238 Dal Pan, Lindquist, and Gelperin, "Postmarketing Spontaneous Pharmacovigilance Reporting Systems,"
148.
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4 MINI-SENTINEL SYSTEM PRE-SCREENING CHECKLIST
As I described in the last section, evidence developed in the Mini-Sentinel System
may not be assumed to produce causal inferences. However, causal inference may still be
possible with sufficient covariate data and elimination of systematic biases. Alternatively,
causal inferences may still be possible even in the presence of known but unmeasured
bias when the effect size and direction 2 39 are of such a magnitude that the impact of the
bias is inconsequential.2 40 In these circumstances, it may be unnecessary (and an
inefficient use of public dollars) to more precisely quantify the biases.
This section first summarizes sources of bias using a framework from the
epidemiologic literature 2 4 1 that was adopted by the Institute of Medicine (IOM). 2 4 2 Using
this framework, I then address the potential for elimination of these biases in the Mini-
Sentinel System. Finally, I address the precision243 and transportability244 of statistical
inference that can reasonably be supported by Mini-Sentinel System.
The section introduces a qualitative tool - what I call the Mini-Sentinel System Pre-
screening Checklist - to address whether the Mini-Sentinel System is likely to be
sufficient (or insufficient) on its face to generate evidence to resolve a tracked safety
issue. If the pre-screening checklist suggests that the Mini-Sentinel System is insufficient,
239 For a definition of effect size, see supra at note 237.
240 Institute of Medicine (IOM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs,
150. "Very large relative increases in the background rate, such as the almost 1,000-fold increase in
progressive multifocal leukoencephalopathy with natalizumab treatment in patients with multiple sclerosis
or Crohn's Disease ... , or the greater than ten-fold increase in intussusception seen with rotavirus vaccine,
are likely beyond the bounds of anything that can be explained through imbalances on other risk factors for
those outcomes, that is confounders. In the setting of large relative risks for an adverse event, designs with
quite weak control of confounding, ... , might be sufficient for public policy purposes."
241 Hernin and Robins, Causal Inference; Kenneth J Rothman, Sander Greenland, and Timothy L. Lash,
"Validity in Epidemiologic Studies," in Modern Epidemiology, ed. Kenneth J. Rothman, Sander Greenland,
and Timothy L. Lash, Third. (Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins,
2008), 128-147.
242 Institute of Medicine (1OM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs,
103-144.
243 "The statistical precision of a measurement or process is often taken to be the inverse of the variance of
the measurements or estimates that the process produces.. .Precision of estimation can be improved (which
is to say, variance can be reduced) by increasing the size of the study." Rothman, Greenland, and Lash,
Modern Epidemiology, 149.
244 In epidemiology, transportability has been suggested as a more appropriate term for what is commonly
referred to as external validity or generalizability. The IOM has endorsed this term in their most recent
report, explaining "the committee thinks that [the term transportability] reflects a nonbinary characteristic
better. Different effects can occur in a variety of settings, and study results may be transportable to some
populations or settings but not others, so transportability may not be a simple binary property." See
Institute of Medicine (IOM), Ethical and Scientific Issues in Studying the Safety of*Approved Drugs, 118.
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then no further analytics are necessary and regulators may have justification to pursue
alternative evidence generation mechanisms. If the pre-screening checklist suggests that
the Mini-Sentinel System is sufficient for evidence generation to support resolution of a
tracked safety issue, then quantitative tools may be used to refine the estimation of the
Mini-Sentinel System's evidence generation capability, which will be presented in
section 6.
Necessary inputs to the Mini-Sentinel System Pre-screening Checklist are: 1) a
tracked safety issue that identifies a particular exposure-outcome pair of interest; and 2) a
regulator's goal with respect to the strength of causal inference necessary to support
regulatory decision-making as was outlined in the previous section.
4.1 Importance of Effect Sizes
Most epidemiologists presume the presence of bias in any observational study, and
are particularly sensitive to effect sizes that are marginally different than the null
hypothesis. 24 5 Likewise, several regulators have expressed reluctance to rely on
observational studies that demonstrate modest elevated risk (e.g., relative risks less than
246two-fold). However, even small relative risks can be quite important with high
prevalence medications, and in these circumstances, the IOM suggests that "a well-
designed and well-conducted postmarketing randomized clinical trial is the best approach
for characterizing the risk-benefit profile."247 An example of such a scenario is the long-
acting beta agonists-death tracked safety issue that is currently being investigated via
245 Strom notes "A quantitatively small association may still be causal but it could be created by a subtle
error, which would not be apparent in evaluating the study." Strom, "Basic Principles of Clinical
Epidemiology Relevant to Pharmacoepidemiologic Studies," 42. See also Institute of Medicine (IOM),
Ethical and Scientific Issues in Studying the Safety of Approved Drugs, 120-121, 205..."If the estimated
relative risks are small, selection bias, confounding, and measurement error may be alternative explanations
for associations found in an observational study."
246 Temple, "Meta-analysis and Epidemiologic Studies in Drug Development and Postmarketing
Surveillance"; J Woodcock, "Evidence Vs. Access: Can Twenty-first-century Drug Regulation Refine the
Tradeoffs?," Clinical Pharmacology and Therapeutics 91, no. 3 (March 2012): 378-380. See also
comments of Dr. John Jenkins in Food and Drug Administration and Center for Drug Evaluation and
Research, "Transcript of the Joint Meeting of Pulmonary-Allergy Drugs Advisory Committee and the Drug
Safety and Risk Management Advisory Committee", March 11, 2010,
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-
AllergyDrugsAdvisoryCommittee/UCM209124.pdf.
2 Institute of Medicine (IOM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs,
205.
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FDA-required randomized trials.248 In general, a pre-screen criterion for use of the Mini-
Sentinel System should consider the overall effect size that investigators seek to
detect/rule out, and small effect sizes may be a reason for regulators to eliminate
consideration of the Mini-Sentinel System as an evidence generation system.
4.2 Sources of Bias
The IOM defines bias as the "difference between the average effect of many
hypothetical repetitions of a given study and the true effect in the population being
studied." 24 ' Alternatively, Hernin and Robins define bias as instances "whenever the
effect measure (e.g., causal risk ratio or difference) and the corresponding association
measure (e.g., associational risk ratio or difference) are not equal."25 o Systematic biases
are problematic because they are not represented by confidence intervals surrounding risk
estimates. Rather, they shift the mean of confidence intervals in ways that may not be
immediately apparent to investigators. Bias may be controlled for in design or analysis,
and much of the epidemiology literature is devoted to these controls. Bias can be
segregated into three types based on its structure: confounding, selection, and
measurement bias, which are each reviewed in turn.
4.2.1 Confounding Bias
Rothman et al. require a confounding variable to meet three conditions:
"a) the exposure is associated with the confounder,
b) the outcome is independently associated with the confounder,
c) temporally, the confounder is NOT affected by either the exposure or the outcome."
25 1
In other words, confounding occurs "when the populations compared in a study differ in
important predictors of the outcome being studied other than an exposure of interest
248 See transcripts discussing the difficulty in detecting/ruling out a relative risk of <2.0 in observational
studies. Food and Drug Administration and Center for Drug Evaluation and Research, "Transcript of the
Joint Meeting of Pulmonary-Allergy Drugs Advisory Committee and the Drug Safety and Risk
Management Advisory Committee." See also the FDA's announcement on its requirement for randomized
controlled trials, including the decision to pursue a composite endpoint because of the rareness of death as
an outcome. Food and Drug Administration and Center for Drug Evaluation and Research, "FDA Requires
Post-market Safety Trials for Long-Acting Beta Agonists."
249 Institute of Medicine (IOM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs,
116.2 5 0 Hernan and Robins, Causal Inference, 77.
251 Rothman, Greenland, and Lash, Modern Epidemiology, 758.
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(such as exposure to a drug)."25 2 In short, the presence of an uncontrolled confounder
potentially offers an alternative explanation for the cause of the outcome of interest (e.g.,
adverse events). The presence of confounders in an observational study is virtually
guaranteed because treatment assignment is not random. Confounding is more likely to
occur when the disease process itself (independent of the therapy assigned) is a risk factor
for the outcome of interest. Oft-cited examples include diabetes-cardiovascular risk, and
asthma-sudden death. These situations are sometimes referred to as "confounding by
indication."m This same concept can also be called "confounding by contraindication" or
channeling bias, and occurs when a predisposing condition/status of a patient may steer
them away from a particular therapy (e.g., perhaps the patient has a known reaction to a
competing therapy).
In general, pharmacoepidemiologists are accustomed to inevitable confounding in
observational datasets built on secondary data, and consequently, have developed several
adjustment techniques. Schneeweiss 25 and others255 summarize these techniques
depending on whether the covariates are measured, unmeasured, or unmeasureable.25 6
Measured covariates can be adjusted for with design-based mechanisms (e.g.,
matching , restriction 25 8 ) or analysis-based mechanisms (e.g., stratification 2 9 , inverse
2s2 Institute of Medicine (IOM), Ethical and Scientific Issues in Studying the Safety of Approved Drugs,
117.
2s3 Much has been written on confounding by indication. See Ibid., 122; Vandenbroucke and Psaty,
"Benefits and Risks of Drug Treatments"; Strom, "Methodologic Challenges to Studying Patient Safety and
Comparative Effectiveness"; Schneeweiss and Avorn, "A Review of Uses of Health Care Utilization
Databases for Epidemiologic Research on Therapeutics."
254 Sebastian Schneeweiss, "Sensitivity Analysis and External Adjustment for Unmeasured Confounders in
Epidemiologic Database Studies of Therapeutics," Pharmacoepidemiology and Drug Safety 15, no. 5 (May
2006): 291-303.
255 Brookhart et al., "Confounding Control in Healthcare Database Research: Challenges and Potential
Approaches"; Alex D McMahon, "Approaches to Combat with Confounding by Indication in
Observational Studies of Intended Drug Effects," Pharmacoepidemiology and Drug Safety 12, no. 7
(November 2003): 551-558.
256 Unmeasured data are existing data that are missing or unavailable to the investigator whereas
unmeasureable data simply do not exist. In an unrelated policy arena, Donald Rumsfeld famously referred
to the former as known unknowns and the latter as unknown unknowns.
2K7 enneth J Rothman, Sander Greenland, and Timothy L. Lash, "Design Strategies to Improve Study
Accuracy," in Modern Epidemiology, ed. Kenneth J. Rothman, Sander Greenland, and Timothy L. Lash,
Third. (Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008), 168-182.
258 Bruce M Psaty and David S Siscovick, "Minimizing Bias Due to Confounding by Indication in
Comparative Effectiveness Research: The Importance of Restriction," JAMA: The Journal of the American
Medical Association 304, no. 8 (August 25, 2010): 897-898; S. Schneeweiss et al., "Increasing Levels of
Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison with Randomized Trial
Results," Medical Care 45, no. 10 Supl 2 (2007): S131-42.
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probability weighting 260, g-estimation methods261). Unmeasured covariates may be
adjusted for with a subset of internal data2 6 2 , external data2 63 , high-dimensional
propensity scores , or disease risk scores.26s Unmeasurable (i.e., unknown) covariates
may be dealt with via sensitivity analysis (also known as bias analysis) 266, instrumental
variables analysis2 67 or self-controlled study designs2 68 . The key issue for regulators is to
assess the potential for confounding bias with regard to the particular tracked safety issue
259 Sander Greenland and Kenneth J Rothman, "Introduction to Stratified Analysis," in Modern
Epidemiology, ed. Kenneth J. Rothman, Sander Greenland, and Timothy L. Lash, Third. (Philadelphia, PA:
Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008), 258-302.
260 Stephen R Cole and Miguel A Hernin, "Constructing Inverse Probability Weights for Marginal
Structural Models," American Journal ofEpidemiology 168, no. 6 (September 15, 2008): 656-664; Miguel
A Hernin and James M Robins, "Estimating Causal Effects from Epidemiological Data," Journal of
Epidemiology and Community Health 60, no. 7 (July 2006): 578-586.
261 Sarah L Taubman et al., "Intervening on Risk Factors for Coronary Heart Disease: An Application of
the Parametric G-formula," International Journal ofEpidemiology 38, no. 6 (December 2009): 1599-1611.
262 Sengwee Toh, Luis A Garcia Rodriguez, and Miguel A HernAn, "Analyzing Partially Missing
Confounder Information in Comparative Effectiveness and Safety Research of Therapeutics,"
Pharmacoepidemiology and Drug Safety 21 Suppl 2 (May 2012): 13-20.
263 Til Stormer et al., "Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database
Studies Using External Information," Medical Care 45, no. 10 Supl 2 (October 2007): S158-165; Sebastian
Schneeweiss et al., "Adjusting for Unmeasured Confounders in Pharmacoepidemiologic Claims Data Using
External Information: The Example of COX2 Inhibitors and Myocardial Infarction," Epidemiology
(Cambridge, Mass.) 16, no. 1 (January 2005): 17-24.
264 Rassen and Schneeweiss, "Using High-dimensional Propensity Scores to Automate Confounding
Control in a Distributed Medical Product Safety Surveillance System"; Rassen et al., "Privacy-maintaining
Propensity Score-based Pooling of Multiple Databases Applied to a Study of Biologics"; S. Schneeweiss et
al., "High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care
Claims Data," Epidemiology (Cambridge, Mass.) 20, no. 4 (2009): 512-522.
265 Glynn, Gagne, and Schneeweiss, "Role of Disease Risk Scores in Comparative Effectiveness Research
with Emerging Therapies."
266 Timothy L Lash et al., "Methods to Apply Probabilistic Bias Analysis to Summary Estimates of
Association," Pharmacoepidemiology and Drug Safety 19, no. 6 (June 2010): 638-644; Onyebuchi A Arah,
Yasutaka Chiba, and Sander Greenland, "Bias Formulas for External Adjustment and Sensitivity Analysis
of Unmeasured Confounders," Annals of Epidemiology 18, no. 8 (August 2008): 637-646; Lawrence C
McCandless, Paul Gustafson, and Adrian R Levy, "A Sensitivity Analysis Using Information About
Measured Confounders Yielded Improved Uncertainty Assessments for Unmeasured Confounding,"
Journal of Clinical Epidemiology 61, no. 3 (March 2008): 247-255; Sander Greenland, "Multiple-bias
Modelling for Analysis of Observational Data," Journal of the Royal Statistical Society: Series A (Statistics
in Society) 168, no. 2 (2005): 267-306; Timothy L Lash and Aliza K Fink, "Semi-automated Sensitivity
Analysis to Assess Systematic Errors in Observational Data," Epidemiology (Cambridge, Mass.) 14, no. 4
(July 2003): 451-458.
267 M Alan Brookhart, Jeremy A Rassen, and Sebastian Schneeweiss, "Instrumental Variable Methods in
Comparative Safety and Effectiveness Research," Pharmacoepidemiology and Drug Safety 19, no. 6 (June
2010): 537-554; Jeremy A Rassen et al., "Instrumental Variables 1: Instrumental Variables Exploit Natural
Variation in Nonexperimental Data to Estimate Causal Relationships," Journal of Clinical Epidemiology
62, no. 12 (December 2009): 1226-1232; M Alan Brookhart et al., "Evaluating Short-term Drug Effects
Using a Physician-specific Prescribing Preference as an Instrumental Variable," Epidemiology (Cambridge,
Mass.) 17, no. 3 (May 2006): 268-275; S Greenland, "An Introduction to Instrumental Variables for
Epidemiologists," International Journal ofEpidemiology 29, no. 4 (August 2000): 722-729.
268 Self-controlled study designs will be explained in more detail in section 5.1
73
of interest in the Mini-Sentinel System, and particularly to identify whether important
confounding covariates are measured, unmeasured, or unmeasurable.
4.2.1.1 Limited Covariate Data in the Mini-Sentinel System
As a primarily claims-based system with some laboratory results, many commonly
sought confounding covariates 269 - e.g., smoking status, alcohol use, body mass index,
socio-economic status - are simply uncoded in the Mini-Sentinel System. Some of these
uncoded covariates may be measured via medical chart confirmation, but these data are
occasionally missing in medical charts as well. 7 When singular covariates of importance
are not identified, high-dimensional propensity scores and disease risk scores can
potentially account for these covariates. These scores aggregate many covariates into a
single summary measure. A high-dimensional propensity score is a summary measure of
a patient's "propensity" or likelihood of being exposed to the medical product of interest
and a disease risk score is a summary of the patient's likelihood of experiencing the
disease when they are unexposed to the medical product of interest. Theoretically, these
scores can be used to match similar patients and thus eliminate the bias created by
confounding covariates. Also, creation of these summary scores limits sharing of patient-
level data among data partners. For these reasons, the automated use of such techniques
in the Mini-Sentinel System is growing.27 1
In general, absent a self-controlled design or other technique to mimic randomization
(e.g., instrumental variables), observational studies performed in the Mini-Sentinel
System will retain some degree of residual confounding. As of yet, there has been little
routine implementation of sensitivity/bias analyses in the Mini-Sentinel System to
estimate the strength of bias necessary to eliminate findings of an effect size. These
sensitivity analyses would propose the existence of a bias at some level (e.g., the
prevalence of a confounder in both the treatment group and the comparison group) and
then test how the presence of this bias affects the risk estimate. In the future, regulators
269 For more examples of such covariates, see Schneeweiss et al., "Adjusting for Unmeasured Confounders
in Pharmacoepidemiologic Claims Data Using External Information."
270 See, for example, discussion on the difficulty in covariate capture in Dore et al., "A Cohort Study of
Acute Pancreatitis in Relation to Exenatide Use."
2 Rassen and Schneeweiss, "Using High-dimensional Propensity Scores to Automate Confounding
Control in a Distributed Medical Product Safety Surveillance System."
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may make use of these sensitivity/bias analyses to determine whether potential
confounding bias in the Mini-Sentinel System is tolerable. Such determinations would
also require the regulator to estimate the effect sizes of interest.
4.2.2 Selection Bias
Selection bias refers to how people were selected into the analysis, and results when
"the exposure affects selection in the study or analysis and selection is associated with the
outcome of interest."272 Hernin and Robins emphasize that both the exposure and
outcome must be associated with a common effect, or something that follows the
exposure and outcome.2 73 The common effect is typically a censoring condition, or a
condition that causes people to be excluded from a study. Examples of selection bias
include differential loss to follow-up, censoring due to missing data, healthy user bias,
self-selection/volunteer bias, and prevalent user bias. Evidence generation in the Mini-
Sentinel System is more vulnerable to the first two forms of selection bias noted above.
Differential loss to follow-up occurs when persons in the two groups being compared
stop contributing information (i.e., drop out) at different rates. This is problematic
because no one knows what would have occurred had they kept contributing information.
Censoring due to missing data can just be seen as another form of dropout, i.e. the
investigator censors or omits data because it is incomplete. If this missing data is not
random (i.e., presumably distributed in the two groups proportional to their size), this is a
form of selection bias. Unlike confounding bias, which is presumed eliminated via
randomization, any statistical inference can suffer from selection biases. Additionally,
issues such as differential loss-to-follow-up are difficult to predict in prospective designs.
However, these biases may be corrected in data analysis using inverse probability
weighting and g-estimation methods.2 74
With regard to other forms of selection bias, the healthy user bias generally occurs
with therapeutics that are considered "preventative" such as statins, and the concern is
that users of such therapies would also engage in other forms of health-seeking behavior
272 Institute of Medicine (10M), Ethical and Scientific Issues in Studying the Safety of Approved Drugs,
117.
273 Hernin and Robins, Causal Inference, 95-108.
m See supra at notes 260-261.
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and thus, be markedly different than non-users.27 This concern is generally mitigated in
the design by choice of comparator group, and specifically, avoiding comparisons
between users and non-users. 2 7 6 Second, self-selection/volunteer bias will not apply in
database studies because individual consent is not required. Finally, it is now routine for
investigators to adopt "incident user" designs277 to correct for biases created by prevalent
users.278
4.2.2.1 Churn/Database Turnover in the Mini-Sentinel System
Differential loss-to-follow-up in the Mini-Sentinel System is typically related to
changes in insurance coverage and death. For example, inclusion criteria typically
requires a subject of study (i.e., a patient) to have continuous insurance coverage during
the time the subject is "at risk" of developing the adverse event. If some aspect of being
exposed to a particular medical product causes a loss/change in insurance coverage and
the outcome of interest is also associated with a loss/change in insurance coverage, then
selection bias may have occurred. These types of insurance coverage changes may be less
likely due to the "guaranteed issue" and "community rating" provisions of the Patient
Protection and Affordable Care Act of 2010.279 These provisions prevent denial of
coverage as a result of pre-existing conditions. However, increased competition among
insurers may still generate significant churn in health plans, which could lead to
differential loss-to-follow-up. Similarly, if patients die during the at-risk period at notably
different rates, these deaths create differential loss-to-follow-up problems. Unfortunately,
it may be difficult to anticipate the degree to which selection bias may affect evidence
generation for particular tracked safety issues in the Mini-Sentinel System. However,
long follow-up times (i.e., long "at risk" windows following exposure for outcomes such
m William H. Shrank, Amanda R. Patrick, and M. Alan Brookhart, "Healthy User and Related Biases in
Observational Studies of Preventive Interventions: A Primer for Physicians," Journal of General Internal
Medicine 26, no. 5 (May 2011): 546-550.
276 Choice of comparison groups will be discussed at greater length herein in section 5.1.
277 Wayne A Ray, "Evaluating Medication Effects Outside of Clinical Trials: New-user Designs,"
American Journal of Epidemiology 158, no. 9 (November 1, 2003): 915-920.
278 Goodarz Danaei, Mohammad Tavakkoli, and Miguel A Hernin, "Bias in Observational Studies of
Prevalent Users: Lessons for Comparative Effectiveness Research from a Meta-analysis of Statins,"
American Journal of Epidemiology 175, no. 4 (February 15, 2012): 250-262.
279 Patient Protection and Affordable Care Act, P.L. 111-148, 2010.
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as cancer) are likely to be difficult to achieve. Gagne et al. also refer to these concepts as
the onset and duration of the risk window. 2 80
4.2.3 Measurement Bias
Measurement bias (also known as information bias) occurs when "the association
between treatment and outcome is weakened or strengthened as a result of the process by
which the study data are measured." 2 81 Measurement bias with respect to discrete
variables is often referred to as misclassification. Misclassification can occur when
measuring exposures, outcomes, and covariates, and can occur for a variety of reasons in
database systems.282 I focus on misclassification rather than measurement bias because
the Mini-Sentinel System is built around count-based data2 83 , which require discrete
categorizations. Covariate measurement may be discrete or continuous, but generally
continuous covariates require regression models, which are not easily achieved without
pooling data.2 84 However, as mentioned in the section 4.2.1.1, high-dimensional
propensity scores or disease risk scores may circumvent this limitation.
Misclassification is further described as independent or dependent, and as non-
differential or differential. Independent misclassification typically refers to situations
when misclassification of one variable (e.g., exposures) is independent of
misclassification in other variables (e.g., outcomes). Non-differential misclassification
refers to situations when the treatment and comparator groups have identical patterns of
measurement error (i.e., the sensitivity and specificity of the classification are the same)
with respect to a particular variable (e.g., exposure). There are many corrective
techniques to deal with misclassification that is independent and non-differential in
observational data.2 85 For the purposes of the Mini-Sentinel System Pre-screening
280 Gagne et al., "Design Considerations in an Active Medical Product Safety Monitoring System."
281 Hernin and Robins, Causal Inference, 109.
282 For a comprehensive summary, see Jessica Chubak, Gaia Pocobelli, and Noel S Weiss, "Tradeoffs
Between Accuracy Measures for Electronic Health Care Data Algorithms," Journal of Clinical
Epidemiology 65, no. 3 (March 2012): 343-349.e2; Schneeweiss and Avorn, "A Review of Uses of Health
Care Utilization Databases for Epidemiologic Research on Therapeutics."
283 Curtis et al., "Design Considerations, Architecture, and Use of the Mini-Sentinel Distributed Data
System."
284 The Mini-Sentinel System is designed to limit pooling data. See supra at 142.
285 j. P. Mullooly, "Misclassification Model for Person-time Analysis of Automated Medical Care
Databases," American Journal of Epidemiology 144, no. 8 (1996): 782-792; H. Brenner and 0. Gefeller,
"Use of the Positive Predictive Value to Correct for Disease Misclassification in Epidemiologic Studies,"
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Checklist, it is more important to assess whether particular tracked safety issues are more
vulnerable to misclassification, and the ability of the Mini-Sentinel System to adjust for
these biases. Quantitative methods to adjust for misclassification bias are discussed at
length in Section 8.
4.2.3.1 Exposure Misclassification in the Mini-Sentinel System
Exposure to a therapeutic is not often measured, but assumed via proxy variables.
When using claims data, there is an assumption that a medical product that has been
dispensed is a medical product that has been used therapeutically in accordance with the
dispensing instructions. For self-administered therapeutics, these assumptions may be
quite strong as they assume strict adherence to the prescribing regimen. Absent additional
primary data collection mechanisms such as body-based sensors or mobile phone-based
applications for self-reporting, there are few ways to collect validation data to estimate
the potential degree of exposure misclassification. The Mini-Sentinel System is not
designed to enable such primary data collection from patients due to its status as public
health activity.286 Generally, there are fewer adherence concerns for infusions or
injections that are administered in a healthcare setting (i.e., sometimes termed medically-
attended exposures).
Assuming adherence when it is not present creates false positive exposures, but false
negative exposures are also possible. This type of exposure misclassification may arise
when patients obtain therapeutics outside of their insurance coverage. Recent studies
have documented this type of exposure misclassification due to restrictive formularies 287
and due to therapeutics that are available in both prescription and over-the-counter
status.28 8
American Journal of Epidemiology 138, no. 11 (1993): 1007-1015; M. S. Green, "Use of Predictive Value
to Adjust Relative Risk Estimates Biased by Misclassification of Outcome Status," American Journal of
Epidemiology 117, no. 1 (1983): 98-105.
286 See supra at note 19.
287 John-Michael Gamble et al., "Restrictive Drug Coverage Policies Can Induce Substantial Drug
Exposure Misclassification in Pharmacoepidemiologic Studies," Clinical Therapeutics 34, no. 6 (June
2012): 1379-1386.e3.
288 Joseph A C Delaney et al., "Demographic, Medical, and Behavioral Characteristics Associated with
over the Counter Non-steroidal Anti-inflammatory Drug Use in a Population-based Cohort: Results from
the Multi-Ethnic Study of Atherosclerosis," Pharmacoepidemiology and Drug Safety 20, no. 1 (January
2011): 83-89.
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In summary, in terms of the Mini-Sentinel System Pre-screening Checklist, there may
be exposure misclassification when investigating 1) therapeutics with predicted or known
poor adherence patterns (e.g. anti-epileptic medications 289), 2) therapeutics that are
prescribed "as needed" such as migraine medications, 3) therapeutics that are not
routinely included in commercial insurance formularies, and 4) therapeutics that have
both prescription and over-the counter status (e.g., omeprazole).
4.2.3.2 Outcome Misclassification in the Mini-Sentinel System
Outcome misclassification is a major concern in the Mini-Sentinel System, and a
focus of research.2 90 Systematic validation of algorithms to detect particular outcomes has
just begun.29 ' Generally, these validation studies are estimating positive predictive
values, which are only informative with respect to false positives. Estimation of false
negatives, or missed outcomes, is difficult in database systems, although Chubak et al.
suggest that use of narrow identification algorithms are likely to increase false
negatives.292
Outcome misclassification is more likely to occur when diagnostic definitions of
particular outcomes are ambiguous, uncertain, or evolving (e.g., psychiatric disorders)
and diagnoses are made in the absence of laboratory values or other objective criteria.
Error-prone diagnostic tests also contribute to outcome misclassification. Additionally,
outcome misclassification may occur for diseases with slow disease progression because
the "onset" date is unclear (e.g., cancer may be detected at a late stage so the precise
"onset" date of the cancer may be impossible to know). Outcome misclassification may
create problems for identifying the targeted outcome (i.e., the adverse event), but also for
defining the initial cohort. Often, cohorts are defined with respect to the presence/absence
289 Avani C Modi, Joseph R Rausch, and Tracy A Glauser, "Patterns of Nonadherence to Antiepileptic
Drug Therapy in Children with Newly Diagnosed Epilepsy," JAMA: The Journal of the American Medical
Association 305, no. 16 (April 27, 2011): 1669-1676.
290 R. M. Carnahan, "Mini-Sentinel's Systematic Reviews of Validated Methods for Identifying Health
Outcomes Using Administrative Data: Summary of Findings and Suggestions for Future Research,"
Pharmacoepidemiology and Drug Safety 21 Suppl 1 (2012): 90-99.
291 Sarah L Cutrona et al., "Validation of Acute Myocardial Infarction in the Food and Drug
Administration's Mini-Sentinel Program," Pharmacoepidemiology and Drug Safety (June 29, 2012),
http://www.ncbi.nlm.nih.gov/pubmed/227450 3 8 .
292 Chubak, Pocobelli, and Weiss, "Tradeoffs Between Accuracy Measures for Electronic Health Care Data
Algorithms."
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of pre-existing diagnoses. If these baseline outcomes are mismeasured, then the cohort
itself is misclassified.
In general, use of post hoc corrective procedures to deal with misclassification
requires it to be non-differential, which is a strong and untestable assumption in the Mini-
Sentinel System. In fact, therapeutics other than vaccines are given to people with active
disease processes, and additional follow-up medical visits and/or diagnostics tests are
likely to follow from exposure to new therapeutics as part of the normal course of care.
These follow-up visits and tests create differential opportunities to detect adverse events
among the exposed, thereby creating differential misclassification. The use of active
comparators as opposed to non-users may mitigate this possibility of differential
misclassification. Complete medical chart confirmation is the only sure way to correct
outcome misclassification, but these procedures may be very costly and time-consuming.
For the purposes of the Mini-Sentinel System Pre-Screening Checklist, there is a
higher likelihood of outcome misclassification when investigating outcomes that are do
not have clear onsets, or stable and repeatable diagnostic criteria over a variety of
medical settings (e.g., specialty practices as compared to general practitioners, as well as
emergency departments as compared to outpatient clinical settings).
4.2.3.3 Covariate Misclassification in the Mini-Sentinel System
As was discussed earlier, concerns regarding covariates tend to focus on whether they
are measured at all, rather than on how accurately they are measured. If important
covariates include concomitant exposures or co-morbidities, then these types of
covariates are subject to the same misclassification problems described above. Other
covariates tend to be related to demographics, or current health status. Measures of
general health status often are at greater risk for misclassification. For example, although
obesity has a medically specific definition, it is difficult to ascertain when body mass
index is not explicitly coded or annotated in a medical record. Also, discretization of
continuous covariates to enable count-based analyses results in loss of information (e.g.,
a smoker/non-smoker classification may lump together very heavy smokers with
occasional smokers). Validation procedures may solve covariate misclassification issues,
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but these biases may be subsumed by concerns about unmeasured or unmeasurable
covariates that were discussed in subsection 4.2.1.
For the purposes of the Mini-Sentinel System Pre-screening Checklist, regulators
should strongly consider which covariates are relevant to the tracked safety issue, and
what is known about their classification in database systems.
4.3 Issues of Precision or Sample Size
Precision 2 9 3 - or the inverse of the variance - is a function of sample size, and an
advantage of administrative datasets is the capacity for very large sample sizes. To
establish greater precision, one may extend the study period or take other measures to
increase the sample size. In section 6, I will use mathematical models to more finely
address planning for sample size considerations in the Mini-Sentinel System, particularly
with respect to sequential database surveillance. However, without engaging in more
complex analyses, it is useful to simply consider whether exposures in the Mini-Sentinel
System are likely to generate sample sizes that would meet a regulator's requirement for
precision (i.e., the statistical power) when trying to establish postmarket evidence. Thus, I
review circumstances in which sample size is difficult to achieve in the Mini-Sentinel
System.
4.3.1 Route of Administration and Healthcare Setting of Exposure
To start, one should consider both the primary route of administration and healthcare
setting in which the therapeutic is administered, and then determine if it is well captured
in the Mini-Sentinel System. The Mini-Sentinel System is more efficient at capturing
outpatient/"clinic" exposures and less efficient in capturing inpatient or emergency
department exposures. That is, exposures in the latter two settings may not be recorded as
individual line items, but aggregated as part of a diagnosis-related group code. It can be
difficult to identify dates of exposure based on these data.
The Mini-Sentinel System is also more efficient at capturing self-administered
exposures (e.g., oral medication or self-injectables) than at capturing infusions and
injections primarily administered in the "clinic"/outpatient or inpatient setting. Infusions
293 For a definition of precision, see supra at note 243.
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and injections in these settings are treated as procedures, and may be recorded with
Current Procedural Terminology (CPT) or Healthcare Common Procedure Coding
System (HCPCS) codes. There are significant time lags associated with producing new
codes to capture newly-approved infusions or injections, which are often the exposures of
294interest. For reimbursement purposes, temporary codes are relied on but these
temporary codes can create significant instability in data repurposed for secondary use.
In section 9, I analyzed data from the Mini-Sentinel System with respect to new
molecular entities approved in the years 2004-2006. 1 eliminated certain new molecular
entities from the dataset because they were typically delivered in an inpatient setting, and
thus, generally less reliably captured in the Mini-Sentinel System. Of the 78 new
molecular entities approved in those years, 37 were eliminated (i.e., 47%).
4.3.2 Low Exposure Prevalence Therapeutics
Also, by drawing on data held by commercial insurers, the Mini-Sentinel System is
designed to be nationally representative and capture broad patterns in medical care. Even
in a large system, orphan/rare diseases and their accompanying therapeutics will have
low exposure prevalence that may be challenging to study. For example, in Mini-Sentinel
System data accessed in support of this dissertation, orphan-designated drugs had less
than 1500 new users over a 5-year period. One should consider whether exposure-based
registries would be required to generate appropriate sample sizes for certain tracked
safety issues.
Additionally, low exposure prevalence can result from a crowded market or
availability of many substitute products, poor (i.e., high-tiered) placement in formularies
resulting in high co-payments, or non-preferred status in clinical guidelines. In the Mini-
Sentinel System data accessed for this dissertation, two drugs in the same class (i.e.,
competitors) - one with preferred status in clinical guidelines and one without such a
status - had more than a tenfold difference in new users over a five year period.
294 See generally American Medical Association, "CPT@ Process - How a Code Becomes a Code", n.d.,
http://www.ama-assn.org/ama/pub/physician-resources/solutions-managing-your-practice/coding-billing-
insurance/cpt/cpt-process-faq/code-becomes-cpt.page; Centers for Medicare and Medicaid Services,
"Healthcare Common Procedural Coding System (HCPCS) Public Meetings", August 3, 2012,
http://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo/HCPCSPublicMeetings.html.
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4.3.3 Medicare Populations
Medicare - the publicly-funded national insurance system for adults over 65, those
with end-stage renal disease, and the permanently disabled - fundamentally changed on
January 1, 2006. Effective that date, the Medicare Modernization Act of 2003 created
Medicare Part D drug coverage plans, which allowed private insurers to offer prescription
drug coverage benefits. 2 95 Eligible persons could obtain stand-alone prescription drug
coverage or could be enrolled in Medicare Advantage plans with prescription drug
benefits. Although many of the details of this transition are beyond the scope of this
dissertation, the net result is that the Mini-Sentinel System is a less than ideal setting to
evaluate exposure-outcome pairs that primarily affect Medicare populations because they
may not have complete coverage (i.e., drug and medical benefits coverage) in a single
296 rsacdata source. New research shows this same potential in the elderly who are also
veterans.297 In general, it is likely that individuals without complete coverage would be
excluded from pharmacoepidemiologic studies.
Additionally, the elderly that do have complete coverage under one insurer may be
unique and not representative of the elderly population generally, leading to
transportability issues, which will be discussed in subsection 4.4. The FDA's
collaboration with other federal partners like the Centers for Medicare and Medicaid
Services may alleviate some of these concerns. However, if an elderly person's coverage
is scattered among several insurers, then complete capture is undoubtedly problematic.
4.3.4 Long Follow-up Times
If the tracked safety issue requires a long follow-up time (i.e., there is a long latency
period before the event is biologically expected to occur following exposure), then the
Mini-Sentinel System may have too much "churn" to allow for these long follow-up
times, which contributes to small sample size and selection bias as discussed previously
295 Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Public Law 108-173, 2003.
296 For more details on Medicare Part D coverage patterns, see Gerald F. Riley, Jesse M. Levy, and Melissa
A. Montgomery, "Adverse Selection In The Medicare Prescription Drug Program," Health Affairs 28, no. 6
(December 2009): 1826-37; Amy J. Davidoff et al., "Lessons Learned: Who Didn't Enroll In Medicare
Drug Coverage In 2006, And Why?," Health Affairs 29, no. 6 (June 2010): 1255-63.
297 See Amal N Trivedi et al., "Duplicate Federal Payments for Dual Enrollees in Medicare Advantage
Plans and the Veterans Affairs Health Care System," JA MA: The Journal of the American Medical
Association 308, no. 1 (July 4, 2012): 67-72.
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in section 4.2.2.1. This problem may become exacerbated by the implementation of the
Patient Protection and Affordable Care Act 2 98, which intends to increase competition
among health insurers for enrollees. For surveillance purposes, increases in churn
effectively reduce sample sizes.
4.4 Issues related to Transportability
Transportability describes how well the inference can be applied (i.e., transported) to
other populations. 2 99 Recall that the Mini-Sentinel System is comprised of databases of
commercially-insured persons. If a tracked safety issue affects an uninsured population,
then an alternative evidence generation system may be necessary. The Mini-Sentinel
System is generally composed of commercially insured individuals with medical and
drug benefits coverage under the age of 65. Therefore, the transportability of results to
other populations is uncertain.
4.5 Mini-Sentinel System Pre-Screening Checklist
In summary, every evidence generation system has strengths and weaknesses, and
the particular circumstances of some tracked safety issues may favor some systems over
others. Herein, I have sought to review circumstances that may be unfavorable to using
the Mini-Sentinel System as an evidence generation system and compress these
weaknesses into the Mini-Sentinel System Pre-screening Checklist in Table 2. This
checklist is intended as a qualitative aid to prompt thoughtful analysis on whether the
Mini-Sentinel System is likely insufficient on its face to evaluate a particular tracked
safety issue. Key inputs include the tracked safety issue being investigated and the
regulators' estimation of the strength of causal inference necessary to support regulatory
decision-making.
If regulators proceed through this checklist without eliminating the Mini-Sentinel
System as an evidence generation system, then I presume they have found it likely to be
sufficient, per the statute 300, to resolve the tracked safety issue. The FDA may also wish
to establish some similar procedures to decide whether its other postmarket evidence
298 Patient Protection and Affordable Care Act, P.L. 111-148.
299 For a definition of transportability, see supra at note 244.
300 See supra at note 217.
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generation systems - e.g., the spontaneous reporting systems - are also deemed sufficient,
but I leave that to others.
MINI-SENTINEL SYSTEM PRE-SCREENING CHECKLIST
Bias Issues (General)
- Is there a need to detect/rule out small effect sizes (i.e., relative risks less than 2)?
To mitigate:
- Is a self-controlled design possible?
Bias Issues (Confounding Bias)
- Is there likely to be confounding by indication/confounding by contraindication/channeling bias?
- Are known important confounders unmeasured or unmeasurable?
To mitigate:
- Is a self-controlled design possible?
- Do instrumental variables (e.g., required formularies) exist?
- Is medical chart confirmation in a subset of the study population feasible?
Bias Issues (Selection Bias)
- Are changes in insurance coverage potentially associated with the exposure AND outcome of
interest?
- Are there other censoring conditions (e.g., death) that are associated with the exposure and
outcome of interest?
To mitigate:
- Is post hoc analysis likely to account for selection biases? How sensitive are the results to such
biases?
Bias Issues (Measurement Bias)
- Do the exposures have predicted or known poor adherence patterns?
- Are the exposures prescribed "as needed"?
- Are the exposures not consistently included in commercial insurance formularies, or are there
other conditions that would cause patients to purchase out-of-pocket?
- Are the exposures ones for which prescription and over-the-counter equivalents exist?
- Are the outcomes related to diagnoses that are evolving, ambiguous or uncertain?
- Do the outcomes have an unclear onset?
- What is the existing validation data regarding sensitivity and specificity of the algorithm in the
Mini-Sentinel System?
- Are the outcomes likely to be diagnosed in a variety of practice settings or by a variety of
practitioners?
- Are important covariates continuous variables? Are measures of these variables unsettled?
To mitigate:
- Is medical chart confirmation in a subset of the study population feasible?
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Precision/Sample Size Issues
- Is the exposure primarily expected to occur in an inpatient or emergency department setting?
* Is the exposure via intravenous infusion or medically attended injection?
To mitigate:
- Has the intravenous infusion or medically attended injection been available for 18 months-2 years
(i.e., has enough time elapsed that procedure codes should be stable)?
- Is low exposure prevalence likely due to either the rareness of the disease being treated, the
availability of substitute therapies, suboptimal insurance coverage (e.g., tiering), or non-preferred
status with respect to clinical guidelines?
* Is the population affected likely to have different insurers for medical benefits and drugs? Is the
exposure in question likely covered under Medicare Part D?
- Is a long follow-up time required (i.e., is there an induction period of several months or years)?
Generalizability/Transportability/External Validity
- Is the tracked safety issue likely to substantially affect an uninsured or underinsured population?
Table 2. The Mini-Sentinel System Pre-Screening Checklist
If the Mini-Sentinel System is likely to be sufficient on itsface to resolve the tracked
safety issue, then I presume the FDA's next decision (shown as Decision 5 in Figure 5)
regards whether to perform retrospective or prospective sequential analysis in the Mini-
Sentinel System. This calculation is often a function of sample size at the time of
initiation of the analysis, and that approximate sample size can be ascertained via
modular programs as described in subsection 2.2.2.1. I focus the rest of this dissertation
on prospective sequential methods because the conduct of protocol-based one-time
assessments (described in subsection 2.2.2.3) is very similar to traditional retrospective
pharmacoepidemiologic studies, which have been well-studied. However, the desire to
avoid pooling data in the Mini-Sentinel System when performing these types of studies
does pose some new challenges in this area.
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301 See supra at note 142.
Regulatory Actions to Influence Utilization Outcomes
Figure 5. FDA Decision Process AFTER the Mini-Sentinel System is Deemed Sufficient
Abbreviations: TSI, tracked safety issue; FDA, Food and Drug Administration; PMR, postmarket
requirement; CDER, Center for Drug Evaluation and Research; AERS, Adverse Event Reporting System;
SDS, sequential database surveillance.
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5 PROSPECTIVE SEQUENTIAL DATABASE SURVEILLANCE
At this point in regulatory decision-making process, I assume that: 1) a tracked safety
issue has been initially evaluated, 2) the Mini-Sentinel System has been deemed
sufficient for regulatory decision-making using qualitative tools such as the Mini-Sentinel
System Pre-screening Checklist, and 3) regulators are pursuing sequential prospective
methods for the tracked safety issue (i.e., a pre-specified exposure-outcome pair) using
the Mini-Sentinel System.
Briefly, I review the conduct of a prospective sequential database surveillance (SDS)
evaluation. First, one prospectively gathers data from multiple databases (e.g.,
population-based health data) to monitor the incidence rate of an exposure-outcome pair
under surveillance. One then compares the observed incidence rate to an expected rate,
which is calculated based on either a concurrent-, historical-, or self-controlled group.
Comparisons are made at regular intervals as data accrue using sequential statistical tests
with pre-specified signaling thresholds. If the test statistic exceeds the threshold, then a
statistical signal of excess risk is identified, the hypothesized exposure-outcome
association is strengthened, and the null hypothesis of no excess risk is rejected. This
signal is ordinarily followed by confirmatory assessments and review to validate or refute
the finding. SDS analyses depend on amassing sufficient exposed person-time (i.e.,
sample size) to reach a stopping point, either by rejecting the null (i.e., detecting a safety
signal) or ending surveillance (i.e., failing to signal).
Beyond feasibility, another important consideration is the context of safety
surveillance, and specifically, what is known, if anything, about the tracked safety issue.
SDS may be undertaken in circumstances when there is little expectation that a safety
problem exists, but surveillance is performed for reassurance. It may also be undertaken
when data from spontaneous reporting systems or underpowered pre-licensure data
suggest the possibility of a safety signal. These considerations are unique to the post-
licensure environment when individuals outside of the observed population are affected
by the speed and confidence (i.e., statistical power) with which a safety signal is detected
or ruled out.
302 J. C. Maro and J. S. Brown, "Impact of Exposure Accrual on Sequential Postmarket Evaluations: a
Simulation Study," Pharmacoepidemiology and Drug Safety 20, no. 11 (2011): 1184-1191.
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Of prospective sequential surveillance methods, the Food and Drug Administration
(FDA) either can perform formal prospective SDS methods as described above or
repeatedly execute modular programs3 03 at set time intervals. Recall that Modular
Program 3 is a computer program for safety signal assessment that can be used to
calculate crude (i.e., mostly unadjusted) associational measures of medical product-
associated adverse event rates. Data in Modular Program 3 can be subjected to post hoc
statistical testing, but there is no ability to automatically control for multiple hypothesis
tests and there are no "stopping boundaries." There is also no identified comparator group
and very limited confounding control (i.e., stratification by age, sex, site only). I will
return to a consideration of these two options after reviewing the state of the science with
regard to prospective sequential surveillance methods next.
5.1 Epidemiological Design Considerations
Often, epidemiologists approach new research/surveillance questions by considering
various epidemiologic designs along scientific, public health, ethical, and practical axes.
With systems like the Mini-Sentinel System in mind, Gagne et al. 304 and.others3 05 have
written extensively on considerations that should inform the epidemiologic design in an
"active monitoring" context. Important factors include the exposure persistence (e.g., is it
a continuing exposure like a statin or a brief one like an antibiotic), the onset and duration
of the risk window period (e.g., is it biologically plausible that the exposure caused the
outcome 1-10 days post-exposure or 30-365 days post-exposure), the strength of
confounding, and the timing of the onset of the outcome of interest (e.g., short for allergic
reactions, quite long for cancers and other chronic diseases that include undiagnosed
subclinical activity).306 All told, consideration of these factors leads epidemiologists to
choose either between-person study designs or within-person study designs, and
sometimes both are employed for reassurance. 307
303 Modular Programs are explained herein in 2.2.2.1.
304 Gagne et al., "Design Considerations in an Active Medical Product Safety Monitoring System."
30s D. L. McClure et al., "Comparison of Epidemiologic Methods for Active Surveillance of Vaccine
Safety," Vaccine 26, no. 26 (2008): 3341-3345.
306 Gagne et al., "Design Considerations in an Active Medical Product Safety Monitoring System."
347 See, for example, a summary of vaccine safety studies in Yih et al., "Active Surveillance for Adverse
Events: The Experience of the Vaccine Safety Datalink Project." Nearly all employ both designs and
designate one as the primary.
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Between-person study designs compare information contributed by different persons
whereas within-person study designs compare information contributed by the same
person during periods of exposure and non-exposure. Functionally, these designs dictate
the choice of comparator group. In a between-person design, the comparator group can be
a historical cohort of similarly situated individuals, or a concurrent cohort matched on
either exposure (i.e., presence or absence of medical product use) or outcome status (i.e.,
presence or absence of adverse event of concern). Typically, these designs may sample
data from the entire cohort of individuals (e.g., a full cohort study) or a smaller subset of
the cohort (e.g., a case-control study). 30 8 Gagne et al. argue that case-control studies
provide no meaningful gains in an administrative database setting when a pre-specified
exposure-outcome pair exists.309
In a within-person design or self-controlled design, the comparator group is the
treatment group, except the individuals are sampled during a different time period. In a
self-controlled design, the individuals may be sampled based on their exposure status
(e.g., a self-controlled risk interval design3 10 ) or outcome status (e.g., a self-controlled
case seriesm3 1 ). Self-controlled designs are a useful technique to mitigate unmeasured and
unmeasureable confoundingm3 ", but there are limited opportunities to employ such
designs because of their many assumptions. As Gagne et al. point out:
"When the key assumptions of self-controlled designs are fulfilled (i.e., lack of within-
person, time-varying confounding; abrupt HOI [health outcome of interest] onset; and
transient exposure), within-person comparisons are preferred because they inherently
avoid confounding by fixed factors."3 13
5.2 Sequential Statistical Methods
It is important to note that the choice of epidemiologic design and comparator group
limit the selection of available sequential statistical methods to analyze the data collected.
308 For more on case-control studies and cohort studies in epidemiology, see Rothman, Greenland, and
Lash, Modern Epidemiology, Chapter 7 and 8.
309 Gagne et al., "Design Considerations in an Active Medical Product Safety Monitoring System."
310 For examples of a self-controlled risk interval designs, see Alison Tse et al., "Signal Identification and
Evaluation for Risk of Febrile Seizures in Children Following Trivalent Inactivated Influenza Vaccine in
the Vaccine Safety Datalink Project, 2010-2011," Vaccine 30, no. 11 (March 2, 2012): 2024-2031; Lee et
al., "HIN I and Seasonal Influenza Vaccine Safety in the Vaccine Safety Datalink Project."
31 For an example of a self-controlled case series design, see S. K. Greene et al., "Near Real-Time
Surveillance for Influenza Vaccine Safety: Proof-of-Concept in the Vaccine Safety Datalink Project,"
American Journal of Epidemiology (2009).
m For more on confounding, see section 4.2.1.
313 Gagne et al., "Design Considerations in an Active Medical Product Safety Monitoring System."
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Epidemiologic Designs
Within-Person Comparisons
Self Controls
Self-
Controlled
Case Series
(matched on
outcome)
Self-
Controlled
Risk Interval
(matched on
exposure)
Poisson MaxSPRT
Conditional Poisson
MaxSPRT
Binomial MaxSPRT** X X
Exact Sequential
Analysis**
Group Sequential
Likelihood Ratio Test** X X
Conditional Sequential
Sampling Procedure
(CSSP)
Propensity Score-
Enabled CSSP
Group Sequential
Estimating Equations***
Group Sequential Lan
Demets***
Between-Person
Com arisons
Historical Concurrent
Controls Controls
Cohort Design
(matched on exposure)*
X
X
X
X
X
X
X X
X X
Table 3. Compatibility of Epidemiologic Designs and Sequential Statistical Methods
*It is possible to use between-person comparisons and match on outcome. This would be a case-control
design, which generally is not used in this context.314
**It is not applicable to a continuous exposure setting for which the number of exposed days will vary by
each patient (e.g., most drugs). This is a quite limiting feature.
***It is generally not feasible when the outcome is rare or very rare.315
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test; CSSP, Conditional Sequential
Sampling Procedure
While the choice of epidemiologic design and comparator group affect data collection
(i.e., how we sample the database of individuals), the choice of sequential statistical
m Ibid.
315 For definitions of rare or very rare outcomes, see The Council for International Organizations of
Medical Sciences (CIOMS) Working Group III, Guidelines for Preparing Core Clinical Safety Information
on Drugs.
92
0
C,)
COP)
0
000
0
0~
0
0
0
,,
method largely affects data analysis. Table 3 presents the compatibility of epidemiologic
designs with sequential statistical methods, which are explained in detail in this section.
Generally, different methods can be compared with respect to their treatment of type I
error and its distribution over multiple hypothesis tests, type II error/statistical power, the
time to detect a signal (i.e., what I will later describe as the median sample size), and the
maximum sample size. Sequential statistical methods also require that investigators set a
stopping boundary, or a way to interrupt and end surveillance through signaling. The
shape of this boundary dictates the likelihood of signaling at various interim hypothesis
tests and determines some of the tradeoffs between power (i.e., sample size) and the
timeliness of signal detection. Others3 16 have reviewed sequential statistical methods that
can be employed to perform SDS, which will be briefly summarized here.
A broad and important classification of the methods regards the frequency of multiple
hypothesis testing. Continuous hypothesis testing methods perform hypothesis tests with
the arrival of each observation. Group sequential testing methods specify the number of
interim hypothesis tests based either on how information accrues in exposed-time or
calendar-time increments. There are generally fewer interim tests than under a continuous
hypothesis testing regimen. Group sequential clinical trials, which employ the same
statistical models, commonly only allow 1-3 interim tests. In general, more frequent
testing (i.e., continuous) performs better on timeliness by minimizing sample size, but
does less well with regard to type I and type II errors.
Often, the choice of a continuous or group sequential statistical method is defined by
logistic feasibility rather than epidemiologic choices. First, the frequency of testing
should be conducive to the way in which data arrive. Specifically, hypothesis tests only
need to be performed as often as new data are expected to arrive. Second, in order to keep
with the assumptions of the underlying statistical models, one must understand how much
316 A. J. Cook et al., "Statistical Approaches to Group Sequential Monitoring of Postmarket Safety
Surveillance Data: Current State of the Art for Use in the Mini-Sentinel Pilot," Pharmacoepideniology and
Drug Safety 21 Suppl 1 (2012): 72-81; J. C. Nelson et al., "Challenges in the Design and Analysis of
Sequentially Monitored Postmarket Safety Surveillance Evaluations Using Electronic Observational Health
Care Data," Pharmacoepidemiology and Drug Safety 21 Suppl 1 (2012): 62-71; Jennifer C Nelson et al.,
"Methods for Observational Post-licensure Medical Product Safety Surveillance," Statistical Methods in
Medical Research (December 2, 2011), http://www.ncbi.nlm.nih.gov/pubmed/22138688; Martin Kulldorff,
"Sequential Statistical Methods for Prospective Postmarketing Safety Surveillance," in
Pharmacoepidemiology, ed. Brian L. Strom, Stephen E. Kimmel, and Sean Hennessy, Fifth. (John Wiley &
Sons, 2011), 852-867.
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new information arrives in each download of new data. For continuous sequential
methods that perform a new hypothesis test on each new observation, if several
observations were to arrive simultaneously, then there would be a mismatch between the
statistical model assumptions and real-world surveillance. Consequently, as Cook et al.
describe: "[the] use of continuously-designed [statistical] thresholds when testing is
actually performed [less frequently] means that higher-than-necessary thresholds are
used. This yields a type I error rate that is lower than desired and suboptimal statistical
power."317 Thus, the overall type I error threshold is set too conservatively. Further, "the
magnitude of the conservatism increases with the amount of new data received between
discrete testing points." 318
5.2.1 Continuous Sequential Testing Methods - SPRT Adaptations
In the initial proof-of-principle analysis within the Vaccine Safety Datalink319 ,
statistical analysis was performed using Wald's Sequential Probability Ratio Test
(SPRT)320 to analyze vaccinated cohorts and compare them to historical data on a weekly
basis.3 2 ' The SPRT is a continuous hypothesis testing method as described above.
Acceptance or rejection of the null hypothesis of no excess risk is dependent on the value
of a test statistic, which is posed as a log likelihood ratio. The SPRT's stopping
boundaries use a "flat threshold," meaning that the critical value for the test statistic is
constant across all hypothesis tests. Although this threshold is mathematically simple and
easy-to-understand, others have noted that a flat threshold may yield more false positives
early in monitoring when there is less data, and lower power (i.e., higher type II error) at
later points.3 22 One way to overcome this limitation of a flat spending boundary while
317 Cook et al., "Statistical Approaches to Group Sequential Monitoring of Postmarket Safety Surveillance
Data: Current State of the Art for Use in the Mini-Sentinel Pilot."
318 Nelson et al., "Methods for Observational Post-licensure Medical Product Safety Surveillance."
319 The Vaccine Safety Datalink is a precursor to the Mini-Sentinel System and is described by Baggs et al.,
"The Vaccine Safety Datalink: a Model for Monitoring Immunization Safety."
320 A. Wald, "Sequential Tests of Statistical Hypotheses," The Annals of Mathematical Statistics 16, no. 2
(1945): pp. 117-186.
m R. L. Davis et al., "Active Surveillance of Vaccine Safety: a System to Detect Early Signs of Adverse
Events," Epidemiology (Cambridge, Mass.) 16, no. 3 (2005): 336-341.
322 Nelson et al., "Challenges in the Design and Analysis of Sequentially Monitored Postmarket Safety
Surveillance Evaluations Using Electronic Observational Health Care Data."
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still performing continuous testing is to delay hypothesis testing until a certain number of
events or exposures have accrued.m Such a delay prevents early signaling on little data.
Adjustment for confounding is done by stratifying the historical count data according
to a limited set of covariates (e.g., age, sex, site), and then performing a logistic
regression to calculate a risk-adjusted probability of the outcome in question.324 The log
likelihood ratio is the product of the likelihoods in the various strata. This approach limits
the total number of confounders that can be considered to prevent multiple strata that are
uninformative or too small.
Wald's SPRT requires a simple alternative hypothesis (e.g., a specific risk estimate
such as an incidence rate ratio of 5). Kulldorff et al. have shown that the method is highly
dependent on the selecting the correct alternative hypothesis (i.e., if an excess risk exists,
then this presumption implies knowing the approximate value of that elevated risk, which
is improbable).3 2 5 Subsequent analyses in the Vaccine Safety Datalink utilized an
adaptation of that method, Kulldorffs maximized sequential probability ratio test
(MaxSPRT).32 6 The MaxSPRT uses a composite alternative hypothesis as opposed to
Wald's simple alternative. Initially, two variants of the MaxSPRT were posed: a binomial
and a Poisson variant.
5.2.1.1 Binomial Variants
The binomial variant has been used for concurrent-327 and self-controlled 328 analyses.
Like Wald's SPRT, the binomial MaxSPRT model typically uses a flat threshold
although Kulldorff indicates that it can support other types of sequential statistical
323 Martin Kulldorff and Ivair Silva, "Continuous Sequential Analysis with Delayed Start", Unpublished
Manuscript, 2012.
324 S H Steiner, R J Cook, and V T Farewell, "Risk-adjusted Monitoring of Binary Surgical Outcomes,"
Medical Decision Making: An International Journal of the Society for Medical Decision Making 21, no. 3
(June 2001): 163-169.
325 M. Kulldorff et al., "A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety
Surveillance," Seq Anal 30, no. 1 (2011): 58-78.
326 ibid.
327 T. A. Lieu et al., "Real-time Vaccine Safety Surveillance for the Early Detection of Adverse Events,"
Medical Care 45, no. 10 Supl 2 (2007): S89-95.
328 Tse et al., "Signal Identification and Evaluation for Risk of Febrile Seizures in Children Following
Trivalent Inactivated Influenza Vaccine in the Vaccine Safety Datalink Project, 2010-2011"; Lee et al.,
"HINI and Seasonal Influenza Vaccine Safety in the Vaccine Safety Datalink Project"; Greene et al.,
"Near Real-Time Surveillance for Influenza Vaccine Safety: Proof-of-Concept in the Vaccine Safety
Datalink Project."
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boundaries. 32 9 Confounding is controlled through matching. Early implementations of the
binomial variant required a fixed matching ratio of the treatment group to the comparator
330
group, which became difficult to implement in practice . Specifically, investigators had
to tradeoff more stringent matching criteria (i.e., better confounding control) against loss
of information that resulted from the inability to find a match.
Subsequent improvements to the method relaxed this restriction and allowed the
number of matched controls to vary by making use of an exact binomial test. The Exact
Sequential Analysis 331 , as it is now known, also can accommodate multiple sequential
stopping boundaries. It is important to note that neither the binomial MaxSPRT model
nor the Exact Sequential Analysis can be utilized with continuous exposures because of
the inability to control the ratio of exposed/unexposed persons at each hypothesis test.
Practically, it means that these tests cannot be used with most drugs and therapeutic
biologics. As noted before, this is a major limitation in the Mini-Sentinel System.
5.2.1.2 Poisson Variants
The Poisson MaxSPRT variant is used with historical control groups, assumes a flat
threshold, and assumes that the historical comparison rate is known (i.e., calculated from
a large sample of the historical cohort). Confounding control is via stratification and then
regression modeling as described above. The Poisson MaxSPRT model has been used in
extensively in vaccine safety surveillance 3 32 and has been piloted for use in drug
surveillance3 33 . This sequential statistical test was later adapted into the conditional
329 Kulldorff, "Sequential Statistical Methods for Prospective Postmarketing Safety Surveillance."
330 Lieu et al., "Real-time Vaccine Safety Surveillance for the Early Detection of Adverse Events."
331 J. Gee et al., "Monitoring the Safety of Quadrivalent Human Papillomavirus Vaccine: Findings from the
Vaccine Safety Datalink," Vaccine 29, no. 46 (2011): 8279-8284.
332 Lieu et al., "Real-time Vaccine Safety Surveillance for the Early Detection of Adverse Events"; E. A.
Belongia et al., "Real-Time Surveillance to Assess Risk of Intussusception and Other Adverse Events After
Pentavalent, Bovine-Derived Rotavirus Vaccine," The Pediatric Infectious Disease Journal 29, no. 1
(2010): 1-5; N. P. Klein et al., "Measles-mumps-rubella-varicella Combination Vaccine and the Risk of
Febrile Seizures," Pediatrics 126, no. 1 (2010): el-8; W. K. Yih et al., "An Assessment of the Safety of
Adolescent and Adult Tetanus-diphtheria-acellular Pertussis (Tdap) Vaccine, Using Active Surveillance for
Adverse Events in the Vaccine Safety Datalink," Vaccine 27, no. 32 (2009): 4257-4262; Gee et al.,
"Monitoring the Safety of Quadrivalent Human Papillomavirus Vaccine: Findings from the Vaccine Safety
Datalink."
m J. S. Brown et al., "Early Adverse Drug Event Signal Detection Within Population-based Health
Networks Using Sequential Methods: Key Methodologic Considerations," Pharmacoepidemiology and
Drug Safety 18, no. 3 (2009): 226-234; J. S. Brown et al., "Early Detection of Adverse Drug Events Within
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MaxSPRT (CMaxSPRT) 334 model to account for uncertainty in expected event rate in the
historical comparison group. The CMaxSPRT model has been used for influenza vaccine
surveillance.3 35
5.2.2 Group Sequential Testing Methods
Group sequential methods have a well-established statistical literature that was
developed primarily in a randomized controlled trial setting. 336 Like continuous testing
methods, these methods also allow a statistically valid way to stop a clinical trial early as
a result of evidence of excess harm or demonstrated benefit. That is, it would be unethical
to continue to allow the unexposed group to remain unexposed if the harmful or
beneficial effect were proven statistically at an interim test. Typically, only a limited
number of interim tests are performed in a clinical trial because of concerns related to
loss of power. Additionally, group sequential clinical trials often were based on efficacy
endpoints, and so approaches to deal with rare safety endpoints (e.g., Type B adverse
reactions) are underdeveloped. Very recently, these techniques have been proposed and
simulated in an observational safety surveillance context 337, although no actual
surveillance activities have yet been completed with these methods.
5.2.2.1 Lan-Demets Group Sequential Approach
The Lan and Demets statistical model is widely used in clinical trials.338 Lan and
Demets developed a general statistical sequential boundary function for any
Population-based Health Networks: Application of Sequential Testing Methods," Pharmacoepidemiology
and Drug Safety 16, no. 12 (2007): 1275-1284.
334 L. Li and M. Kulldorff, "A Conditional Maximized Sequential Probability Ratio Test for
Pharmacovigilance," Statistics in Medicine 29, no. 2 (2010): 284-295.
m3 Tse et al., "Signal Identification and Evaluation for Risk of Febrile Seizures in Children Following
Trivalent Inactivated Influenza Vaccine in the Vaccine Safety Datalink Project, 2010-2011"; Lee et al.,
"HINI and Seasonal Influenza Vaccine Safety in the Vaccine Safety Datalink Project."
336 For summaries, see John Whitehead, The Design and Analysis of'Sequential Clinical Trials (Wiley,
1997); Christopher Jennison and Bruce W. Turnbull, Group Sequential Methods with Applications to
Clinical Trials (Boca Raton: Chapman & Hall/CRC, 2000).
337 Cook et al., "Statistical Approaches to Group Sequential Monitoring of Postmarket Safety Surveillance
Data: Current State of the Art for Use in the Mini-Sentinel Pilot"; Nelson et al., "Methods for
Observational Post-licensure Medical Product Safety Surveillance."
338 D L DeMets and K K Lan, "Interim Analysis: The Alpha Spending Function Approach," Statistics in
Medicine 13, no. 13-14 (July 15, 1994): 1341-1352; discussion 1353-1356; D L Demets, "Group
Sequential Procedures: Calendar Versus Information Time," Statistics in Medicine 8, no. 10 (October
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asymptotically normal test statistic, which means it performs well with frequent
observations. However, in practice, for sequential surveillance with rare events, the
asymptotic properties of the boundary fail to hold.339 Consequently, such an approach has
limited applicability in safety surveillance for Type B adverse events, but may still prove
quite worthwhile for Type A or Type C adverse events. 340
5.2.2.2 Group Sequential Likelihood Ratio Test
Cook et al. extended the binomial MaxSPRT model as described in subsection 5.2.1.1
and adapted it to accommodate situations in which multiple observations are likely with
each arrival of new data. 34 ' Like the Lan-Demets method, this approach - the group
sequential likelihood ratio test (GS LRT) - is potentially well adapted to Type A or Type
C adverse events. As in other group sequential methods, a hypothesis test is not
performed at the arrival of each new observation of an outcome, but rather based on the
total exposure time accrued between hypothesis tests. Similar to the binomial MaxSPRT
model, the GS LRT employs a fixed matching ratio, but accommodates multiple
sequential stopping boundaries. However, its matching requirements create problems for
use of the approach with continuous exposures because of the inability to keep the same
ratio of person time contributed (i.e., exposed person-time/unexposed person-time) at
each hypothesis test.
5.2.2.3 Conditional Sequential Sampling Procedure
The conditional sequential sampling procedure (CSSP) 34 2 is a group sequential
method created to accommodate continuous exposures and concurrent comparison groups
with active comparators as opposed to non-users. The choice of the sequential stopping
boundary is flexible, and confounding control is performed via stratification on
1989): 1191-1198; K. K. Gordon Lan and David L. Demets, "Discrete Sequential Boundaries for Clinical
Trials," Biometrika 70, no. 3 (December 1, 1983): 659-663.
339 Cook et al., "Statistical Approaches to Group Sequential Monitoring of Postmarket Safety Surveillance
Data: Current State of the Art for Use in the Mini-Sentinel Pilot."
340 For more on Types A, B and C adverse reactions, see Meyboom, Lindquist, and Egberts, "An ABC of
Drug-related Problems."
341 Cook et al., "Statistical Approaches to Group Sequential Monitoring of Postmarket Safety Surveillance
Data: Current State of the Art for Use in the Mini-Sentinel Pilot."
34 2 L. Li, "A Conditional Sequential Sampling Procedure for Drug Safety Surveillance," Statistics in
Medicine 28, no. 25 (2009): 3124-3138.
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categorical confounders. The CSSP is efficient for evaluating rare events, but becomes
less useful with very frequent testing or stratification on many confounders. 34 3
Subsequent improvements to the procedure include enabling it to handle propensity
scores to enhance confounding control. 34 4
5.2.2.4 Group Sequential Estimating Equations
Cook et al. developed the group sequential estimating equation approach, which is a
regression-based group sequential test analyzed with a score test statistic. 34 5 It can handle
continuous exposures and multiple continuous confounders, but it relies on significant
information at the first analysis to estimate the parameters of the regression model. As
noted by Nelson et al., approaches that delay hypothesis testing until a sufficient amount
of information has accrued may solve these problems. 34 6
Fireman et al. are using a regression-based approach with a Cox proportional hazards
model in the pilot sequential database surveillance activity of the Mini-Sentinel
System. 34 7 Confounding is being controlled through propensity-score matching.
5.3 Formal Sequential Database Surveillance Methods Compared to Modular
Programs
Sequential database surveillance methods as discussed herein require specification of
epidemiologic designs, comparator groups, and sequential statistical models, whereas
repeated execution of modular programs does not require such specification. Modular
program outputs are stratified incidence rates, which when compared, can produce mostly
unadjusted associational measures. If desired, these measures can be subject to
hypothesis testing although there are no formal means to control for multiple hypothesis
343 Cook et al., "Statistical Approaches to Group Sequential Monitoring of Postmarket Safety Surveillance
Data: Current State of the Art for Use in the Mini-Sentinel Pilot."
344 Lingling Li et al., "A Propensity Score-Enhanced Sequential Analytic Method for Comparative Drug
Safety Surveillance," Statistics in Biosciences 3, no. 1 (2011): 45-62.
345 Cook et al., "Statistical Approaches to Group Sequential Monitoring of Postmarket Safety Surveillance
Data: Current State of the Art for Use in the Mini-Sentinel Pilot."
346 Nelson et al., "Challenges in the Design and Analysis of Sequentially Monitored Postmarket Safety
Surveillance Evaluations Using Electronic Observational Health Care Data."
347 Fireman et al., "A Protocol for Active Surveillance of Acute Myocardial Infarction in Association with
the Use of a New Antidiabetic Pharmaceutical Agent."
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tests. When might one prefer repeated execution of modular programs to a formal
sequential statistical method?
A key determination for each tracked safety issue being considered is twofold:
whether there is enough information to suggest a clinically relevant control group and
whether more precise quantification of the safety signal relative to that control group is
necessary. The first point speaks to the case when little is known about what patients
might use as a substitute product, or if a suitable substitute product even exists. This
situation may present itself for medical products with potentially diverse patient
populations, or medical products that are monitored soon after the time of approval. In
these circumstances, undertaking prospective sequential database surveillance may be
premature.
Second, circumstances in which further quantification may be unnecessary include 1)
when the background rate of the outcome occurring spontaneously in the clinical
population of concern is very rare or near zero, 2) when the outcome of concern is
biologically and temporally clearly drug-induced. In such cases, little is likely to be
gained from quantification using formal sequential prospective surveillance methods. In
the past, these tracked safety issues were resolved with evidence from case series
analyses. 34 8
5.4 Lessons Learned
I now turn to lessons learned in prospective sequential database surveillance. An early
concern regarding these studies was the potential for false positive signals that might
overwhelm regulators and manufacturers performing post-signal investigations. Yih et
al.349 report on the early Vaccine Safety Datalink experience investigating thirty
designated vaccine-outcome combinations, which resulted in ten statistical signals of
excess risk while performing SDS analyses. However, following further investigation,
only one of the initial statistical signals was confirmed to be a true association, and thus a
true signal of a serious risk. I have already discussed the sources of bias in observational
studies that may lead to false positive conclusions. In general, nearly all of the false
348 Dal Pan, Lindquist, and Gelperin, "Postmarketing Spontaneous Pharmacovigilance Reporting Systems."
349 W. K. Yih et al., "Active Surveillance for Adverse Events: The Experience of the Vaccine Safety
Datalink Project," Pediatrics 127 Suppl I (May, 2011), S54.
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signals were due to confounding bias or measurement bias, while a few appeared to be
transient early signaling which has since been corrected with improved statistical designs.
Another concern that has emerged is the potential for prolonged surveillance
activities resulting from a lack of adoption of the medical product. In these instances,
there is literally an inability to reach a stopping point resulting from the slow arrival of
new information. An analogous concern in prospective postmarket clinical trials is under-
enrollment, which results in underpowered trials. Generally, sequential analyses require
managing two time-scales: calendar time and information time. Attention to calendar
time is important because of potential excess harms to the population that may result
from delayed detection of a safety problem. Attention to information time - how sample
size is accrued - is important for statistical considerations. In that sense, the balance
between timeliness and sample size is more challenging in prospective sequential
database surveillance than in sequential clinical trials because the need to minimize
calendar time while resolving a tracked safety issue has a greater priority.
For these reasons, decisions to proceed with prospective sequential database
surveillance will, in part, hinge on whether accrual of information (i.e., sample size)
occurs within a calendar time frame appropriate for regulatory decision-making. To wit,
the advantage of such surveillance occurs when information accumulates rapidly enough
to provide regulators an earlier opportunity for regulatory intervention than would be
possible via another evidence generation system.
Next, I develop a tool - the Sequential Database Surveillance Simulator - to allow
regulators or public health investigators to explore quantitative assessments of sufficiency
of the Mini-Sentinel System under varying conditions of uncertainty. The simulator is
intended to be a learning tool and quantitative aid to decision-makers that must
simultaneously manage information time and calendar time while performing prospective
sequential database studies. The simulator allows regulators/investigators to explore the
many potential surveillance scenarios they could face. With such modeling and
simulation tools, regulators may more precisely deploy evidence generation systems like
the Mini-Sentinel System, and further refine their assessments of its sufficiency for
evidence generation.
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6 SEQUENTIAL DATABASE SURVEILLANCE SIMULATOR
At this point in the Food and Drug Administration (FDA)'s decision algorithm, I
assume that the FDA is proceeding with sequential database surveillance and is seeking
to refine its understanding of the potential surveillance scenarios that it may encounter for
a particular tracked safety issue of interest. In systems like the Mini-Sentinel System,
sequential database surveillance is performed in an observational setting where the
regulator/public health investigator has no control over information accrual. However, in
light of new safety information suggesting medical product-associated harm, the efficient
use of the Mini-Sentinel System requires a more refined understanding of whether
accrual of information (i.e., sample size) occurs within a calendar time frame appropriate
for regulatory decision-making. In other words, evaluating the Mini-Sentinel System's
evidence generation capabilities necessitates the translation of information time into
calendar time.
In this section and the following two sections, I perform this translation by modeling
and then simulating sequential database surveillance scenarios in the Mini-Sentinel
System via the Sequential Database Surveillance Simulator. I developed this quantitative
tool with the intention to aid the regulator/public health investigator in the initial planning
stages of surveillance when pursuing a tracked safety issue of interest. By demonstrating
how surveillance may unfold given various sets of initial circumstances, the tool is
designed to allow the regulator/public health investigator to explore the performance
limitations and capabilities of sequential database surveillance virtually and in a low-cost
way. That is, in this planning stage, there is no need to "learn-by-doing" while expending
public health resources. In general, this tool is not intended to be strictly predictive or to
forecast exactly how sequential database surveillance of a particular tracked safety issue
will occur. Rather, it more akin to a "management flight simulator,"35 0 which allows the
regulator/public health investigator to explore different potential paths to manage
sequential database surveillance activities.
350 Sterman has pioneered the development of management flight simulators for business operations and
described them thusly, "Virtual worlds for learning and training are commonplace in the military, in pilot
training, in power plant operations, and in many other real time tasks where human operators interact with
complex technical systems." See John Sterman, Business Dynamics: Systems Thinking and Modelingfor a
Complex World (Boston: Irwin/McGraw-Hill, 2000), 35.
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The Sequential Database Surveillance Simulator is compromised of three interlinked
sub-models: the information time sub-model, the calendar time sub-model, and the
analysis sub-model. I walk through an explanation of these sub-models in this section. I
presume the user of the Sequential Database Surveillance Simulator is a regulator or
public health investigator, but I forthwith refer to the "user" to be more general.
As a note, the current version of the Sequential Database Surveillance Simulator
accommodates two specific sequential statistical models that have been frequently used
in prior vaccine safety surveillance.35' I began this process using these models because
they are well-established in this still developing field. However, this simulator could be
built out to accommodate other models, such as the group sequential models reviewed in
subsection 5.2.2. An important aspect of future work will be to increase representation of
group sequential models to better under their comparative performance characteristics.
6.1 Information Time Sub-Model: Sample Size Calculations
6.1.1 Information Time Sub-Model Inputs
The user begins with the following inputs to support the information time sub-model:
1) the sequential statistical model to be used for analysis; and 2) the expected incidence
rate of the outcome of interest in the comparison population, i.e., the background rate.
First, the sequential statistical model specifies the type of hypothesis testing that will be
performed (e.g., continuous or group sequential), and what types of sequential statistical
boundaries can be accommodated. Additionally, each sequential statistical model has its
own set of parameters that need specification. That is, each model uses particular test
statistics, assigns some quantities as known and others as random, etc. Second, the
background rate is the incidence rate of the outcome expected under the null hypothesis,
i.e. that there is no excess risk in the treatment group.
The information time sub-model helps the user to perform sample size calculations
considering a range of effect sizes35 2, and to get a general idea of how much information
is required to make a particular finding. Typical sample size calculations for non-
"' Yih et al., "Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink
Project."
m For a definition of effect size, refer to supra at note 237.
104
sequential statistical methods require investigators to calculate the relationship between
the pre-specified upper limit for accepting false positive results (i.e., type I error), the
statistical power to detect a particular effect size (i.e., type II error), and the sample size.
Sample size calculations for sequential statistical models are similar except they
incorporate the ability to interrupt surveillance by rejecting the null hypothesis at a point
earlier than the prescribed end of surveillance. Thus, in sequential database surveillance,
there are two sample sizes to consider: one is the sample size needed to reject the null
hypothesis (i.e., the time to detect a signal) and the other is the maximum sample size
(i.e., the maximum length of surveillance). More modest (i.e., numerically smaller) true
effect sizes require larger samples. Additionally, sequential statistical models require
specification of the sequential stopping boundary3 5 3 , which relates to how type I error is
apportioned among multiple hypothesis tests and also limits the statistical power that can
be achieved at any interim testing point. Therefore, one must consider six variables in the
sample size calculation: (a) the sequential stopping boundary; (b) the overall type I error
across all hypothesis tests; (c) the true effect size; (d) the statistical power; (e) the
maximum sample size; and (f) the time to detect a safety signal. These last three
quantities are random variables that are easiest to understand with a brief example that
will also allow the reader to observe sequential database surveillance scenarios.
Let us use the Mini-Sentinel System pilot project as our tracked safety issue of
interest. In the pilot project, investigators wished to detect a 1.33 incidence rate ratio of
acute myocardial infarctions among new users of saxagliptin as compared with new users
of other oral anti-diabetic agents with 80% power and 5% overall type I error.3 54 The
investigators specified the background incidence rate in the comparator group to be nine
acute myocardial infarctions per 1000 person years among diabetics. While the
investigators ultimately chose a Cox proportional hazards model with 10 interim tests
(i.e., a group sequential statistical model), let us explore how those same parameters
would play out in the two continuous sequential statistical models supported in the
simulator: the Poisson Maximized Sequential Probability Ratio Test (MaxSPRT) and
binomial MaxSPRT models.
m For a discussion on sequential statistical boundary types, see subsection 5.2
m Fireman et al., "A Protocol for Active Surveillance of Acute Myocardial Infarction in Association with
the Use of a New Antidiabetic Pharmaceutical Agent."
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6.1.2 Poisson MaxSPRT Model
Recall that a Poisson MaxSPRT model supports a cohort design with a historical
comparator group, and that the historical comparator group is defined by the incidence
rate of the outcome of interest expected in that group (i.e., the background rate). I
simulate data on treatment and comparator populations in accordance with an assigned
true effect size, and then analyze these data with the assigned sequential statistical model
(i.e., the Poisson MaxSPRT).
Simulated Data for Surveillance using the Poisson MaxSPRT Model
IRR=1.33, Type I Error=0.05, Type II Error=0.20
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Figure 6. Example Sequential Database Surveillance Scenario Analyzed using the Poisson MaxSPRT
Model
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test. IRR, incidence rate ratio.
First, I simulate an effect size equivalent to a 1.33 incidence rate ratio, and power my
surveillance to limit overall type I error to 0.05, and type II error to 0.20 (i.e., statistical
power is 0.80).3 I use a flat sequential stopping boundary consistent with the default for
3 In the Poisson MaxSPRT model, one must specify the upper limit on the number of outcomes expected
in the comparator group under the null hypothesis. This value represents the maximum sample size, which
will be explained in greater detail in this section. Practically, it is more sensical to set this upper limit based
on the statistical power that is desired, which in this case is 0.80, and then calculate the upper limit from
that threshold. The upper limit that satisfies the condition of at least 80% statistical power to detect a 1.33
incidence rate ratio is 111.75 outcomes.
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the MaxSPRT models, and similar to the sequential stopping boundary chosen for the
Cox proportional hazards model in the Mini-Sentinel System pilot.356 In other words, the
null hypothesis is rejected when the test statistic exceeds a set threshold that does not
change over the course of surveillance (i.e., the "flat" characterization, which is easy to
see by observing the shape of the "Threshold" line in Figure 6).
One instantiation of this simulation produces the scenario depicted in Figure 6. In this
particular instantiation, the number of outcomes in the treatment group separates enough
from the comparator group when the test statistic crosses the threshold value at 65
outcomes, and the sequential statistical model correctly detects a signal of excess risk.
Using simple algebra and the background rate of 9 acute myocardial infarctions per 1000
person-years, 65 outcomes are equivalent to 7,222 person-years. Then, I repeat this
analysis 100,000 times, and display the results as a distribution in Figure 7.
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Figure 7. Distribution of the Information Time to End Surveillance for 100,000 Simulations Analyzed
using the Poisson MaxSPRT Model
Parameters: Incidence Rate Ratio=1.33, overall type I error=0.05, statistical power=0.80. The left panel
represents the overall (i.e., unconditional) distribution. The right upper panel represents the conditional
distribution when a signal was (correctly) detected. The lower right panel represents the conditional
distribution when a signal (incorrectly) failed to be detected.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test.
356 Fireman et al., "A Protocol for Active Surveillance of Acute Myocardial Infarction in Association with
the Use of a New Antidiabetic Pharmaceutical Agent."
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In Figure 7, the left panel is a distribution of the information time required to end
surveillance, and includes the full 100,000 instances of simulation. On the right panel, I
break this histogram into two circumstances: the upper portion represents the instances
when a signal was detected correctly (i.e., the null hypothesis was rejected) and the lower
portion represents the instances when a signal was missed (i.e., the null hypothesis
incorrectly failed to be rejected). These distributions provide us with three important
values.
First, the statistical power is simply the percentage of time that the statistical model
correctly rejects the null hypothesis of no excess risk (i.e., the total frequency counts in
the upper right panel of Figure 7). In this case, the surveillance was powered to limit type
II error to <0.20 when the effect size was equal to an incidence rate ratio of 1.33. Second,
the maximum sample size, which represents the stopping boundary when one fails to
reject the null, takes on one value when using the Poisson MaxSPRT model (i.e., shown
in the lower right panel of Figure 7) and is a consequence of having reached the
maximum expected number of outcomes under the null hypothesis. In this case, the
maximum number of outcomes is 111.75, which means that the maximum sample size is
12,416.67 person-years. Last, the information time required to detect a safety signal (i.e.,
the other stopping boundary) is represented by the median of the information time until
surveillance ends (i.e., the median of the left panel of Figure 7), irrespective of whether a
signal is detected. In this case, the median is 56.4 outcomes, which translates into 6,269
person-years.
I choose the unconditional median as a summary statistic to represent the distribution
in the left panel of Figure 7 for several reasons. First, the unconditional median assures
an accurate comparison of the time-to-signal for different systems with different
statistical power. I only use this statistic when the statistical power is at least 50%,
ensuring the median reflects a time when a signal was detected. If I had used the median
conditioned on when a signal was detected (i.e., the median of the upper portion of the
right panel of Figure 7), then the amount of information that contributes to the
distribution varies based on the statistical power, which generates misleading
comparisons. Second, the unconditional mean is clearly influenced by outliers that
become more prominent as statistical power decreases. Henceforth, I refer to this
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summary statistic as the median sample size, which is analogous to the average or
expected sample size in the group sequential trials literature. 357 Generally, smaller
median sample sizes are preferred because less information is needed to detect a safety
problem.
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Figure 8. Relationship between Statistical Power, Median Sample Size, Maximum Sample Size, and
True Effect Size Analyzed using the Poisson MaxSPRT Model
Statistical power isolines travel from northwest to southeast. Median sample size isolines travel from
southwest to northeast. Overall type I error set to 0.05.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test; Pr, power.
Let us return to the relationships among the six variables in the sample size
calculation: (a) the sequential stopping boundary; (b) the overall type I error across all
hypothesis tests; (c) the true effect size; (d) the statistical power; (e) the maximum sample
size; and (f) the median sample size. To evaluate the relationships among the six
quantities described above, I perform the same simulations that allowed the creation of
m5 Demets, "Group Sequential Procedures"; Scott S Emerson, John M Kittelson, and Daniel L Gillen,
"Frequentist Evaluation of Group Sequential Clinical Trial Designs," Statistics in Medicine 26, no. 28
(December 10, 2007): 5047-5080; J M Kittelson and S S Emerson, "A Unifying Family of Group
Sequential Test Designs," Biometrics 55, no. 3 (September 1999): 874-882.
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Figure 7 and I repeat this process for a range of effect sizes of interest (e.g., incidence
rate ratios of 1.2 to 10). For each effect size, I use the same number of simulations:
100,000. I display an abbreviated version of my results compactly in Figure 8.
In Figure 8, the independent variables - in the mathematical, not the statistical sense -
are the sequential stopping boundary, the overall type I error, the true effect size, and the
maximum sample size. The flat sequential stopping boundary and the overall pre-
specified type I error (0.05) are constant throughout Figure 8. The other two independent
variables - the true effect sizes and the maximum sample sizes - do vary over the figure.
The true effect sizes, illustrated along the x-axis, are given in two scales. The upper scale
is an absolute risk measure. The lower scale is defined using the equivalent relative risk
measure. The y-axis is the maximum sample size, i.e., the stopping boundary for
surveillance when one fails to reject the null. The maximum sample size is shown in
person-years (as opposed to expected outcomes in the comparator group under the null
hypothesis) to be more descriptive and explanatory to the user. 358 In summary, these four
independent variables are fixed to evaluate their effect on statistical power and median
sample size.
The dependent variables - in the mathematical, not the statistical sense - are the
statistical power and the median sample size. In Figure 8, the effects of the independent
variables on the dependent variables are depicted in two sets of isolines. Statistical power
is depicted in the first set of isolines that travels from northwest to southeast. These
isolines are downward sloping because the same statistical power can be attained with
smaller sample sizes when greater true effect sizes exist. Statistical power is higher as the
maximum sample size increases because there are more opportunities to detect a signal.
Median sample size is depicted in the second set of isolines that travels from southwest to
northeast. For a given effect size, there are minimal increases in the median sample size
by increasing the maximum sample size. Vertically asymptotic behavior dominates as
statistical power approaches unity. The values of the median sample size isolines become
smaller as the true effect size increases because smaller sample sizes will signal under
conditions of greater risk.
358 Note that this formulation necessitates specification of the incidence rate expected under the null
hypothesis. However, both expected outcomes in the comparator group under the null hypothesis and their
equivalent person-years are information time measures.
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These figures are shown with an arbitrarily chosen reference outcome of interest of
1/10,000 person-years. Therefore, to use the same figures universally, the user must
calculate an appropriate "k" scaling constant to account for differences between the
problem-specific outcome frequency and the reference outcome frequency (i.e., when
k--1, the problem-specific outcome occurs in the control group at 1 outcome/10,000
person-years). A user simply should divide the reference outcome by the user-specified
outcome to generate the k value.
Briefly, I walk through how to read Figure 8 and again employ the example used in
the Mini-Sentinel pilot project. Recall that the intent was to detect an incidence rate ratio
of 1.33 with 80% power. Figure 8 is marked with a star at this point. However, to
interpret the maximum and median sample sizes, it is necessary to first calculate the k
scaling constant by dividing the reference outcome (i.e., 1 outcome/i 0,000 person-years)
by the problem-specific outcome of interest (i.e., 9 outcomes/1000 person-years),
yielding a k scaling constant of 0.0111. As the reader would expect from the previously
simulated distributions shown in Figure 7, the maximum sample size is 12,416.67 person-
years (~1.1M*k=.0111) and the median sample size is 6,269 person-years
(~600,000*k=.01 11).
The objective of Figure 8 is to show the user the realm of other possibilities for
surveillance, and to allow them to draw comparisons. Depending on whether the
maximum sample size and median sample size are believed to be feasible given the data
available, the user can employ this figure to gain an understanding of the tradeoffs that
occur by moving away from the baseline scenario (i.e., the starred point). For example, if
the user believes that these baseline sample sizes are easily attainable, then one might
consider detecting a 1.33 incidence rate ratio with higher power (e.g., 90%). That
northward jump in the statistical power isoline would increase maximum sample size but
might only modestly increase median sample size because of the verticalness of the
median sample size isolines. Practically, that means there may be a small price to pay
regarding losses in the timeliness of signal detection when seeking higher statistical
power. On the other hand, if the user believes these baseline sample sizes are not
attainable, then the user can consider reducing power, or detecting a numerically larger
effect size (e.g., an incidence rate ratio of 2). Numerically larger effect sizes tend to
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accompany less vertical portions of the median sample size isolines indicating real
tradeoffs start to occur between statistical power and the timeliness of signal detection.
Now, let us investigate the same scenario with the other supported model in the
simulator: the binomial MaxSPRT model. "9
6.1.3 Binomial MaxSPRT Model
Recall that the binomial MaxSPRT model supports concurrent and self-controlled
comparator groups, but requires the user to specify the matching ratio between the
treatment group and comparator group. Using a 1:1 matching ratio, I simulate data on the
treatment and comparator populations in accordance with an assigned true effect size, and
then analyze these data with the binomial MaxSPRT model using a flat sequential
stopping boundary. Again, I first simulate an effect size equivalent to a 1.33 incidence
rate ratio, and power my surveillance to limit overall type I error to 0.05, and type II error
to 0.20 (i.e., statistical power is 0.80).
Simulated Data for Surveillance using the Binomial MaxSPRT Model
IRR=1.33, Type I Error=0.05, Type 11 Error=0.20
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Figure 9. Example Sequential Database Surveillance Scenario Analyzed using the Binomial
MaxSPRT Model
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test; IRR, incidence rate ratio.
359 I show the binomial MaxSPRT model to familiarize the reader with this model since I will use it
extensively and the simulator supports it. However, the binomial MaxSPRT model would most likely have
been ruled out for use in the Mini-Sentinel System pilot project because it does not accommodate
continuous exposures. See subsection 5.2.1.1.
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As before in Figure 9, I show one instantiation of the sequential database surveillance
scenario. In this particular instantiation, the number of outcomes in the treatment group
separates enough from the comparator group when the test statistic crosses the flat
threshold value at 89 outcomes (or 9,888 person-years), detecting a signal of excess risk.
Then, I repeat this analysis 100,000 times, and display the results as a distribution in
Figure 10.
Information Time to End Surveillance Information Time to End Surveillance when Signal is Detected
6000 ,e 6000
Histogram
o. Mean 5000
0 Median 4000
5000 o -
3000
2000
4000 -4 ,oo AL i -x100
30001
20001
0 -
0 -
0.-
0 30 60 90 120 150 180 210 240 270
Outcomes in the Comparator Group under the Null Hypothesis
Information Time to End Surveillance when Signal is Not Detected
1500
1000
500
p
0 30 60 90 120 150 180 210 240 270 "0 30 60 90 120 150 180 210 240 270
Outcomes in the Comparator Group under the Null Hypothesis Outcomes in the Comparator Group under the Null Hypothesis
Figure 10. Distribution of the Information Time to End Surveillance for 100,000 Simulations
Analyzed Using the Binomial MaxSPRT Model
Parameters: Incidence Rate Ratio=1.33, overall type I error=0.05, statistical power=0.80, matching
ratio= 1:1. The left panel represents the overall (i.e., unconditional) distribution. The right upper panel
represents the conditional distribution when a signal was (correctly) detected. The lower right panel
represents the conditional distribution when a signal was (incorrectly) not detected.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test.
Again, as in Figure 7 and here in Figure 10, the left panel is a distribution of the
information time required to end surveillance, and includes the full 100,000 instances of
simulation. On the right panel, I break this histogram into two circumstances: the upper
portion represents the instances when a signal was correctly detected (i.e., the null
hypothesis was rejected) and the lower portion represents the instances when a signal was
missed (i.e., the null hypothesis incorrectly failed to be rejected). As before, I use the
unconditional median of the left panel to describe the median sample size: 114 outcomes
or 12,666 person-years. However, note that in the lower right panel of Figure 10, the
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maximum sample size is now a distribution as opposed to a singular value as it was in the
Poisson MaxSPRT model. If I chose the median of this distribution, which is conditioned
on failing to detect a signal, then I will be inappropriately comparing systems with
different power. Therefore, to appropriately represent the maximum sample size, I re-
perform the simulations again, except that I set the effect size to be equal to the effect
size assumed in the null hypothesis (i.e., in other words, I create a situation when the null
hypothesis is true). These results are shown in Figure 11.
In Figure 11, the unconditional median of the leftmost panel is 265 outcomes or
29,444.4 person-years. 360 In the upper right panel of this figure, one sees instances in
which the null hypothesis is rejected inappropriately (i.e., false positives occur in
accordance with the set type I error margin).
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Figure 11. Distribution of the Information Time to End Surveillance for 100,000 Simulations
Analyzed Using the Binomial MaxSPRT Model
Parameters: Incidence Rate Ratio=1, overall type I error=0.05, statistical power=0.80, matching ratio=1:1.
The left panel represents the overall (i.e., unconditional) distribution. The right upper panel represents the
conditional distribution when a signal was (incorrectly) detected. The lower right panel represents the
conditional distribution when a signal was (correctly) not detected.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test.
360 In Figure 11, 1 could also use the mean or median conditioned on the times when a signal is not
detected. The amount of contributing information would be the same as long as the number of simulations
and the overall type I error was kept the same. However, for consistency, I use the unconditional median.
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Again, I repeat this process for a range of effect sizes of interest, holding the number
of simulations constant at 100,000. I display an abbreviated version of my results
compactly in Figure 12, which again contains a starred mark for the intersection of an
incidence rate ratio=1.33 and statistical power=0.80, the intended effect size to be
detected in the Mini-Sentinel System pilot project. As was evident from Figure 10, and
again is shown here in Figure 12, the median sample size is 12,666 person-years
(~ 1.14M*k=0.01 11). Similarly, as was shown in Figure 11 and again here in Figure 12,
the maximum sample size is 29,444.4 person-years (~2.65M* k=0.01 11).
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Figure 12. Relationship between Statistical Power, Median Sample Size, Maximum Sample Size, and
True Effect Size Analyzed using the Binomial MaxSPRT Model
Statistical power isolines travel from northwest to southeast. Median sample size isolines travel from
southwest to northeast. Overall type I error set to 0.05.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test; Pr, power.
6.1.4 Importance of Comparison
Why is it important for the user to take into account the comparisons available in
Figure 8 and Figure 12? The most important point to consider is that moderate decreases
in statistical power (i.e., jumps in the isolines traveling from northwest to southeast) may
or may not decrease the median sample size depending on whether one is operating in the
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nearly vertical portions of the median sample size isolines. That is, some of the time,
decreasing power (i.e., increasing type II error and the chance of a missed signal) results
in faster detection of a signal (i.e., smaller median sample sizes). Is this tradeoff worth it?
Should a user take on the bigger risk of missing the signal if it means they can find it
faster?
These tradeoffs have more concrete meaning by translating the information time
concepts into calendar time. A user may value the decrease in median sample size (i.e.,
the quicker detection time) differently depending on whether the quicker detection occurs
in 1 month or 12 months. These considerations are also influenced by the user's prior
perceptions of whether an excess risk is likely or not. The user's prior perception is
sometimes referred to as a Bayesian prior belief, so named for the statistician Thomas
Bayes who is responsible for the subfield of Bayesian statistics and inference that allows
one to incorporate existing knowledge or belief into analysis.361
For example, if a user believes there is a significant possibility of excess risk to be
detected, then waiting an additional 11 months to detect such a risk may be unacceptable
because real harm occurs in the greater population (i.e. external to the one under
observation) during that additional detection time. In summary, information time is an
important first step to understanding sequential database surveillance scenarios, but
public health policymakers must consider how information time translates into calendar
time to meaningfully assess sample size considerations. In the simulator, this step is
performed with the Calendar Time Sub-Model, explained next.
6.2 Calendar Time Sub-Model
The calendar time sub-model estimates adoption and utilization of the medical
product under surveillance using the databases proposed for inclusion in sequential
database surveillance. This sub-model generates estimates of information time as a
function of calendar time.
361 An overview of the differences between Bayesian and frequentist statistical inference is beyond the
scope of this dissertation. Generally, the FDA informally operates in a "Bayesian" framework as it
continually updates and incorporates new knowledge regarding particular tracked safety issues. For
information on formal use of Bayesian methods in healthcare decision-making and and policy, see David J.
Spiegelhalter, "Incorporating Bayesian Ideas into Health-care Evaluation," Statistical Science 19, no. 1
(2004): 156-174.
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6.2.1 Inputs to the Calendar Time Sub-Model: Surveillance-specifics
The user begins with the following surveillance-specific inputs to the calendar time
sub-model: the exposure-outcome pair to be evaluated, an epidemiologic design, and the
corresponding sequential statistical model to be used for analysis. The sequential
statistical models should be the same ones investigated in the information time sub-
model.
6.2.1.1 Exposure-Outcome Pair / Tracked Safety Issue
First, the exposure-outcome pair is presumably the tracked safety issue of interest.
The description of the exposure-outcome pair must include specific details about when an
exposed person is considered "at risk" to develop the outcome of interest. These details
include: 1) specification of the onset of the "at risk" period; and 2) specification of the
duration of the "at risk" period. The onset and duration are driven by pharmacokinetic
and biological parameters related to the medical product, i.e., when could the medical
product reasonably cause the outcome in question. For example, anaphylaxis (i.e., a
severe allergic reaction) may reasonably be plausible immediately after administration of
a medical product whereas an acute myocardial infarction might require more time to
elapse before a medical product could have plausibly caused it. The period before the
onset of the "at risk" period is also referred to as the induction period or the latency
period. Once the onset of the "at risk" period begins, the user will also have to specify the
duration of the "at risk" period, which is referred to as the risk window. This period
typically extends some time after the last administration of the particular medical product
because the medical product is still believed to be "active" in a person's body.
6.2.1.2 Epidemiologic Design
An epidemiologic design indicates the way the population of interest and the
comparison population will be sampled for statistical inference. Epidemiologic designs
are discussed herein in subsection 5.1. For planning purposes, the important point is that
historical and self-controlled designs are one-group study designs 36 2 (i.e., they require
362 Rothman, Greenland, and Lash, Modern Epidemiology, 758
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continuous observations of only one population) and the user is only concerned with
modeling one subpopulation. Concurrent-controlled designs are two-group study designs,
necessitating additional modeling. When the user specifies the epidemiologic design to be
modeled (and most specifically, the comparison population), it is also necessary to
specify the expected incidence rate of the outcome in the comparison population, which
is also referred to as the background rate. The background rate is the incidence rate of the
outcome expected under the null hypothesis (i.e., that there is no excess risk in the
treatment group).
For self-controlled designs363, two additional quantities must be specified: the
"washout" period and the comparison window. The former is a period of time when the
person is neither exposed nor unexposed and during that time, the person contributes no
information to the surveillance. The latter is a period when a person contributes
"unexposed" time. Unexposed time refers to time when the person is presumed to be
unexposed to the medical product and either occurs prior to the administration of a
medical product or after a medical product has cleared their system. Typically, there are
concerns related to confounding by indication/contraindication364 if a "pre-exposure"
comparison period is used, and so "post-exposure" comparison periods are preferred.365
Figure 13 shows an example diagram of these time periods, and the index event is the
time of initial exposure. To be clear, it is possible to have a washout period equal to zero.
If a "pre-exposure" comparison window is planned, then no washout period is necessary.
Days after 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
index eventII
Induction Risk Washout Comparison
Period Window Period Window
Figure 13. Example Diagram of Time Periods in Self-Controlled Epidemiologic Designs
The index event is typically the date of exposure.
363 For more on self-controlled designs, see section 5.1.
364 For more on confounding by indication/contraindication, see section 4.2.1.
3 Specifically, if a person experiences the outcome of interest (i.e., adverse event) during a "pre-exposure"
comparison window, then that person may be more or less likely to then be subsequently exposed to the
medical product of interest. This change in their likelihood of being exposed introduces a bias.
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6.2.1.3 Sequential Statistical Model
The sequential statistical model specifies the type of hypothesis testing that will be
performed (e.g., continuous or group sequential), and what types of sequential statistical
boundaries can be accommodated. The sequential statistical model in the information
time sub-model should correspond to the sequential statistical model used here. Table 3
in section 5.2 indicates the compatibility between epidemiologic designs and sequential
statistical models.
6.2.2 Inputs to the Calendar Time Sub-Model: Database-specifics
The following inputs are necessary for each database that may contribute to
sequential database surveillance: a) the size of the subpopulation of interest; b) an
estimated mathematical function that describes the adoption/uptake pattern; c) the refresh
delay time; d) the processing delay time; and e) any exposure and outcome
misclassification estimates. The first two inputs allow the user to model how medical
product adoption evolves in calendar time. The remaining three inputs - the refresh delay
time, the processing delay time, and exposure and outcome misclassification estimates -
allow the user to model how exposures and outcomes appear to the user conducting
sequential database surveillance. Recall that validated exposure and outcome data are
unavailable to the user at the time of surveillance. Instead, the user must rely primarily on
electronic claims data that arrives with some lag time. Modeling these database delays
mimics the near-real time366 aspects of surveillance.
6.2.2.1 Subpopulation Size
The size of the subpopulation of interest (e.g., persons over 18 with a diagnosis of
diabetes) can be ascertained in the Mini-Sentinel System using modular programs (i.e.,
database queries) while planning surveillance. In particular, summary tables or modular
367programs 1, 2, and 4 can be used for this purpose.367 This subpopulation is the pool of
potential adopters of the medical product.
366 For discussion of near-real time surveillance, see supra at note 21.
367 See explanation of summary tables and modular programs in subsection 2.2.2.1.
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6.2.2.2 Estimated Adoption Functions
The estimated adoption function for the medical product is perhaps the most
substantial uncertainty in the sub-model, and is the subject of more analysis in section 9.
Certain products, like vaccines, which are routinely administered for enrollment in
school, childcare, etc., may be less complicated to model. However, adoption of new
drugs is influenced by many more factors (e.g., formulary policy, co-payments, the
availability of substitute therapies, treatment guidelines, etc.), and is considerably more
complex. An adoption function may be based on historical data on similar products, early
adoption data on the product in question, or no data at all.
6.2.2.3 Refresh Delay Time
The refresh delay time is the frequency with which a participating data partner in the
Mini-Sentinel System renews their dataset and makes it available for analysis.
Essentially, as a participant in the Mini-Sentinel System, data partners agree to update
their data on some periodic basis. For most partners, this is monthly or quarterly, but can
be as long as annually. In a similar, precursor system - the Vaccine Safety Datalink -
refreshes are performed weekly.368
6.2.2.4 Processing Delay Time
The processing delay time, or the claims lag time, is the time that elapses between
when an exposure or outcome occurs, and when it is recorded and available for analysis
in the Mini-Sentinel System. Different data streams have different processing delay times
even if they originate from the same data partner. Generally, exposure data (specifically,
pharmacy dispensing data) are available sooner than outcome data. Also, outcome data
may have differing lag times based on their origin (e.g., ambulatory encounter data may
become available more quickly than inpatient data). 369 These incoming datastreams may
be modeled explicitly, and the additional modeling efforts are likely worthwhile when
calendar time for surveillance is very short (e.g., influenza vaccination surveillance).
368 Baggs et al., "The Vaccine Safety Datalink: a Model for Monitoring Immunization Safety."
369 S. K. Greene et al., "Near Real-time Vaccine Safety Surveillance with Partially Accrued Data,"
Pharmacoepidemiology and Drug Safety 20, no. 6 (2011): 583-590.
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Else, one can use the maximal processing delay across all incoming datastreams as the
input parameter. Allowing this "data settling" period also may mitigate issues associated
with latent data correction, and potential instability in sequential database surveillance.
6.2.2.5 Misclassification Parameters
The misclassification estimates - data on the sensitivity and specificity 3 7 1 of the
exposure and outcome classifications - allow the investigator to model noisy data. For the
calendar time sub-model, I focus on the sensitivity and positive predictive value 37 2 of
outcomes only. As was discussed earlier in subsection 4.2.3.1, validation data for
exposures is essentially unavailable because of the secondary data collection mechanism.
One could do a sensitivity analysis and speculate on exposure sensitivity and specificity. I
focus on the positive predictive value of the outcomes (as opposed to specificity) because
it would be implausible with this data collection mechanism to validate "true negative"
cases of the outcomes. That is, it is unlikely that resources would be expended to perform
medical chart validation on exposed individuals who are not electronically identified as
having experienced the outcome.
6.2.3 Modeling Database-Specific Inputs to Surveillance
6.2.3.1 Modeling Exposures
Together, the inputs above parameterize a customizable delay differential equation
model (sometimes referred to as a "compartment model") to estimate adoption and
utilization of the medical product under surveillance. Figure 14 shows the general model
that can be adapted for the particular circumstances of the exposure-outcome pair being
monitored.37 3
370 Sensitivity is equal to the number of true positive cases/(true positive cases + false negative cases).
371 Specificity is equal to the number of true negative cases/(false positive cases + true negative cases).
372 Positive predictive value is the number of true positive cases/(true positive cases + false positive cases).
373 Note, in Figure 14, I do not show the general compartmental model to include a pre-exposure control
period, which is possible but not preferred in self-controlled designs. See supra at note 365.
121
Figure 14. General Compartmental Model of Adoption and Utilization of Medical Products
It begins with the subpopulation identified as the pool of adopters. From there, they
may adopt according to some adoption function or exit the system as non-adopters. Once
a person has adopted, an induction period/latency period elapses and the exposed person
may become "at risk" for the medical-product associated health outcome of interest (i.e.,
in the risk window for the purposes of surveillance). Once an exposed person becomes
"at risk", that person may leave the category for three reasons: 1) that person is censored
(i.e., removed from the data analysis); 2) the risk window elapses without being censored;
or 3) the surveillance ends.
For point/discrete exposures such as vaccinations, the time spent in the risk window is
fixed and entirely defined by the time of initial exposure. However, for continuous
exposures (e.g., most drugs and therapeutic biologics), the time spent in the risk window
will vary based on patterns of patient adherence, tolerance of side effects, etc. Thus, in
addition to modeling adoption, one must also monitor continued utilization of the medical
product. Future versions of the simulator will be able to incorporate data on utilization
patterns derived from the Mini-Sentinel System. Modular programs to create those
datasets are still being tested.
As a note, compartmental models are only designed to handle population averages. If
there is significant variation anticipated in continued medical product utilization, an
agent-based model that can accommodate more heterogeneity may be more appropriate.
For concurrently-controlled epidemiologic designs when the concurrent control is
defined with an active comparator (i.e., two separate populations exposed to two separate
medical products need to be monitored), a compartmental model needs to be estimated
for both groups, and then additional assumptions are necessary with respect to matching.
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When the design is self-controlled and the comparison period of "unexposed time"
occurs post-exposure to the medical product, it is necessary to track time after the "at
risk" period. In some instances, a "washout" period occurs between the "at risk" window
and the comparison window. Following the washout period, or directly following the "at
risk" period if the "washout" period does not exist, a person contributes time to the
comparison window.
For any sequential database surveillance problem, a person can be censored for a
variety of reasons, but one common issue is the loss of insurance coverage benefits,
which is regarded as a loss-to-follow-up. Other censoring criteria are likely specific to the
exposure-outcome pair being evaluated.
Once the general delay differential equation model has been customized to the
particulars of the exposure-outcome pair (i.e., programmed to account for surveillance-
specific inputs listed in 6.2.1), each database will make unique contributions to adoption
and utilization. That is, the same set of general delay differential equations will be solved
with the database-specific inputs listed in 6.2.2, making it a linear system of delay
differential equations with one stratum for each database contributing information.
Solving the system of delay differential equations produces a pattern of exposure (i.e.,
information time or sample size contributions) in calendar time.
6.2.3.2 Modeling Outcomes
Given a pattern of exposures as a function of person-time, then the calendar-time
sub-model generates outcomes for each database based on the incidence rate under the
null hypothesis, input effect sizes, and misclassification estimates. The first two variables
are the same across databases but the misclassification estimates are particular to the
database being considered.
An example of the output of the calendar time sub-model is shown as a table shell in
Table 4 for one particular effect size. This table is repeatedly populated for the range of
effect sizes of interest. It is also populated for each database being evaluated for use in
surveillance.
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Database i
Incidence Rate Ratio=Y
Cumulative True Positive False Negative False Positive
Time Exposure Outcomes Outcomes Outcomes
(months) (person-
months) 1 ... Nsim I ... Nsim 1 ... Nsim
0 0 0 0 0 ... 0 0 ... 0
1. . . . . . ... ... ... ... ... ... ...
.. . ... . . . . . .
T-End XXX XX XX XX ... XX XX ... XX
Table 4. Example Blank Output of the Calendar Time Sub-Model for an Effect Size of Interest
Abbreviations: Nsim, number of simulations; T-end, Time at the end of surveillance.
6.3 Analysis Sub-Model
The analysis sub-model allows the user to perform sequential database surveillance
on simulated data, produce tabular or graphical results, and account for prior knowledge
regarding the tracked safety issue when exploring sequential database surveillance.
6.3.1.1 Decision Analysis with Uncertainty
There are many parameters that a user can vary in sequential database surveillance
that may lead to substantial changes in the statistical power, median sample size, or
maximum sample size. Each set of parameters can be thought of as a unique
configuration for surveillance. In this version of the simulator, there is some basic
decision support to choose the optimal configuration among the remaining candidates.
For these scenarios, a user needs to indicate the outcomes or measures on which a
particular configuration is deemed to be "best." When there are multiple measures, these
decisions can be performed with a multi-attribute utility function. 74 These decisions are
examined under conditions of uncertainty, particularly related to the uncertainty of the
true effect size. In general, one should consider at least two scenarios in all
configurations: when an elevated risk exists and when it does not. Figure 15 is a basic
schematic of decision tree that can be used to choose an optimal configuration.
3 Ralph L. Keeney, "Utility Functions for Multiattributed Consequences," Management Science 18, no. 5,
Theory Series, Part 1 (1972): 276-287.
124
Surveillance CostsTrue IRD = 0- < Health OutcomesConfiguration 1
True IRD > 0- <
True IRD = 0- <Configuration X a"
True IRD > 0- <
Figure 15. Basic Schematic of Decision Analysis under Uncertainty
6.4 Intention of the Simulator
In short, the Sequential Database Surveillance Simulator uses, in sequence, the
information time sub-model, the calendar time sub-model, and the analysis sub-model to
allow the user to experiment virtually with various sequential database surveillance
scenarios. The goal of such a simulator is to be a learning tool for the user so they may
gain intuition about the range of potential scenarios that could occur given certain
problem-specific input parameters. The simulator is not meant to be a forecasting tool.
Rather, it is meant to be a quantitative decision tool that sheds light on the evidence-
generation capabilities of the Mini-Sentinel System when using the system to perform
sequential database surveillance.
Next I show how to use the Sequential Database Surveillance Simulator with a fully
worked example.
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7 VACCINE EXAMPLE
I plan surveillance for a single-dose, newly available live attenuated childhood
vaccine that is being evaluated for an elevated risk of idiopathic thrombocytopenic
purpura (ITP). ITP is bleeding disorder in which the immune system impairs the body's
ability to perform normal blood clotting. Intracranial and gastrointestinal bleeding are
severe complications. ITP is known to occur after many types of infections, including
numerous vaccine-preventable diseases.3 75 Biologically, vaccines induce an immune
response, and it is theoretically possible that abnormal responses could trigger ITP.
I chose this example because exposure is discrete, the risk window is finite, and the
adoption pattern is simple (i.e., children receive routine vaccinations during well visits).
Throughout this example, I will make choices to tailor this example and simulated
surveillance to mirror previously completed vaccine surveillance activities.376
Accordingly, I will plan for two concurrently performed epidemiologic designs and
accompanying analyses, which has been common practice.
7.1 Model Inputs
7.1.1 Information Time Sub-Model
I will use both the Poisson and binomial MaxSPRT sequential statistical models. I
assume ITP in infants is expected to occur at a rate of 2 outcomes per 100,000 person-
years in a clinically relevant comparison group (i.e., the background rate).37 7
7.1.2 Calendar Time Sub-Model
7.1.2.1 Surveillance-Specific Parameters
Table 5 lists relevant user-specified surveillance parameters and database-specific
parameters. The primary design will be a cohort design with a historical comparison
cohort of infants exposed to other vaccines. The secondary design will be a self-
3s Sean T O'Leary et al., "The Risk of Immune Thrombocytopenic Purpura After Vaccination in Children
and Adolescents," Pediatrics 129, no. 2 (February 2012): 248-255.
376 See summary in Yih et al., "Active Surveillance for Adverse Events: The Experience of the Vaccine
Safety Datalink Project."
37 Deirdra R Terrell et al., "Determining a Definite Diagnosis of Primary Immune Thrombocytopenia by
Medical Record Review," American Journal of Hematology 87, no. 9 (September 2012): 843-847.
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controlled risk interval design. The primary design will be analyzed using the Poisson
MaxSPRT model and the secondary design will be analyzed using the binomial
MaxSPRT model. Based on the incubation period of the live virus, I assume that it is only
biologically plausible that ITP could be vaccine-associated if it occurs between 1-42 days
post-vaccination, which is the risk window. Therefore, both the primary and secondary
designs employ a 1-day induction period (i.e., 0-1 days post-vaccination) and then a 41-
day risk window (i.e., 1-42 days post-vaccination). The secondary design requires two
additional values: a washout period of 1 day (i.e., 42-43 days post-vaccination) and a 41-
day comparison window (i.e., 43-84 days post-vaccination). Each dose of vaccination
contributes 41 person-days to the analysis, resulting in a background rate of -1 case of
ITP for every 445,427 doses.
This event is very rare and therefore, it is possible to signal on very little accrued
data.378 Therefore, I require a minimum of four outcomes to signal using the Poisson
MaxSPRT. 379 I use a flat sequential statistical boundary, which is conventional for the
MaxSPRT analyses and set overall type I error to 0.05. I chose this particular
combination of epidemiological designs and supporting sequential statistical analyses to
mimic prior analyses.
7.1.2.2 Database-Specific Parameters
To familiarize the reader with the planning process, I begin by modeling just one
database: the aggregate Mini-Sentinel System Distributed Database. Using a dataset
current through 2010, 1 used the mean enrollment data across the years 2008-2009 to
generate a cohort of ~564,000 0-1 year olds, which I use as the size of my subpopulation
of interest. I used these years because all data partners contributed data in the dataset
available to me. Assuming approximately 4 million children are born in the US
annually 380 , this represents -14% of the US population of this age group.
I model the adoption function linearly (i.e., adoption is coincident with one-year well-
visits and children are assumed to be equally likely to be born on any day of the year),
378 For evidence of this phenomenon, refer back to Figure 7 and note the higher frequency of earlier
signaling in the leftmost panel.
379 See supra at note 323.
380 Centers for Disease Control and Prevention, "National Vital Statistics System", n.d.,
http://www.cdc.gov/nchs/nvss.htm.
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and allow for a 5% probability of non-adoption (i.e., vaccine refusers). I assume a one-
month refresh delay (i.e., I receive new data monthly in the Mini-Sentinel System 38 ) and
a two-month processing delay. In the base case, I assume no known or estimated
misclassification.
Surveillance Parameters
Primary Design Secondary Design
8 excess outcomes/ 8 excess outcomes/
Effect Size of Interest 100,000 person-years 100,000 person-years
Comparator 2 outcomes/ 2 outcomes/
Outcome Rate (p) 100,000 person-years 100,000 person-years
Induction Period (62) 0-1 days post-vaccination
Risk Window (62) 1-42 days post-vaccination
Washout Period (83) N/A 42-43 days post-vaccination
Comparison Window (64) N/A 43-84 days post-vaccination
Statistical Model Poisson MaxSPRT with Binomial MaxSPRTStatistical_____Model__ minimum of 4 outcomes
Matching Ratio N/A 1:1
Type I Error 0.05
Database Parameters
Subpopulation Size (M) 564,000 0-1 year olds
Probability of Adoption (p) 0.95
Database Delay 2 months
Refresh Delay 1 month
Table 5. User-Specified Surveillance and Database Parameters in the Simulated Vaccine Example
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test
7.2 Performing Sample Size Calculations
7.2.1 Primary Design: Cohort Design with the Poisson MaxSPRT Model
The initial surveillance goal will be to detect an incidence rate ratio of 5 (i.e., an
incidence rate difference of 8 excess outcomes/100,000 person-years) with 90% power.
Using the information sub-model, I produce a compact display of my sample size choices
381 Here, I am treating the entire Mini-Sentinel System as though it were one giant database to illustrate
how the simulator works. In reality, each participating component database would have a different refresh
time.
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using the Poisson MaxSPRT model with a minimum of 4 outcomes, shown as Figure 16.
To properly read Figure 16, I calculate my k scaling constant as 5 (i.e., [(1 outcome
/10,000 person-years) / (2 outcomes / 100,000 person-years)]). I find the intersection of
an incidence rate ratio of 5 and 90% power, marked with a star in Figure 16. The
maximum sample size required is 75,000 person-years (1 5,000*(k=5) person-years on the
y-axis), or 668,140 doses. The median sample size is just to the left of the 7000*k person-
years isoline (i.e., 35,000 person-years when scaling by k). To generate a more precise
median sample size, I perform a simulation as described in the previous section and find
the unconditional median of the information time until the end of surveillance. The
median sample size is 36,658 person-years (i.e., 326,567 doses).38 2
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Figure 16. Relationship between Statistical Power, Median Sample Size, Maximum Sample Size, and
True Effect Size Analyzed using the Poisson MaxSPRT Model with a minimum of four events
Statistical power isolines travel from northwest to southeast. Median sample size isolines travel from
southwest to northeast. Overall type I error set to 0.05. The star represents the starting point of the
example.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test; P-Y, person-years; Pr, power.
382 Every dose contributes 41 person-days to the analysis, allowing for a conversion from events/person-
year to events/dose.
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7.2.2 Secondary Design: Self-Controlled Design with the Binomial MaxSPRT
Model
Similarly, I produce Figure 17 for use with the binomial MaxSPRT model. The k
scaling constant remains 5 and the effect size of interest remains 8 excess outcomes per
100,000 person-years or a fivefold incidence rate ratio. Using Figure 17, the maximum
sample size required is 625,000 person-years (125,000*(k=5) person-years), and the
median sample size is between 10,000*k and 20,000*k person-years. Because
information time is based on the number of outcomes and only integer-valued outcomes
can occur, this estimation is as precise as I can be using the binomial MaxSPRT model
and information time.3 83
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Figure 17. Relationship between Statistical Power, Median Sample Size, Maximum Sample Size, and
True Effect Size Analyzed using the Binomial MaxSPRT Model
Statistical power isolines travel from northwest to southeast. Median sample size isolines travel from
southwest to northeast. Overall type I error set to 0.05. The star represents the starting point of the
example.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test; P-Y, person-years; Pr, power.
383 The reference outcome of interest is I outcome / 10,000 person-years. Because the binomial model
requires the end of surveillance to occur coincident with the arrival of an outcome, the median sample size
can only occur at discrete values of exposed person-years.
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7.3 Estimating Database-specific Contributions to Surveillance
Using the calendar time sub-model, I model sets of delay differential equations to
describe potential adoption patterns. The adoption function must be specified for each
epidemiologic design. Once the set of delay differential equations are solved to generate
adoption patterns, I use these patterns to simulate a range of potential effect sizes. For
these simulations, I perform 10,000 repetitions per effect size, which is recommended
when analysis is exploratory. It is always possible to perform more repetitions later with
a narrower set of surveillance configurations that are most important to the user.
As mentioned previously, I chose a linear adoption pattern to model adoption of new
routine childhood vaccinations that will be explained in detail next. Later, I obtained data
from the Mini-Sentinel System to validate this choice and that data is described in
Appendix A.
7.3.1 Primary Design: Cohort Design with the Poisson MaxSPRT Model
For the cohort design, the general model as shown in Figure 14 can be simplified into
one compartment: "exposed persons at risk," Ei, for databases i=1, 2, ... m, specified by
equation (1):
dE = s16pIM(t - 61) - pEi(t) - s2 s1 6p M (t - 61 - 62) (1)
dt
Mi is the subpopulation size in database i. This formulation assumes a linear adoption
function coincident with annual well visits and is reflective of the rate at which data
arrive (0 = 12 months-'). It also allows for a proportion of these children to be non-
adopters (9t=0.95). The input flow to Ei, (i.e., "exposed persons at risk" category) is
proportional to the input flow to the "adoption category" and is delayed by the induction
period (62). The proportionality constant is the survival probability si = exp(-p62) when
an adopter "survives" the induction period (61) without being censored for experiencing
the outcome of interest (i.e., ITP) at the background rate (p). This formulation results
from treating the occurrence of ITP as a Poisson process that occurs over the induction
period (62). The outflow from Ei occurs by either 1) being censored if one experiences the
outcome according to the background rate (-pEi); or 2) completing the time in the risk
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window (62) according to the proportionality constant S2 = exp(-p62). The reader can
compare the first term of equation 1 with the third term and note they are only different
based on the survivability constant and the added delay. I assume that exit and entry from
the system (e.g., perhaps due to a change in health coverage or other loss to follow-up) is
constant and equal, which is reasonable given the very short period of follow-up. The
equation can also be written in vector form, as shown in equation (2) although all
multiplication is element-wise.
= s1pM(t - 81) - pE(t) - ss<OpM(t - 61 - 2))
dt
7.3.2 Secondary Design: Self-Controlled Design with the Binomial MaxSPRT
Model
The self-controlled design requires a slightly different adaptation of the general
model as shown in equation (3).
dSC = s 3s1OpMi(t - (61 + 62 + 63 + 64)) (3)
dt
In addition to the induction period (6 2) and risk window (62), the self-controlled
design contains a washout period (63) and a comparison window (64). While the adoption
function is the same (i.e., 0cpiMi), persons that contribute to the analysis are not censored
for experiencing the outcome of interest (i.e., ITP) during the risk window or comparison
window. However, they may still be censored for experiencing the outcome during the
induction period or the washout period. Consequently, survivability constants are used to
account for loss-to-follow-up that occurs during these respective periods (i.e., si = exp(-
p6 ) and s3 = exp(-p63) ). Essentially, to contribute to the analysis, the person must have
completed both the risk window and the comparison window, and these persons can be
simplified into a single compartment, the study completions (SCi) for databases i=1, 2, ...
m. Therefore, the input to the SC; is the adoption inflow modified by survivability
constants and delayed by the various time constants that each person must complete in
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order to complete the study. Equation (3) can also be written compactly in vector notation
as shown in equation (4) although element-wise multiplication operations are required.
d SC
d - s3 s1 <pM(t - (i1 + 62 + 63 + 64))
(4)
7.3.3 Modification by Database-Specific Delay and Misclassification Parameters
Once a pattern of information accrual in calendar time is estimated, the pattern must
be altered to reflect when the data become accessible for analysis by incorporating the
refresh delay time, processing delay time and outcome misclassification parameters.
Additionally, it is at this point when the information accrual (i.e., the pattern of exposures
in calendar time) is used to simulate outcomes for a pre-specified set of effect sizes. A
sample of the dataset is shown in Table 6. This table is repeatedly populated for the range
of effect sizes of interest. The reader should note that neither exposures nor outcomes
occur until Month 3, reflecting the two-month processing delay assumption. Also, the
data are only updated monthly, reflecting the one-month refresh delay.
Database 1 (Mini-Sentinel Distributed Database)
Incidence Rate Ratio=5
Cumulative True Positive False Negative False PositiveTime Exposure Outcomes Outcomes Outcomes(months) (person-
months) 1 ... Nsim I ... Nsim I ... Nsim
0 0 0 ... 0 0 ... 0 0 ... 0
1 0 0 ... 0 0 ... 0 0 ... 0
2 0 0 ... 0 0 0 0 ... 0
3 20,562 0 ... 0 0 ... 0 0 ... 0
100 5,851,056 46 ... 44 0 ... 0 0 ... 0
101 5,911,201 48 ... 44 0 ... 0 0 ... 0
149 8,798,136 63 65 0 0 0 ... 0
150 8,858,281 63 65 0 ... 0 0 ... 0
Table 6. Partial Dataset for the Simulated
No Misclassification
Abbreviations: Nsim, number of simulations
Vaccine Example with a Fivefold Incidence Rate Ratio and
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7.4 Analysis Sub-Model
7.4.1 Performance Measure: Calendar Time to End Surveillance
I take the simulated data produced by the calendar time sub-model and perform
sequential database surveillance on these data, thereby syncing my information time sub-
model and calendar-time sub-model. Recall that I have specified what the true effect sizes
are, and therefore, I am simply exploring the ability of my surveillance configuration
(i.e., composed of particular databases) to detect these pre-specified effect sizes. Now, I
observe the distributions of the calendar time to end surveillance under both my
primary and secondary designs, which may be more meaningful to users who are
managing the surveillance process. In other words, while information time is useful and
necessary to understand statistical performance, it is the calendar time that helps the user
estimate the impact on public health that the potential excess risk could have.
Initially, I look at how surveillance occurs when the true effect size is equal to the
effect size I wish to detect (i.e., incidence rate ratio of 5). These results are in Figure 18.
In this figure, the primary design/analysis (i.e., cohort design with a Poisson MaxSPRT
model) is shown in the left panel and the secondary design/analysis (i.e., self-controlled
design with a Binomial MaxSPRT model) is shown in the right panel. The reader will
note that the statistical power is a bit higher in secondary design/analysis. This occurs
because of the desire to achieve >0.90 statistical power while requiring integer-valued
outcomes.
Also, the median sample size is higher in the secondary design/analysis. This occurs
for two reasons. The primary reason is that only individuals who experience the outcome
contribute information to the binomial model. That is, the binomial model is indifferent
to individuals exposed to the medical product who do not experience the outcome of
interest - these individuals are non-informative. In contrast, the Poisson model
incorporates information from individuals who experience the outcome and individuals
who do not. Because the Poisson model makes greater use of the information available, it
is able to detect the differences between the treatment group and the comparison group
more quickly. The secondary reason that the binomial model has a higher median sample
size is that individuals have to contribute 84 days before their information is available to
the user as compared with 42 days in the primary design.
135
Poisson MaxSPRT Model with Minimum of Four Events Binomial MaxSPRT Model
m Histogram MHistogram
Mean 800 " * Mean
1000- 0 Median 0 Median
* 80th * 80th
700
800-
600 *
500
600
400
400 300
200-
200-
Power:0.8993 100. Power:0.9126
Incidence Rate Ratio:5 Incidence Rate Ratio:5
Type I Error:0.05 Type I Error:0.05
12 15 18 0 3 6 9 12 15 18 2124 27 30 33 36 39
Calendar Time to End Surveillance in Months Calendar Time to End Surveillance in Months
Figure 18. Distribution of Calendar Time to End Surveillance in Months in the Vaccine Example
The left panel is the primary design and analysis (i.e., cohort design with the Poisson MaxSPRT model
with a minimum of four events) and the right panel is the secondary analysis (i.e., self-controlled design
with the binomial MaxSPRT model). Nsim=1 0,000. All other parameters are as shown in Table 5.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test.
Recall that these distributions are the unconditional distributions that show the
calendar time until surveillance ends, irrespective of whether a signal was detected.
However, particularly with the primary design/analysis in the left panel of Figure 18, the
user can also observe the rightmost bar of the distribution (i.e., the 18 month bar), which
represents the instances when the surveillance configuration has incorrectly failed to
reject the null hypothesis. The frequency count of this bar is the type II error. This is
harder to observe in the- secondary design/analysis when the instances of the failure to
signal are a distribution rather than a singular value.
Figures like these can be produced for every true effect size that a user wishes to
evaluate, and the shape of these distributions is similar when the surveillance
configuration is powered correctly to detect the effect size. These figures start to look
quite different when the null hypothesis is true (i.e., the pre-specified true effect size is an
incidence rate ratio of 1), or when the surveillance configuration is underpowered. Refer
back to Figure 11 in the previous section for an example of this circumstance.
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Next, to evaluate how surveillance performs over a range of effect sizes, I extract key
points in these distributions and present them in Table 7. In a simpler version of this
table, I could show only the two sample sizes of interest: median sample size and
maximum sample size. Recall that the median sample size is the summary statistic that I
chose to represent the time-to-detect-a-signal. A user might wish to use a more
conservative measure for planning, e.g., the 8 0 th percentile of the distribution. Such a
measure would be more conservative because it would plan the end of surveillance with
an 80% probability rather than a 50% probability (i.e., the median). In any case, these
tables are customizable to the user's desires and can include a number of user-specified
summary statistics to describe these distributions.
True Risks Signal Mean Median 80th 95th
(%) (months) (months) (months) (months)
IRD IRR Poi Bin Poi Bin Poi Bin Poi Bin Poi Bin
0 1.0 0.05 0.05 17.8 69.3 18 70 18 81.5 .18 94
1 1.5 0.14 0.16 17.3 52.9 18 55 18 65 18 75
2 2.0 0.28 0.32 16.5 41.5 18 44 18 54 18 62
4 3.0 0.56 0.64 14.7 27.2 16 28 18 38 18 45
8 5.0 0.90 0.91 11.2 15.4 11 14 14 21 18 27
18 10.0 0.999 0.993 7.3 9.2 7 8 9 11 11 14
Table 7. Descriptive Statistics of the Calendar Time to End Surveillance for the Primary and
Secondary Design/Analyses over a Range of True Risks
Nsim= 10,000. Shading indicates when the maximum sample size is reached and the null hypothesis is not
rejected. Signal is the percent of time the null hypothesis is rejected. Incidence Rate Difference (IRD) is
given in events per 100,000 person-years.
Abbreviations: IRD, incidence rate difference; IRR, incidence rate ratio; Poi, Poisson MaxSPRT Model;
Bin, Binomial MaxSPRT Model.
The user can learn much about the performance of sequential database surveillance
from Table 7. First, as expected, when the true effect size is numerically smaller than an
incidence rate ratio of 5, the surveillance is underpowered. Similarly, when the true effect
size is greater than the effect size that I set out to detect, power is greater. The gray
shading indicates places in the distribution when the signal was not detected, which only
correctly occurs when the incidence rate ratio is equal to 1 (i.e., the null hypothesis is
true).
Second, the user should note that while the primary and secondary designs have
similar median sample sizes when surveillance is powered appropriately (i.e., when the
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incidence rate ratio > 5), these sample sizes start to diverge quickly when surveillance is
underpowered and the secondary design/analysis (i.e., the binomial MaxSPRT model)
has notably higher median sample sizes. This higher median sample size in the binomial
MaxSPRT model occurs because the maximum sample size is a random variable in this
model, and the median is pulled increasingly rightward in the distribution with decreasing
statistical power. By contrast, with the Poisson MaxSPRT model, because the maximum
sample size is a fixed value, the median sample size has a more limited range (i.e., it will
be capped at the maximum sample size of 18 months).
Third, the maximum sample sizes - equivalent to the median sample sizes when the
incidence rate ratio is 1 - diverge significantly between the two designs (i.e., compare 18
months to 70 months). Practically, this divergence means that if there were no excess risk
in the environment, the cohort design reaches the maximum sample size (i.e., the
stopping point when one fails to reject the null hypothesis) at 18 months whereas the self-
controlled design reaches the maximum sample size at 70 months. To a planner
concerned with generating findings within a particular calendar period of time, these
calendar time differences are substantial, particularly if there is strong prior assumption
that there is no excess risk in the environment.
Fourth, the much larger maximum sample size required when using the secondary
design/analysis is particularly an issue when a signal is missed but a true risk exists (i.e.,
type II error) because surveillance will have ended by failing to reject the null and
avoidable excess events will continue to occur until some other evidence generation
mechanism uncovers the true risk. That is, suppose the true effect size in the environment
is equivalent to an incidence rate ratio of 2. The primary design/analysis with the current
surveillance configuration will miss this result 72% percent of the time and the secondary
design/analysis only performs slightly better by missing it 68% of the time. However, the
primary design/analysis would have (incorrectly) declared surveillance over at a median
of 18 months while failing to detect the risk whereas the secondary design/analysis would
require a median of 44 months to reach the same (incorrect) result.
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7.4.2 Performance Measures: Nationally Projected Excess Events
Calendar time is important for planning (i.e., when will surveillance end), but it is
also important to get a sense of the avoidable excess events that might occur while
surveillance is ongoing. To do this, it is important to project nationally because the
population affected by a true excess risk in the environment extends beyond the observed
population for the purposes of surveillance. If I assume that the rough overall size of the
0-1 year old cohort in the United States is 4 million children 384 and 95% of them receive
their routine vaccinations, then I can assume 316,667 are vaccinated monthly. Given a
vaccination rate in doses/month, a true effect size in excess events/doses, and the
distribution of months to end surveillance, I can perform an algebraic transformation on
Figure 18 to reflect the distribution of excess events that may occur if the effect size is
equal to an incidence rate ratio of 5, shown in Figure 19.
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Figure 19. Distribution of Excess Events that Occur During Surveillance in the Vaccine Example
The left panel is the primary design/analysis (i.e., cohort design with the Poisson MaxSPRT model with a
minimum of four events) and the right panel is the secondary design/analysis (i.e., self-controlled design
with the binomial MaxSPRT model). Nsim=10,000. All parameters are as stated in Table 5.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test.
34 Centers for Disease Control and Prevention, "National Vital Statistics System."
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It is important to note that when the surveillance incorrectly fails to reject the null, the
excess events calculated are the minimum that might occur. The actual number of excess
events that will occur is dependent on how quickly the true effect size can be detected via
other mechanisms. Likewise, I can produce a transformation of Table 7 to be in excess
events, shown as Table 8. Again, the excess events when the null hypothesis fails to be
rejected are shown as being the minimum possible.
Tru Riks Signal Mean MedianTrue Risks ignal Men (een 80th (events) 95th (events)(%) (events) (events)
IRD IRR Poi Bin Poi Bin Poi Bin Poi Bin Poi Bin
0 1.0 0.05 0.05 0 0 0 0 0 0 0 0
1 1.5 0.14 0.16 >6.1 >18.4 >6.3 >19.3 >6.3 >22.8 >6.3 >26.3
2 2.0 0.28 0.32 >11.6 >29.1 >12.6 >30.8 >12.6 >37.8 >12.6 >43.4
4 3.0 0.56 0.64 20.5 37.6 22.4 37.8 >25.2 >53.3 >25.2 >63.1
8 5.0 0.90 0.91 31.2 43.0 30.8 39.2 39.2 58.9 >50.5 >75.7
18 10.0 0.999 0.993 45.8 57.5 44.1 50.5 56.8 69.4 69.4 88.3
Table 8. Descriptive Statistics of the Excess Events During Surveillance for the Primary and
Secondary Analyses over a Range of True Risks
Nsim=10,000. Shading indicates when the maximum sample size is reached and the null hypothesis is not
rejected. Signal is the percent of time the null hypothesis is rejected. Incidence Rate Difference (IRD) is
given in events per 100,000 person-years.
Abbreviations: IRD, incidence rate difference; IRR, incidence rate ratio; Poi, Poisson MaxSPRT Model;
Bin, Binomial MaxSPRT Model.
7.4.3 Incorporating the User's Prior Assumptions Regarding Excess Risk
As the reader may have guessed, the interpretation of tables such as Table 7 and
Table 8 may be different depending on the user's prior assumptions/beliefs (i.e.,
hypotheses) regarding the likelihood of the true effect size in the environment. That is,
when planning surveillance and anticipating both its calendar time until completion and
potential excess harm in the environment that occurs while an excess risk is being
detected, the user may be influenced by the strength and quantity of the existing
supporting data that suggested the potential for a true excess risk in the first place (i.e.,
the culmination of the signal detection phase discussed in section 2.1.1). While most
users may be hesitant to numerically quantify their prior assumptions, this simulator
provides a way to do so. It weights the outcomes shown in Table 7 and Table 8 according
to the user-specified likelihood of those true effect sizes actually occurring.
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Here, a user specifies the probability distribution of the true effect sizes they believe
to be possible by assigning a likelihood over the range of true effect sizes being
considered, known as a Bayesian prior probability. There are many different ways to
create such a distribution and there is a significant literature about how to choose a prior
that is beyond the scope of this research 385, but I prefer the "lump-and-smear" and I will
use that with this example. The "lump" is a lump of probability on the null hypothesis,
and the "smear" spreads the remaining probability over the range of alternative effect
sizes. Some authors have constructed the smear with a truncated normal distribution
whereas others use a uniform distribution over an appropriate range. Of course, in all
cases, the final probability distribution function must sum to one.
Lump-and-Smear Prior Assumption 1 Lump-and-Smear Prior Assumption 2
0.7- 0.7-
0.6- 0.6-
0.5- 0.5-
0.4- 0.4-
0.3- 0.3-
0.2- 0.2-
0.1 - 0.1
C- 01 23 45 67 89 10 1 23 45 67 8 910
Incidence Rate Ratios of Interest Incidence Rate Ratios of Interest
Figure 20. Two Example Prior Distributions regarding Likelihood of True Effect Size
I begin with two lump-and-smear prior assumptions of the true effect size with the
following values: 1) the lump is equal to 0.75 and the smear is a truncated normal with a
mean equivalent to the incidence rate ratio that I have powered the surveillance to detect
(i.e., 5), a sigma of 1.0, and truncation bounds of 1 and 10; and 2) the lump is equal to
3 See D J Spiegelhalter et al., "Bayesian Methods in Health Technology Assessment: a Review," Health
Technology Assessment (Winchester, England) 4, no. 38 (2000): 1-130.
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0.25 and all else the same. These two prior assumptions are shown respectively in Figure
20. The leftmost panel represents the prior assumption when the user has a strong feeling
that there is little likelihood of a true excess risk. This circumstance might occur if the
user had an obligation to monitor a set of adverse events for each new vaccination, but
lacked any data to support a potential association. The rightmost panel represents the
prior assumption when the user has a strong feeling that there is an excess risk in the
environment. This circumstance might occur if data from spontaneous reporting systems
prompted the creation of the tracked safety issue. Again, the user can create many
potential prior distributions to explore, but I assume the user is, in part, relying on
whatever existing data suggested a tracked safety issue was worth evaluating in the first
place.
To make use of these prior distributions, I sample them using an importance
sampling scheme 386 and then, using the sampled effect size, I run the simulator. I do this
with 10,000 samples. From these numbers, I can produce a new weighted distribution of
the time to end surveillance and the excess events to end surveillance for both the
primary and secondary analyses with the weighting reflecting the prior assumptions
regarding the likelihood of a true excess risk.
7.4.3.1 Prior Assumption with a Lower Likelihood Assigned to a True Excess
Risk
Figure 21 shows the distribution of the time to end surveillance in the circumstance
that the prior assumption that assigned a lower likelihood to a true excess risk existing
was true (i.e., lump-and-smear prior 1 or the leftmost graph of Figure 20). The user
should note the significant differences in the time to end surveillance for the primary v.
secondary design are consistent with instances of no excess risk shown in Table 7 on
page 137 (i.e., when the incidence rate ratio is equivalent to 1).
386 See Reuven Y. Rubinstein and Dirk P. Kroese, Simulation and the Monte Carlo Method, vol. 2
(Hoboken, N.J.: John Wiley & Sons, 2008), 131-140.
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Figure 21. Distribution of the Calendar Time to End Surveillance in Months when Applying Lump-
and-Smear Prior Assumption 1 in the Vaccine Example
The left panel is the primary design/analysis (i.e., cohort design with the Poisson MaxSPRT model with a
minimum of four events) and the right panel is the secondary design/analysis (i.e., self-controlled design
with the binomial MaxSPRT model). Nsim=10,000. All parameters are as stated in Table 5.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test
Figure 22 shows the distribution of excess events that occur during surveillance in the
circumstance when the prior assumption that assigned a lower likelihood to a true excess
risk existing was true (i.e., lump-and-smear prior assumption 1). As should be expected,
when no excess risk exists, there are no excess events that occur during surveillance.
Since the user expects this situation 75% of the time in lump-and-smear prior assumption
1, the user would really be looking to understand the distribution of excess events that
could occur based on their smaller assigned probability that a true excess risk exists.
Optimization for surveillance criteria could take a form that relates to minimizing these
potential excess events below a particular ceiling with a particular probability.
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Figure 22. Distribution of Excess Events that Occur During Surveillance when Applying Lump-and-
Smear Prior Assumption 1 in the Vaccine Example
The left panel is the primary design/analysis (i.e., cohort design with the Poisson MaxSPRT model with a
minimum of four events) and the right panel is the secondary design/analysis (i.e., self-controlled design
with the binomial MaxSPRT model). Nsim=10,000. All parameters are as stated in Table 5.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test.
7.4.3.2 Prior Assumption with a Higher Likelihood Assigned to a True Excess
Risk
Figure 23 and Figure 24 show the same distributions with the second lump-and-smear
prior assumption that places considerable likelihood on the existence of an excess risk.
As expected, in Figure 23, the time to end surveillance is faster than in Figure 21
reflecting the increased likelihood of a true excess risk. Figure 24 also reflects the greater
probability of excess events that occur during surveillance as a result of the belief that a
true excess risk exists.
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Figure 23. Distribution of the Calendar Time to End Surveillance in Months Applying Lump-and-
Smear Prior Assumption 2 in the Vaccine Example
The left panel is the primary design/analysis (i.e., cohort design with Poisson MaxSPRT model with a
minimum of four events) and the right panel is the secondary design/analysis (i.e., self-controlled design
with binomial MaxSPRT model). Nsim=10,000. All parameters are as stated in Table 5.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test
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Figure 24. Distribution of Excess Events that Occur During Surveillance Applying Lump-and-Smear
Prior Assumption 2 in the Vaccine Example
The left panel is the primary design/analysis (i.e., cohort design with the Poisson MaxSPRT model with a
minimum of four events) and the right panel is the secondary design/analysis (i.e., self-controlled design
with the binomial MaxSPRT model). Nsim=10,000. All parameters are as stated in Table 5.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test
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7.5 Summary
In this example, I have not delved into a choice among surveillance configurations in
the interest of showing the user how the simulator operates with a simple example.
Clearly, the user could initiate surveillance configuration choices by varying the detection
criteria, the choice of primary design, and the many epidemiologic choices related to how
exposures and outcomes are counted and compared. Next, I turn to an example with a
surveillance configuration choice to illustrate how the user might draw comparisons and
learn about potential scenarios. I do this by relaxing the assumptions relating to zero
misclassification, which are quite unrealistic, but have thus far allowed the reader to
explore the simulator without additional levels of complication.
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8 VACCINE EXAMPLE WITH MISCLASSIFICATION
8.1 Modeling Misclassification
Let us take our existing example, and examine the effects of outcome
misclassification on statistical power, and the two sample sizes of interest, maximum and
median sample size. For these purposes, I will always assume non-differential
misclassification although in certain circumstances, this assumption may be quite
strong.387 Many statisticians and epidemiologists have studied non-differential
misclassification in traditional retrospective epidemiologic studies 388 and several have
published post hoc correction techniques. 389 However, very little has been written about
misclassification with respect to sequential analysis. This absence is likely because it was
a problem not previously encountered. Most sequential analysis has been done in support
of clinical trials that analyze primary data. Because these data are gathered explicitly,
there is a much lower likelihood of misclassification. To wit, misclassification might
occur in these circumstances because of scientific differences in interpretation of data.
Sequential statistical analysis of secondary data is expected to contain some degree of
misclassification but these effects have not been evaluated. I extend the same
mathematical proofs of prior authors who examined non-sequential misclassification to a
sequential setting.
For each database i=1,2,...,m under consideration, I now assign a positive predictive
value (PPV) in the comparator group (PPVi") and a sensitivity ($i). I assign the PPV to
the comparator group only because Green has shown that the PPV in the treatment group
(PPVil) is always higher than in the comparator group when an excess risk exists while
assuming non-differential misclassification. 3 90 The reason is that the treatment group is
actually composed of two different sub-groups that are impossible for the user to
differentiate. The sub-groups are 1) those that experience the outcome for reasons
387 See section 4.2.3.2 for a discussion on differential and non-differential outcome misclassification.
388 S Greenland, "Basic Methods for Sensitivity Analysis of Biases," International Journal ofEpidemiology
25, no. 6 (December 1996): 1107-1116.
389 Mullooly, "Misclassification Model for Person-time Analysis of Automated Medical Care Databases";
Brenner and Gefeller, "Use of the Positive Predictive Value to Correct for Disease Misclassification in
Epidemiologic Studies"; Green, "Use of Predictive Value to Adjust Relative Risk Estimates Biased by
Misclassification of Outcome Status."
390 Green, "Use of Predictive Value to Adjust Relative Risk Estimates Biased by Misclassification of
Outcome Status."
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independent of their exposure at the background incidence rate of the outcome and 2)
those that experience the outcome because of their exposure. The first sub-group
resembles the comparator group and would have the same PPV. The second sub-group is
responsible for the numerically higher PPV (i.e., PPVvx or PPV due to vaccination) in the
treatment group, which is modeled using the incidence rate ratio (IRR). Equation (5)
describes this circumstance with the first half of the equation describing the first sub-
group and the second half of the equation describing the second sub-group:
PPVi= (PPVo)*(1/IRR) + (PPVvx)*((IRR-1)/IRR) (5)
As the reader can see, when the IRR=1 (i.e., there is no excess risk), the second part of
equation 5 is zeroed out and PPVi=PPVo.
For these purposes, PPVi can be derived from PPVo, which depends on additional
information about the relative size of the comparator population to the treatment
population and the true effect size. Equation (6) is that algebraic derivation under the
assumption of non-differential disease misclassification.
PPVi=(IRR*z)/(IRR*z -1 + (1/PPVo)) (6)
z=ratio of person-time contributed in the comparator population to person-time
contributed in the treatment population.
Given an incidence rate in the comparator group (p) that is assumed true, the
database-specific sensitivity and PPV in the comparator group as described above, it is
possible to calculate true positive cases, false positive cases, and false negative cases of
the outcome of interest in both the treatment and comparator populations. A compact
explanation of these rates is shown in Table 9 below. However, these rates will produce
deterministic totals of cases in calendar time according to these average values, and
create non-integer valued case totals. Such an approach is inconsistent with how these
data actually arrive and so I treat each of these rates as an input to a Poisson process and
simulate actual case arrivals.
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Exposed Coded Had Case Type Modeled Rate of Occurrence
with Outcome
Outcome
Treatment Population
1 0 0 TN N/A
1 0 1 FN [(IRR-1)* p + p]*(1-#)
1 1 0 FP IRR*p*(#/PPV1)
1 1 1 TP [(IRR-1)* p + p]*#
Comparator Population
0 0 0 TN N/A
0 0 1 FN p*(1-#)
0 1 0 FP p* (0) [(1/PPVo) -1)]
0 1 1 TP p*#
Table 9. Rates of Occurrence of Outcomes of Interest when Modeling Misclassification
Abbreviations: TN, true negative; FN, false negative; FP, false positive; TP, true positive; IRR, incidence
rate ratio.
8.1.1 Primary Design: Cohort Design with the Poisson MaxSPRT Model
Prior to assuming any misclassification, in the vaccine example in the previous
section, I set surveillance to detect a fivefold incidence rate ratio with 90% power.
Keeping those same detection criteria, I run my simulation again and set the true effect
size to the effect size I wish to detect, i.e., a fivefold incidence rate ratio. Now, to
illustrate the negative effects of misclassification on sequential database surveillance, I
vary sensitivity from 0 to 1 and PPV in the comparator group from 0 to 1 and explore the
changes to my surveillance scenario in Figure 25. Aside from these new changes to
misclassification, all other parameters remain as they were in Table 5. That is, all
exposure accruals occur as they did before in section 7 with the assumption of no
exposure misclassification. However, now outcomes are simulated as explained in the
previous subsection and sequential database surveillance is performed on these new data.
Figure 25 addresses the primary design and analysis only (i.e., cohort design analyzed
with the Poisson MaxSPRT model).
10,000 simulations were performed for each combination of sensitivity and PPVo
listed in Figure 25. In this set of three panels, the boxed upper righthand cell reflects what
happens with zero misclassification and is identical to analyses shown previously. The
top, middle and bottom panels respectively show the changes in statistical power, median
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sample size, and maximum sample size that occur as a result of the presence of
misclassification. As one moves away from zero misclassification (i.e., the upper
righthand cell), some combination of the following effects happen: statistical power
deteriorates, and sample sizes to detect the true effect size increase.
1.0
0.9
0.8
0.*7
0.6
0.5
0.4
0.3
0.2
0.1
0.1 0.2
0.61WER
0.57 0.69
A$ 0.58 0.61
0.3 0.4 0.57 0.67 0.7 0.409
PPV
MEDIAN SAMPLE SIZE IN CALENDAR MONTHS
1.0 5 6 8 9
0.9 5 7 8 10
0.8 5 7 9 11
g 0.7 5 8 10 12
2 0.6 6 8 11 13
0.5 6 9 12 15
0.4 7 11 15 18
0.3 8 13 18 23
0.2 11 18 26 34
0.1 18 34 49 64
16
19
16
20
15 15
17 17
20 21
18
21
|0.1 0.2 | 0.3 0.4 | 0.5 1 0.6 | 0.7 | 0.8 | 0.9 | 1.0
PPV
MAXIMUM SAMPLE SIZE IN CALENDAR MONTHS
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1 18
15
17
18
21
23
17
18
20
23
26
31
18
34
0.1 7 0.2 
0.3
PPVo I
Figure 25. Misclassification Matrix for the Vaccine Example using the Primary Design/Analysis
Nsim =10,000. All parameters, with the exception of misclassification estimates, are as stated in Table 5.
Abbreviations: PPV, positive predictive value.
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First, the reader should note that declines in sensitivity (i.e., increases in the number
of missed cases) do not change the surveillance's statistical power to detect the signal
since it will still require the same number of outcomes to reach one of the two stopping
points. Missed cases simply cause surveillance to take longer to complete, which is
evidenced by the higher median and maximum sample sizes in the middle and lower
panels of Figure 25.
Second, as PPV in the comparator group declines, false positive cases (i.e., noise)
begin to dilute the true signal and the surveillance is less frequently able to correctly
detect the excess risk (i.e., statistical power decreases). This result is consistent with what
would be expected for non-differential disease misclassification in a non-sequential
analysis. Both median and maximum sample sizes decrease, which would seem like an
improvement over a zero misclassification case because now both stopping points to
surveillance occur earlier. However, this interpretation would be mistaken. Recall that in
the Poisson MaxSPRT model, the comparison group outcomes are deterministically
calculated by incrementing the background rate (i.e., the expected incidence rate of the
outcome of interest in that population). With non-differential disease misclassification,
noise (in the form of false positive cases) is systematically added to this rate, meaning
that one arrives at the maximum sample size uniformly earlier than would otherwise have
occurred. Therefore, the entire distribution is shifted leftward or earlier in terms of
calendar months, including the median. So, while it is tempting to think that the earlier
median sample size is an improvement, it simply reflects how the Poisson MaxSPRT
model is systematically more affected by noise.
To be clear, in the less frequent scenarios when a signal is detected, surveillance is
still correctly detecting it (i.e., it would be considered a true positive signal when
defining a classification matrix based on the signal). However, it is detecting it using
some mixture of true cases and noise. If one were to perform medical chart validation on
all the electronic cases (i.e., true positive and false positive cases) that led to signal
detection, then one would likely still see evidence of an excess risk but the precision of
that estimate would be worse than anticipated in the presence of misclassification.
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Third, the median sample size when the statistical power is less than 0.50 represents
surveillance that (incorrectly) fails to reject the null hypothesis (i.e., detect a signal) a
majority of the time. These numbers are shown, but do not get the same highlighting
treatment as the others because they are less meaningful.
8.1.2 Secondary Design: Self-Controlled Design with the Binomial MaxSPRT
Model
I produce the same figure for the secondary design/analysis (i.e., self-controlled
design with the binomial MaxSPRT model) in Figure 26. Again, all parameters with the
exception of the outcome misclassification estimates are the same as those listed in Table
5. Also, as before, I set the true effect size to be equivalent to an incidence rate ratio of 5.
Overall, the patterns are similar in the secondary design/analysis as they are in the
primary, however there are some important and notable differences that really allow the
user to compare the Poisson MaxSPRT model to the binomial MaxSPRT model.
First, the binomial MaxSPRT model retains statistical power better in the face of
misclassification. This result is because the binomial MaxSPRT model is not
systematically adding noise in the same way the Poisson MaxSPRT model is. In the
binomial MaxSPRT model, the occurrence of false positive cases is stochastic for both
the treatment and comparison groups as compared to the Poisson MaxSPRT model,
which is stochastic for the treatment group alone. Therefore, the binomial MaxSPRT
model is less sensitive to the presence of noise in the form of false positive cases. In that
way, the deterministic component of the Poisson MaxSPRT model works as a double-
edged sword. One is able to build statistical power faster and reach a stopping point to
surveillance uniformly faster in the Poisson MaxSPRT model as compared to the
binomial MaxSPRT model under zero misclassification conditions. However, for the
same reasons, misclassification erodes statistical power faster in the Poisson MaxSPRT
model as compared to the binomial MaxSPRT model.
Second, the median sample size in the binomial MaxSPRT model slightly increases
with lower PPV as opposed to decreasing as it does in the Poisson MaxSPRT model.
Again, this result is because the overall distribution of the binomial MaxSPRT model is
less affected by the presence of false positives. Intuitively, this result is expected and
152
consistent with non-sequential analysis. That is, in the presence of noise, the surveillance
is less able to distinguish differences between the treatment and comparison groups and
takes longer to detect a signal.
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Figure 26. Misclassification Matrix for the Simulated Vaccine Example using the Secondary
Design/Analysis
Nsim =10,000. All parameters, with the exception of misclassification estimates, are as stated in Table 5.
Abbreviations: PPV, positive predictive value.
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Finally, recall that the maximum sample size in calendar months for the binomial
MaxSPRT model is calculated by taking the median of the time to end surveillance when
the incidence rate ratio is 1. For significant decreases in sensitivity, the maximum sample
size is likely unacceptable to any user (i.e., ranges in excess of 120 calendar months).
8.2 Likely Misclassification in the Simulated Vaccine Example
Continuing with the vaccine example I have been using throughout, let us examine
what kind of misclassification might be expected in this example based on previous
validation studies. Outcome misclassification depends on the electronic algorithm used to
detect the outcome of interest. As Chubak et al. point out, when an electronic algorithm is
very inclusive (i.e., casts a wide net), there are likely to be more false positive cases that
occur and fewer missed cases (i.e., PPV is low and sensitivity is high).39' Conversely,
when an electronic algorithm is fairly narrow, there are likely to be more missed cases
that occur but there is a higher probability of correct identification when a case is
identified (i.e., sensitivity is low and PPV is high). The user will likely choose the
algorithm based on the priorities for the study, i.e. whether false positives or false
negatives are more costly. Again, the user's sense of the likelihood that a true excess risk
exists is likely a large determinant of their preferences. Let us examine three algorithms
that have been studied that could be used to detect the outcome of interest, idiopathic
thrombocytopenic purpura (ITP).
The first algorithm detects the occurrence of ICD-9 392 code 287.3. Terrell et al.
performed a validation study using this algorithm in both children and adults, but I limit
the application of these results to the studies in children, which is reflective of the
example. 393 She finds a combined PPV of 0.54 (225/323 records in the outpatient setting
and 12/118 records in the inpatient setting) for a definitive diagnosis of ITP. There were
no data reported on sensitivity. The reader should note the significant differences in
391 Chubak, Pocobelli, and Weiss, "Tradeoffs Between Accuracy Measures for Electronic Health Care Data
Algorithms."
392 An ICD-9 code is used in medical billing and coding to describe diseases, injuries, symptoms and
conditions.
393 Terrell et al., "Determining a Definite Diagnosis of Primary Immune Thrombocytopenia by Medical
Record Review."
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misclassification depending on the healthcare delivery setting as this report reinforces
previous findings. 394
The second algorithm (hereafter Algorithm 2 in subsequent figures) requires the
occurrence of any of the following ICD-9 codes (287, 287.0, 287.1, 287.2, 287.3 287.31,
287.39, 287.4, 287.5, 287.8, 287.9) plus a laboratory value of <50,000 platelets. This
study was done in five databases that are now a part of the Mini-Sentinel System. 395 The
use of additional laboratory data is because these five databases originate from integrated
delivery systems where laboratory data are available. I will use the published results from
the years 2005-2008. The PPV for this algorithm is 0.53 and the sensitivity for this
algorithm is 0.99.396
The third algorithm (hereafter Algorithm 3 in subsequent figures) comes from the
same study and requires the occurrence of ICD-9 code 287.31 plus a lab value of <50,000
platelets. The PPV for this code is 0.79 and the sensitivity is 0.59.397 As expected, this
narrower algorithm has a higher PPV and lower sensitivity when compared with the
broader Algorithm 2.
To illustrate the impact of these different algorithms on the analysis, I reperform the
baseline analyses from the previous section while relaxing my assumption regarding
perfect outcome classification. As before, I first create figures showing what happens
when the true effect size happens to be equivalent to the effect size specified as the effect
size of interest (i.e., a fivefold incidence rate ratio). Again, I do this for both the primary
and secondary designs/analyses. Figure 27 shows the results when using Algorithm 2. As
discussed earlier, low positive predictive values degrade statistical power in the Poisson
MaxSPRT model (shown on the left) to a greater degree than the binomial MaxSPRT
model (shown on the right). Compare a statistical power of 0.6045 in the former to
0.7351 in the latter. In comparison to the zero misclassification results shown in Figure
18 on page 136, statistical power is lower and the median sample sizes are lower since
false positive cases are contributing to signal detection. For the Poisson MaxSPRT
394 Greene et al., "Near Real-time Vaccine Safety Surveillance with Partially Accrued Data."
395 O'Leary et al., "The Risk of Immune Thrombocytopenic Purpura After Vaccination in Children and
Adolescents."
396 I calculate the sensitivity for this algorithm by counting the number of confirmed missed cases with
respect to other algorithms.
397 See supra at note 396.
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model, the zero misclassification baseline has a statistical power of 0.8993 and a median
sample size of 11 calendar months whereas Algorithm 2 has a statistical power of 0.6045
and a median sample size of 10 calendar months. For the binomial MaxSPRT model, the
zero misclassification baseline has a statistical power of 0.9126 and a median sample size
of 14 calendar months whereas Algorithm 2 applied to this model has a statistical power
of 0.7351 and a median sample size of 16 calendar months.
Algorithm 2 with Poisson MaxSPRT Model with Minimum of Four Events Algorithm 2 with Binomial MaxSPRT Model
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Figure 27. Distribution of Calendar Time to End Surveillance in Vaccine Example with
Misclassification per Algorithm 2
The left panel is the primary design/analysis (i.e., cohort design with the Poisson MaxSPRT model with a
minimum of four events) and the right panel is the secondary design/analysis (i.e., self-controlled design
with the binomial MaxSPRT model). Misclassification parameters are given by Algorithm 2 and shown on
the graph. Nsim=10,000. All other parameters are as stated in Table 5.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test, PPV, positive predictive value.
Figure 28 shows the results when using Algorithm 3, which creates a different
misclassification pattern. Again, the left panel shows the primary design/analysis whereas
the right panel shows the secondary design/analysis. Statistical power is not nearly so low
as it is when using Algorithm 2. However, the reduced sensitivity has increased sample
sizes relative to both the zero misclassification results shown in Figure 18 on page 136
and to the Algorithm 2 results. As explained earlier, statistical power in the secondary
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design/analysis (i.e., binomial MaxSPRT Model) is less responsive to changes in PPV
when compared to the primary design/analysis.
Algorithm 3 with Poisson MaxSPRT Model with Minimum of Four Events Algorithm 3 with Binomial MaxSPRT Model
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Figure 28. Distribution of Calendar Time to End Surveillance in Vaccine Example with
Misclassification per Algorithm 3
The left panel is the primary design/analysis (i.e., cohort design with the Poisson MaxSPRT model with a
minimum of four events) and the right panel is the secondary design/analysis (i.e., self-controlled design
with the binomial MaxSPRT model). Misclassification parameters are given by Algorithm 3 and shown on
the graph. Nsim=10,000. All other parameters are as stated in Table 5.
Abbreviations: MaxSPRT, Maximized Sequential Probability Ratio Test, PPV, positive predictive value.
As before, to evaluate how surveillance performs over a range of effect sizes, I extract
key points in these distributions and present them in Table 10. The patterns observed in
the figures above play out over the range of true effect sizes. In the middle panel of Table
10, with respect to Algorithm 2, statistical power falls below 0.5 for all effect sizes
numerically less than the fivefold incidence rate ratio that the surveillance was powered
to detect.
In general, these results allow the user to consider how different algorithms will shift
the statistical power and sample size requirements of surveillance. The problem specifics
will likely influence whether the user favors maintaining a robust statistical power or
minimizing median sample size.
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Zero Misclassification Case
Signal Mean Median 80th 95thTrue Risks ()(months) (months) (months) (months)
IRD IRR Poi Bin Poi Bin Poi Bin Poi Bin Poi Bin
0 1.0 0.05 0.05 17.8 69.3 18 70 18 81.5 18 94
1 1.5 0.14 0.16 17.3 52.9 18 55 18 65 18 75
2 2.0 0.28 0.32 16.5 41.5 18 44 18 54 18 62
4 3.0 0.56 0.64 14.7 27.2 16 28 18 38 18 45
8 5.0 0.90 0.91 11.2 15.4 11 14 14 21 18 27
18 10.0 0.999 0.993 7.3 9.2 7 8 9 11 11 14
Algorithm 2: Sensitivity=0.99 and PPV=0.53
Signal Mean Median 80th 95thTrue Risks (%)o (months) (months) (months) (months)
IRD IRR Poi Bin Poi Bin Poi Bin Poi Bin Poi Bin
0 1.0 0.05 0.06 10.9 50.0 11 50 11 58 11 67
1 1.5 0.06 0.12 10.8 41.7 11 43 11 50 11 57
2 2.0 0.11 0.24 10.7 35.3 11 37 11 44 11 50
4 3.0 0.31 0.48 10.2 26.0 11 28 11 34 11 40
8 5.0 0.60 0.74 9.1 16.3 10 16 11 22 11 27
18 10.0 0.95 0.97 6.9 9.5 7 9 8 12 11 15
Algorithm 3: Sensitivity=0.59, PPV=0.79
True Risks Signal Mean Median 80th 95th
T eis (months) (months) (months) (months)
IRD IRR Poi Bin Poi Bin Poi Bin Poi Bin Poi Bin
0 1.0 0.05 0.05 23.7 100.4 24 101 24 119 24 137
1 1.5 0.13 0.16 23.1 78.7 24 82 24 96 24 111
2 2.0 0.21 0.30 22.3 62.5 24 67 24 81 24 94
4 3.0 0.47 0.59 20.2 41.5 24 44 24 59 24 70
8 5.0 0.83 0.86 15.8 22.7 15 21 21 33 24 43
18 10.0 0.995 0.992 9.9 11.9 9 11 12 15 16 21
Table 10. Descriptive Statistics of the Calendar Time to End Surveillance in Months for the Primary
and Secondary Analyses over a Range of True Risks with Misclassification
Nsim=10,000 Simulations, Overall Type I Error: 0.05, Shading indicates when the maximum sample size is
reached and the null hypothesis is not rejected. Signal is the percent of time the null hypothesis is rejected.
Incidence Rate Difference is given in events per 100,000 person-years.
Abbreviations: IRD, incidence rate difference; IRR, incidence rate ratio; Poi, Poisson MaxSPRT Model;
Bin, Binomial MaxSPRT Model; PPV, positive predictive value.
In these figures, I have shown the user what might occur if the user has set their
detection criteria and assumed perfect misclassification and then actually performed
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surveillance in the presence of the misclassification. However, if the user has obtained
estimates of misclassification, then an obvious solution is to adjust the way that the
surveillance detection criteria is set a priori based on these misclassification estimates.
That adjustment entails artificially increasing the maximum sample size. By performing
this adjustment, one can try to isolate the variations related to statistical power above (at
least for one particular effect size), and examine performance in terms of sample size
only. I do that next when I show a partitioning of the Mini-Sentinel System. Adjustments
were performed by varying the adjustment factor until the appropriate statistical power
was obtained. Adjustment factors differed for the two models. The primary
design/analysis (i.e., cohort design analyzed using the Poisson MaxSPRT model)
required a larger adjustment factor than the secondary design/analysis (i.e., self-
controlled design analyzed using the binomial MaxSPRT model). This difference in
factors is unsurprising when considering the statistical power of the primary design is
more affected by changes in positive predictive value when compared to the secondary
design.
8.3 Partitioning the Mini-Sentinel System
Up until now, I have treated the Mini-Sentinel System as one aggregate database and
obscured the differences among its components in order to show the capabilities of the
Sequential Database Surveillance Simulator. However, these component databases are
qualitatively different, and this variation across these databases provides opportunities for
a user to tailor the performance of sequential database surveillance to the specific
circumstances of the public health question being evaluated. For example, of the three
algorithms discussed above, only Algorithm 1 (claims only) can be executed across the
Mini-Sentinel System. Algorithms 2 and 3 both require laboratory data that is only
available in a subset of component databases. These qualitative differences merit further
investigation.
There are three important sources of variation across the Mini-Sentinel System that
affect the timeliness and accuracy with which signals of excess risk are detected. First,
uptake/adoption of medical products is highly dependent on formulary status, clinical
guidelines, and the practice of medicine within particular healthcare systems. Second,
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misclassification error or noise in component databases varies across algorithms and the
databases themselves. Third, the costs, in time and money, associated with the correction
of misclassification bias via medical chart validation procedures are highly variable
across the databases that comprise the Mini-Sentinel System.
In general, component databases of the Mini-Sentinel System fall into two categories:
1) databases from large, national health insurers that are aggregations of hundreds of
regional healthcare plans, and 2) databases from smaller integrated delivery systems.
Databases in the first category are typically claims-only data with open (i.e., less
restrictive) formularies. These databases also account for the bulk of data in the Mini-
Sentinel System. Databases in the second category have richer clinical data (e.g.,
laboratory data) to supplement claims data, but have more controlled formularies.
Medical chart validation procedures are significantly less time-consuming and costly in
the integrated delivery system databases.
Why is this important? A subset of the Mini-Sentinel System data is high quality with
minimal noise. Does this high quality data contribute unique value that should be
considered when estimating the demand for the Mini-Sentinel System? What are the
tradeoffs between the quantity and the quality of the sample size? Let us re-examine the
problem and disaggregate the Mini-Sentinel System. If we take the cohort of 0-1 year
olds available in the Mini-Sentinel System and partition it according to the capability to
get laboratory data, then we can expect 40% of the original cohort to have laboratory data
available. As a note, this is not necessarily the typical breakdown of the Mini-Sentinel
System today. This example reflects circumstances that occurred for this cohort of
interest at the time the dataset was created. The Mini-Sentinel System is a dynamic data
system and circumstances may be quite different for other tracked safety issues evaluated
at other timepoints. However, for the user planning on conducting surveillance, they will
have be able to execute modular programs to find out this exact information.
In this portion of the example, I imagine the user is either choosing to apply
Algorithm I broadly across the Mini-Sentinel System or to apply Algorithm 3 to the
subset of the data that also has laboratory data (i.e., 40%). I assume sensitivity is 0.99
with Algorithm 1. 1 will rerun the analyses with these database sizes but also by applying
an adjustment factor to the maximum sample size (i.e., the upper limit on the length of
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surveillance). I perform this step to try to force these analyses to have comparable
statistical power. Results are shown in Table 11.
Algorithm 1 (PPV=0.52, Sensitivity=0.99), Database Size=564,000
True Risks Signal Mean Median 80th 95th(%) (months) (months) (months) (months)
IRD IRR Poi Bin Poi Bin Poi Bin Poi Bin Poi Bin
8 5.0 0.90 0.91 13.7 18.0 12 16 21 26
Algorithm 3 (PPV=0.79, Sensitivity=0.59), Database Size=.4*564,000
True Risks Signal Mean Median 80th 95th(%) (months) (months) (months) (months)
IRD IRR Poi Bin Poi Bin Poi Bin Poi Bin Poi Bin
8 5.0 0.91 0.92 38.0 50.1 33 43 55 77 ''fo
Table 11. Descriptive Statistics of the Calendar Time to End Surveillance in Months for the Primary
and Secondary Analyses with A Priori Adjustments for Anticipated Misclassification
Nsim=1 0,000 Simulations, Overall Type I Error: 0.05, Shading indicates when the maximum sample size is
reached and the null hypothesis is not rejected. Signal is the percent of time the null hypothesis is rejected.
Incidence Rate Difference is given in events per 100,000 person-years.
Abbreviations: IRD, incidence rate difference; IRR, incidence rate ratio; Poi, Poisson MaxSPRT; Bin,
Binomial MaxSPRT Model, PPV, positive predictive value.
The important finding is that when one adjusts the analysis to preserve statistical
power in the face of noise created from false positives, there appears to be no time
advantage to using the more accurate (i.e., higher PPV) algorithm on a smaller subset of
higher quality data. That is, if the true risk existed at the level that we have powered
surveillance to detect (i.e., fivefold incidence rate ratio), then the size advantage
outweighs the data quality because lower median sample sizes still imply quicker
detection. Also, by artificially inflating statistical power, theoretically there still would be
enough true positive cases to signal if the signal were based on true positive cases alone.
As a sensitivity analysis, I tested how low the PPV of Algorithm I would have to be
before the size advantage was negated. In this case, it turned out to be a PPV of 0.06 for
the binomial MaxSPRT model, and closer to a PPV of 0.13 for the Poisson MaxSPRT
model. Those results are shown in Table 12. The reader should note that this might not
always be the case and is entirely dependent on the numbers that pertain to this tracked
safety issue. In this example, I have assumed that the user would cope with poor PPV by
adjusting the analysis with a correction factor. However, it is possible that a user may
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have a threshold below which they would not consider using a particular detection
algorithm even if a correction factor were applied because they would be unsure about
the validity of the final results.
If the user decided that chart validation were required for the more poorly performing
algorithm, then the decision calculus would change considerably. First, recall that the
largest data holders in the Mini-Sentinel System have the most expensive and least timely
chart validation procedures. The time to end surveillance considered in Table 12 does not
consider additional time for chart validation. If these time and cost considerations are
accounted for, then - depending on the specific values attributed to the time and cost of
chart validation - it is possible that the size advantage is negated and the user might
prefer the slower uptake and more accurate electronic algorithm without chart validation.
The frequency of the outcome also plays a considerable role in this decision. When
detecting very rare outcomes, such as ITP, it may be plausible to perform chart validation
on every outcome. However, more frequent outcomes like acute myocardial infarctions
may require some subset or sampling of outcomes.
Algorithm 1, (PPV of P01=0.13, PPV of BIN= 0.06, Sensitivity=0.99), Database
Size=564,000
True Risks Signal Mean Median 80th 95th(%) (months) (months) (months) (months)
IRD IRR Poi Bin Poi Bin Poi Bin Poi Bin Poi Bin
8 5.0 0.89 0.91 37.3 53.9 33 49 61 85 78 1-10
Algorithm 3 (PPV=0.79, Sensitivity=0.59), Database Size=.4*564,000
True Risks Signal Mean Median 80th 95th(%) (months) (months) (months) (months)
IRD IRR Poi Bin Poi Bin Poi Bin Poi Bin Poi Bin
8 5.0 0.91 0.92 38.0 50.1 33 43 55 77 1 77
Table 12. Sensitivity Analysis on Calendar Time to End Surveillance in Months for the Primary and
Secondary Analyses with A Priori Adjustments for Anticipated Misclassification
Nsim=10,000 Simulations, Overall Type I Error: 0.05, Shading indicates when the maximum sample size is
reached and the null hypothesis is not rejected. Signal is the percent of time the null hypothesis is rejected.
Incidence Rate Difference is given in events per 100,000 person-years.
Abbreviations: IRD, incidence rate difference; IRR, incidence rate ratio; Poi, Poisson MaxSPRT Model;
Bin, Binomial MaxSPRT Model; PPV, positive predictive value.
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8.4 Summary
When performing sequential database surveillance for a particular exposure-outcome
pair, the user has many choices. A more realistic rendering of a database's capabilities
will account for misclassification. Strategies to cope with misclassification are still
emerging in the sequential database surveillance setting when the goal is take advantage
of available electronic data in a timely fashion to provide early warning of medical
product-associated risks in the environment. However, there is a real balance to be struck
between generating both accurate and timely estimates of those risks. As the reader will
see in the next section, many aspects of sequential database surveillance are beyond the
user's control. When misclassification itself is one of those aspects, the user can
experiment with different misclassification control policies in the Sequential Database
Surveillance Simulator to learn more about the effects of various policies on both the
timeliness and accuracy of signal detection.
163
THIS PAGE INTENTIONALLY LEFT BLANK
164
9 MODELING ADOPTION OF MEDICAL PRODUCTS
Recall that sequential database surveillance requires the simultaneous management of
information time and calendar time. That is, for sequential database surveillance within
the Mini-Sentinel System to be a useful evidence generation capability,
information/sample size accrual (i.e., the adoption and utilization of the medical product
being evaluated) has to occur within a calendar timeframe appropriate to regulatory
decision-making. The ability to reach a stopping point (i.e., either rejection or acceptance
of the null hypothesis of no excess risk) in sequential database surveillance requires a
threshold level of information (i.e., sample size) that clearly varies with the statistical
power desired to detect a true effect size and the frequency of the outcome being
detected, among other things. In short, the advantage of using a simulator such as the one
presented herein is the ability to sort tracked safety issues into instances when sequential
database surveillance might be more or less useful than other research approaches (e.g.,
randomized controlled trials) to evaluate safety.
However, the Sequential Database Surveillance Simulator requires the user to begin
with assumptions regarding parameters that describe medical product adoption and
utilization, and these parameters are among the most uncertain to be modeled. Not only
are they unknown, but, as stated earlier, they are also beyond the user's control. These
parameters include the identification of the potential pool of adopters of a medical
product, the anticipated percentage of non-adopters of a medical product, and the
function describing adoption itself. For vaccines and other "point"/discrete exposures,
adoption parameters alone are sufficient to describe exposure. However, for continuous
exposures (e.g., most drugs and therapeutic biologics), additional information is needed
to describe medical product utilization, or the behavior of patients after initial adoption.
For example, it is important to estimate how long adopters of new medical products
continue to use such products, i.e., adherence. For antibiotics and other short course
medical products, this task is less challenging than for products administered over the
course of a lifetime (e.g., beta blockers).
While sequential database surveillance can occur at any time during a product's
lifecycle, it is anticipated that such surveillance will occur early, typically in the near-
term following approval and/or commercial launch of a new medical product. If
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surveillance is not immediately postapproval, then it may be possible to gather
preliminary data on adoption and utilization patterns. These data may be obtained
through execution of modular programs, and may form the basis for further adoption and
utilization projections. However, if surveillance is planned immediately postapproval,
then it is left to the user to speculate about possible adoption and utilization patterns.
In the routine childhood vaccination example that I have used throughout this
dissertation, an adoption function coincident with a one-year old well visit is not
unreasonable because of public policy requirements that demand immunizations for entry
to school or daycare. Appendix A describes validation data to support linear adoption
patterns for routine childhood vaccinations. However, adoption of new drugs is
influenced by more factors (e.g., formulary policy, co-payments, the availability of
substitute therapies, treatment guidelines, the practice of medicine, advertising, etc.), and
is considerably more complex.
In this section, I evaluate adoption data from previously approved new molecular
entities in an attempt to provide a rational basis for assuming potential adoption functions
in future surveillance. To be clear, manufacturers perform extensive market research and
modeling prior to the launch of a new medical product. They have a unique and detailed
understanding of the pool of potential adopters and their likely adoption patterns. My
purpose is not to try to recreate these models. Rather, public health planners need some
general functional forms to describe medical product adoption that can be used alongside
a sensitivity analysis in sequential database surveillance models employed in the
simulator.
9.1 New Molecular Entity Cohort
To establish these functional forms, I looked to previously approved new molecular
entities398 in the years 2004-2006. 1 selected these years so I could observe enough data to
be comparable to time frames associated with completed sequential database surveillance
398 "Certain drugs are classified as new molecular entities (NMEs) for purposes of FDA review. Many of
these products contain active moieties that have not been approved by FDA previously, either as a single
ingredient drug or as part of a combination product; these products frequently provide important new
therapies for patients." See U.S. Food and Drug Administration and Center for Drug Evaluation and
Research, "Innovation in Development of Drugs and Biological Products," WebContent, n.d.,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Druglnnovation/default.htm.
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analyses. 399 The new molecular entities selected for evaluation were limited to outpatient
medications, which are commonly captured in pharmacy dispensing files based on
national drug codes. Recall that medical products such as medically-attended infusions
and injections, particularly newly available ones, are not well captured in the Mini-
Sentinel System. 40 0 Of the 78 new molecular entities approved between 2004-2006, 40
were included in the "cohort," and are listed in Table 13. The national drug codes
associated with each product in the cohort were identified using the FDA's public
database 40, and checked against a third-party commercial database. Additionally, once I
began working with these data, it became apparent that particular new molecular entities
experienced significant delays between when the product was approved and when it was
commercially available/launched. For example, see Apidra@ (insulin glulisine injection)
and Omacor@/Lovaza@ (omega-3 acid ethyl esters) in Table 13 below. This mismatch
created a problem for trend analysis. Therefore, I had to obtain "launch dates" for the
products in the cohort from the manufacturer's press releases.
Trade Name Generic Name Days Approval Launch
(n=40) (n=40) Supplied Date Date
Amitiza lubiprostone 30 01-31-2006 04-01-2006
Apidra insulin glulisine injection 30 04-16-2004 03-08-2006
Aptivus tipranavir 30 06-22-2005 06-22-2005
Azilect rasagiline mesylate 30 05-16-2006 08-01-2006
Baraclude entecavir 30 03-29-2005 04-01-2005
Byetta exenatide 30 04-28-2005 06-01-2005
Campral acamprosate 30 07-29-2004 01-01-2005
Chantix varenicline 30 05-10-2006 08-02-2006
Cymbalta duloxetine 30 08-03-2004 08-03-2004
Enablex darifenacin 30 12-22-2004 02-09-2005
Exjade deferasirox 30 11-02-2005 01-16-2006
Fosrenol lanthanum 30 10-26-2004 01-01-2005
Invega paliperidone 30 12-19-2006 01-07-2007
Januvia sitagliptin phosphate 30 10-16-2006 10-16-2006
Levemir insulin detemir 30 06-16-2005 03-01-2006
Lunesta eszopiclone 30 12-16-2004 04-03-2005
399 Yih et al., "Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink
Project."
400 See supra at note 294.
401 Center for Drug Evaluation and Research and Food and Drug Administration, "National Drug Code
Directory", n.d., http://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm.
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Trade Name Generic Name Days Approval Launch
(n=40) (n=40) Supplied Date Date
Lyrica pregabalin 30 12-31-2004 09-22-2005
Nevanac nepafenac 15 08-19-2005 09-01-2005
Nexavar sorafenib toylate 30 12-20-2005 12-20-2005
Noxafil posaconazole 14 09-15-2006 09-15-2006
Omacor/Lovaza omega-3 acid ethyl esters 30 11-10-2004 10-05-2005
Omnaris ciclesonide 30 10-20-2006 05-09-2008
Prezista darunavir 30 06-23-2006 07-01-2006
biskalcitrate potassium,
Pylera metronidazole and tetracycline 10 09-28-2006 05-07-2007
hydrochloride
Ranexa ranolazine 30 01-27-2006 03-24-2006
Revlimid lenalidomide 28 12-27-2005 01-01-2006
Rozerem ramelteon 30 07-22-2005 09-01-2005
Sanctura trospium 30 05-28-2004 08-23-2004
Sensipar cinacalcet 30 03-08-2004 04-01-2004
Spiriva tiotropium oral inhalation 30 01-30-2004 05-25-2004
Sprycel dasatinib 30 06-28-2006 07-01-2006
Sutent sunitinib malate 28 01-26-2006 04-01-2006
Symlin pramlintide acetate 30 03-16-2005 04-01-2005
Tarceva erlotinib 30 11-18-2004 11-27-2004
Tindamax tinidazole 5 05-17-2004 07-01-2004
Tyzeka telbivudine 30 10-25-2006 03-16-2007
Veregen sinecatechins 30 10-31-2006 12-14-2008
Vesicare solifenacin 30 11-19-2004 01-21-2005
Xifaxan rifaximin 15 05-25-2004 07-01-2004
Zolinza vorinostat 30 10-06-2006 10-06-2006
Table 13. Cohort of New Molecular Entities Evaluated for Adoption Patterns
Days Supplied indicates average days supplied per prescription.
9.2 Medicaid Data Explorations
Prior to the availability of data from the Mini-Sentinel System, I used U.S. Medicaid
dispensing data40 2 to evaluate the adoption and utilization patterns (i.e., sample size
accrual) of medical products in the cohort. These data are reported quarterly by state to
the Centers for Medicare and Medicaid Services and are available for outpatient drugs
paid for by state Medicaid agencies per the Medicaid Drug Rebate Program. I calculated
exposure profiles from these quarterly Medicaid dispensing data from the time of a
4 Centers for Medicare and Medicaid Services, "Medicaid Drug Programs Data & Resources", n.d.,
http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-
Drugs/Medicaid-Drug-Programs-Data-and-Resources.html.
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product's commercial launch date until the end of the third calendar quarter of 2010.
These publicly available dispensing summaries are based on administrative claims data
403
and represent utilization for approximately 60 million covered lives.
Several adjustments were made to account for extreme values and limited granularity
in the Medicaid data. I removed extreme values 40 4 and replaced them with linearly
interpolated data points based on the nearest neighbors. I generally assumed 30 exposed
days (i.e., days supplied) per dispensing because states limit Medicaid prescription drug
utilization accordingly;405 exceptions are noted in Table 13. Because these data were not
quality-controlled, I assumed exposure could range from half to double the calculated
value. These exposure accrual estimates were likely high because I assumed that every
dispensing contributed exposed person-time to surveillance. In actual surveillance
activities, many exposed days would be excluded because of incident user criteria,
disqualifying prior events, and lapses in drug or medical benefit coverage.
Using Medicaid claims data as a temporary "substitute" for data in the Mini-Sentinel
System had advantages and disadvantages. The primary advantages were its free, public
availability and similarity in structure to Mini-Sentinel Systems claims data. However,
the lack of quality control in these data was a significant disadvantage. Also, these raw
dispensing totals did not provide much insight into "incident user" utilization, which is
typically the design for sequential database surveillance studies. Finally, Medicaid
populations underwent substantial upheaval before and after January 1, 2006 due to
changes in eligibility as a result of the 2003 Medicare Modernization Act.4 06 At the time
of design and subsequent analysis, I chose the cohort so that at least 15 quarters of data
were available. If I were to re-perform this analysis using Medicaid data in the future, I
would limit my cohort to new molecular entities approved after January 1, 2006.
403 U.S. Congressional Budget Office, The Budget and Economic Outlook: Fiscal Years 2011 to 2021
(Washington, DC: Congress of the United States, Congressional Budget Office, 2011),
http://cbo.gov/doc.cfm?index= 12039; U. S. Congressional Budget Office, The Long-term Outlookfor
Health Care Spending (Washington, DC: Congress of the U.S., Congressional Budget Office, 2007),
http://www.cbo.gov/doc.cfm?index=8758; Jean Hearne and Congressional Research Service, Prescription
Drug Coverage Under Medicaid: CRS Report RL30726 (Washington, D.C.: Congressional Research
Service, Library of Congress, February 6, 2008), http://opencrs.com/document/RL30726.
404 I defined extreme values as greater than 3 times the median absolute deviation from the median.
405 Hearne and Congressional Research Service, Prescription Drug Coverage Under Medicaid: CRS Report
RL30726.
406 For more, see section 4.3.3.
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Nonetheless, my intention is using these data with few constraints was to provide
rough estimates of detectable effect sizes based on actual utilization. To do this, I used
the calculated exposure pattern and varied the frequency of the outcome of interest to
evaluate whether simulated true effect sizes were detectable given the sample size. In
other words, if the simulated effect size were the true effect size, then that effect size was
detectable if sequential database surveillance using the Poisson Maximized Sequential
Probability Ratio Test (MaxSPRT) model could detect the risk with a certain success rate
or reach an end to surveillance without signaling (i.e., type II error was constrained to be
<0.20). Several tables in Appendix B show these results that I summarize next. I perform
this analysis with common event rates of 1 event/100 person-years, infrequent event rates
of 1 event/1000 person-years, rare event rates of 1 event/10,000 person-years, and very
rare event rates of 1 event/100,000 person-years.407 Others have performed similar
studies on a potential European equivalent of the Mini-Sentinel System and found similar
results.4 08
9.2.1 Common Event Rates
Table 22 in Appendix B reports the simulated effect sizes that were achievable when
trying to detect an event rate of 1/100 person-years under the Poisson MaxSPRT model
with detection criteria that sets type I error to 0.05 and type II error to 0.20. An example
of a common event rate is the event rate of interest in the Mini-Sentinel System pilot
project: 9 acute myocardial infarctions/1000 person-years among users of oral
hypoglycemics. 409 Of the 40 products listed in Table 13, 1 found that sequential database
surveillance on 8 quarters of data could identify a simulated incidence rate ratio of >2.5
for 30 products with the most generous estimates of exposures and for 23 products with
the most conservative estimates. Expanding surveillance to 15 quarters would have
identified a simulated incidence rate ratio of >2.5 for 34 products with generous estimates
and 24 products with conservative estimates.
407 The use of the terms common, infrequent, rare and very rare are defined per The Council for
International Organizations of Medical Sciences (CIOMS) Working Group III, Guidelinesfor Preparing
Core Clinical Safety Information on Drugs.
408 Preciosa M Coloma et al., "Electronic Healthcare Databases for Active Drug Safety Surveillance: Is
There Enough Leverage?," Pharmacoepidemiology and Drug Safety 21, no. 6 (June 2012): 611-621.
409 Fireman et al., "A Protocol for Active Surveillance of Acute Myocardial Infarction in Association with
the Use of a New Antidiabetic Pharmaceutical Agent."
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9.2.2 Infrequent Event Rates
Table 23 in Appendix B shows results with a different event rate assumption: 1
event/1000 person-years. A comparable event rate was found in a recent study of bipolar
and depressed adults using anti-epileptics, which estimated 1.2-4.4 suicide-related
410
events/ 1000 person-years. Under this event rate assumption, I found that sequential
database surveillance on 8 quarters of data could identify a simulated incidence rate ratio
of >2.5 for 16 products with the most generous estimates of exposures and for 7 products
with the most conservative estimates. Using 15 quarters of data, sequential database
surveillance would have identified a simulated incidence rate ratio of >2.5 for 21
products with generous estimates and 15 products with conservative estimates.
9.2.3 Rare Event Rates
Table 24 in Appendix B repeats the analysis with a rare event rate: 1 event/10,000
person-years. Sequential database surveillance could identify a simulated IRR of >2.5 for
5 products within 8 quarters and 8 products within 15 quarters under generous exposure
estimate assumptions. For reference, the rate of acute renal failures among statin users
has been estimated at 4 events/10,000 person-years ; and the rate of upper
gastrointestinal bleeding episodes among users of non-steroidal anti-inflammatory drugs
412has been estimated at ranges from 3.9 to 11 events/10,000 person-years.
9.2.4 Very Rare Event Rates
I performed the analysis with very rare event rates - 1 event/100,000 person-years -
and the results are shown in Table 25 in Appendix B. Comparable rates are 1-2 cases of
Guillain-Barr6 Syndrome among 100,000 person-years contributed by adolescents
410 A. Arana et al., "Suicide-related Events in Patients Treated with Antiepileptic Drugs," The New England
Journal of Medicine 363, no. 6 (2010): 542-55 1.
411 L. A. Garcia Rodriguez, R. Herings, and S. Johansson, "Use of Multiple International Healthcare
Databases for the Detection of Rare Drug-associated Outcomes: a Pharmacoepiderniological Programme
Comparing Rosuvastatin with Other Marketed Statins," Pharmacoepidemiology and Drug Safety 19, no. 12
(2010): 1218-1224.
412 P. M. Coloma et al., "Combining Electronic Healthcare Databases in Europe to Allow for Large-scale
Drug Safety Monitoring: The EU-ADR Project," Pharmacoepidemiology and Drug Safety 20, no. 1 (2011):
1-11.
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eligible for vaccination against meningococcal disease.4 " A simulated incidence rate
ratio of 2.5 is not achievable for any products after 15 quarters of data have accrued even
under the most generous exposure assumptions.
9.3 Utilization Comparison Among Three Data Sources
To understand the greater context of these results and also how they compared to data
actually in the Mini-Sentinel System, I obtained comparable data from a proprietary drug
use database licensed by the FDA and summary tables414 from the Mini-Sentinel System.
9.3.1 SDI Vector One@: National (VONA)
The VONA database measures retail dispensing of prescriptions. Prescriptions are
captured from a sample of approximately 59,000 retail pharmacies throughout the U.S.
These data are then presented as nationally projected monthly dispensing summaries.
Dispensings from mail order pharmacies and non-retail settings are not represented in
these data. Prior to the availability of the Mini-Sentinel System, these data were the
primary source of utilization data for the FDA. Generally, these data are considered
reliable for outpatient pharmacy dispensings that are not dispensed in specialty
pharmacies or via restricted distribution programs. For medical products with
limited/restricted dispensing patterns, these projections are less reliable because it is
unclear how representative the sample is or how well this sample can be nationally
projected in these circumstances.
9.3.2 Mini-Sentinel System Summary Table Data
Once it became available, I obtained Mini-Sentinel System Summary Table data on
the cohort. These data were also quarterly dispensings for prevalent users. At that time,
enrollment in the Mini-Sentinel System was estimated to cover 38.8 million persons.
However, some data partners were not able to contribute data until after 2007, and
because I was concerned with exposure trends immediately post-approval, I censored any
413 Priscilla Velentgas et al., "Risk of Guillain-Barr6 Syndrome After Meningococcal Conjugate
Vaccination," Pharmacoepidemiology and Drug Safety (July 16, 2012),
http://www.ncbi.nlm.nih.gov/pubmed/22807266.
4 See section 2.2.2.1 for a description of summary tables.
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data partners that did not contribute to the system for the entire evaluation period (2004-
2010). After censoring, my reduced version of the data was estimated to cover 10 million
persons.
9.3.3 Correlation
Unfortunately, these three datasources (i.e., Medicaid, SDI Vector One@, and the
Mini-Sentinel System) uniformly do not support calculation of dispensings per capita,
and the estimated persons covered by the three diverge greatly. Therefore, to compare the
systems and evaluate their correlation, I standardized them so that each quarter's
utilization (U,) is equal to the percent of utilization out of the total utilization over four
years using equation (7) where R, is raw dispensings per quarter.
U RtU = 16t (7)
R,
t-1
I chose this formula because it is easy to understand and it prioritizes utilization
patterns early in a medical product's lifecycle, which would presumably be most
important to understand for support of sequential database surveillance. This reduced the
total cohort to 37 new molecular entities because not all of the medical products had
sixteen quarters of data across the three sources. Figure 29 shows these 37 results, each
medical product is a different color. Individual medical products are not identified to due
to limitations on public sharing of these data.
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Figure 29. Standardized Utilization Patterns for 37 New Molecular Entities Over Four Years.
To calculate the correlation, I treated each utilization pattern as a sequence of values
and calculated the pairwise Pearson correlation distance.415 Table 14 shows these results,
roughly ordered by products with the best correlation among the three data sources to
products with the least correlation. Lower numbers indicate a better correlation and are
color scaled such that green indicates a better correlation than red.
First, Medicaid dispensing data is more dissimilar from the other two data sources.
This dissimilarity tends to be worse in new molecular entities with dispensings that
spanned the significant changes in Medicaid that occurred after January 1, 2006. New
molecular entities that do not cover this span (i.e., were approved after January 1, 2006)
are noted with an asterisk in Table 14. Second, the mean is greater than the median for all
cases, indicating the presence of outliers associated with lower levels of correlation.
Third, the areas of dissimilarity between SDI Vector One@ and Mini-Sentinel System
data mostly involve medical products with restricted distribution programs (e.g.,
Revlimid@, Sutent@, Exjade@, Nexavar@, Zolinza@) where it is assumed that SDI
Vector One@ data will undercount actual utilization. Fourth, correlation tends to be
worse among products with low exposure prevalence due to small total numbers of
dispensings.
415 For formula, see http://www.mathworks.com/help/stats/pdist.html "correlation distance."
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SDI Standardized Utilization Standardized Utilization
rade Name eneric Name SDI-MS MS-MC SDI-MC
indamax tinidazole
anexa* ranolazine
yetta exenatide
ymlin pramlintide
pidra insulin glulisine 0.0630 0.0745
ptivus tipranavir 0.0787
mitiza* lubiprostone 0.0943
rezista* darunavir 0.0725 0.0820
araclude entecavir 0.0929 0.0702
evlimid lenalidomide 0.0724
prycel* dasatinib 0.0768 0.0787
evemir insulin detemir 0.0892 0.1038
macor/Lovaza omega-3 acid ethyl ester 0.0738 0.1253
ozerem ramelteon 0.0774 0.1222
utent* sunitinib malate 0.1023 0.0758 0.0868
Vesicare solifenacin 0.1277 0.1374
zilect* rasagiline mesylate 0.1324 0.1145
hantix* varenicline 0.1371 0.1297
anuvia* sitagliptin phosphate 0.1655 0.1714
oxafil* posaconazole 0.0653 0.1067 0.1952
nvega* paliperidone 0.1417 0.0575 0.1713
Campral acamprosate 0.1814T 0.1846
xade deferasirox 0.2277 0.1584
Tyzeka* telbivudine 0.2499 0.1591
exavar sorafenib 0.2099 0.1540 0.1126
Xifaxan rifaximin 0.2107 0.2678
ymbalta duloxetine 0.36 0.3274
nablex darifenacin itace A e cs C
Aunesta eszopiclone S d M i9d
Tarceva erlotinib
Lyrica pregabalin
Zolinza* vorinostat0.52,61
Nevanac nepafenac
Sanctura trospium
Siriva tiotropiumn
Fosrenol lanthanum
Sensipar cinacalcet
Mean 0.0429 0.2611 0.2755
Median 0.0178 0.1324 0.1297
Standard Deviation 0.0689 0.3046 0.3274
Table 14. Pearson Correlation Distances Among New Molecular Entities in the Cohort
Abbreviations: MS: Mini-Sentinel System data; MC: Medicaid data.
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However, these data suggest that FDA may be able to use SDI data and/or Mini-
Sentinel System data to support adoption and utilization models. However, fitting these
data to a few functional forms proved quite challenging and essentially non-productive.
Consequently, I moved away from use of these data for this reason and two others
explained below.
First, raw dispensings are a less than ideal measure of adoption and utilization
patterns because of the inability to distinguish "incident users" or new adopters from
continuing users. Sequential database surveillance activities are generally planned with
incident user criteria such that a person typically only contributes information to the
surveillance based on their initial adoption and use of the product, i.e. during their "initial
treatment episode." 416 Incident user designs are an important technique for mitigation of
selection bias. Second, I utilize theoretical insights and functional forms from the
diffusion of innovations literature, which is briefly described next. Generally, this
literature focuses on initial adoption of new products, although there has been some work
on repeat purchases. 4 17 Thus, incident user data are a better fit with these theoretical
constructs.
9.4 Mini-Sentinel System Incident User Data
I obtained Mini-Sentinel System incident user data on the cohort described above.
Again, because some data partners did not have complete data for the entire evaluation
period (2004-2010), I removed these data partners from formal analysis although I still
observed their trend data visually. The remaining subset of the dataset is dominated by
one data partner that accounts for 80-90% of the data, depending on the medical product.
Had I been looking at a different evaluation period (i.e., after January 1, 2010), this
would not be the case.
416 For more on treatment episodes, see Mini-Sentinel Operations Center, "Module 3: Drug Use - Incident
Outcomes."
4" Minhi Hahn et al., "Analysis of New Product Diffusion Using a Four-Segment Trial-Repeat Model,"
Marketing Science 13, no. 3 (July 1, 1994): 224-247.
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9.4.1 Diffusion of Innovations Literature - Bass Models
418There is an extensive literature in the diffusion of innovations , and complete
coverage of that literature is beyond the scope of this research. However, modeling the
adoption (and subsequent) utilization patterns of new medical products begins as a
diffusion-related problem, and so it is logical to begin with this literature to find
functional forms to describe new medical product adoption. The most prevalent model in
this literature is the Bass model, which was introduced in 1969419 and has been extended
by numerous authors.42 Bass formulates cumulative adoptions as an S-shaped, or
sigmoid curve, characterized by adoption rates that rise and then fall over time, with the
slowest rates occurring at the beginning and end of the adoption period. Other sigmoid
curves that may be familiar to the reader include the symmetric logistic function and the
asymmetric Gompertz function 4 2 1, which have been used widely in ecology and biology
to describe biological processes such as predator-prey relations and tumor growth.
The Bass model's original premise was to describe the adoption of new durable goods
(e.g., televisions, cars) among a stable, homogenous adopter population that was unlikely
to exhibit repeat purchase behavior. Equation (8) is Bass's cumulative density function
for adoption (i.e., the cumulative probability of adoption up to time t). Equation (9) is the
hazard function, and is the ratio of the probability density function to the survival
function. The hazard function represents the instantaneous probability of adoption at time
t given that one has not already adopted. Note that all potential adopters will adopt in
Bass's formulation so it is important to exclude known non-adopters (e.g., perhaps those
with a contraindication) at the outset. Bass hypothesizes the existence of two types of
adopters that contribute to the overall adoption pattern for a particular product although
he does not establish a priori which adopters belong to which groups. This is easiest to
see in the hazard equation (9) and these two groups are the innovators and imitators.
418 See generally Renana Peres, Eitan Muller, and Vijay Mahajan, "Innovation Diffusion and New Product
Growth Models: A Critical Review and Research Directions," International Journal of Research in
Marketing 27, no. 2 (June 2010): 91-106; Nigel Meade and Towhidul Islam, "Modelling and Forecasting
the Diffusion of Innovation - A 25-year Review," International Journal of Forecasting 22, no. 3 (2006):
519-545; Everett M. Rogers, Diffusion of innovations, 5th ed. (New York: Free Press, 2003).
419 Frank M. Bass, "A New Product Growth for Model Consumer Durables," Management Science 15, no.
5 (January 1, 1969): 215-227.
420 Peres, Muller, and Mahajan, "Innovation Diffusion and New Product Growth Models."
421 Charles P. Winsor, "The Gompertz Curve as a Growth Curve," Proceedings of the National Academy of
Sciences of the United States ofAmerica 18, no. 1 (January 15, 1932): 1-8.
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1 - e- (p+q&
F(t) = 1-
1+I[e-(p+q)t] (8)
h(t) =p+-N(t) (9)1 -F(t) M
The innovators (also called influentials), are accounted for in the first part of the
hazard function, and their adoption is described by the coefficient of innovation known as
p. Essentially, they adopt independently. Imitators, on the other hand, described by
coefficient of imitation, q, adopt based on the decisions of others, as operationalized by
the ratio of the number of adopters at a particular time (N(t)) to the total market size (M).
This effect is alternatively referred to as the social contagion effect, word-of-mouth
effect, etc. The Bass model also has been described as the Mixed Influence Model with
much scholarship devoted to time-dependent marketing efforts aimed at either the
innovators or imitators.4 22
Many extensions of the Bass Model employ a component function that accounts for
"marketing mix" variables (e.g., amount of money spent on promotions) that might drive
overall adoption patterns, and this is known as the Generalized Bass Model.4 3 I do not
make use of that model here because I do not have the data to support it, nor is such data
likely to be available to the FDA at the time of launch of a new medical product. Other
relevant extensions of the Bass Model include those that more formally segment the
aforementioned two populations and describe their behaviors.4 24 These models have been
generically categorized as "two segment mixture models." Some authors describe these
two segments (i.e., the early and late markets) as belonging to a single market and model
one pooled market size. Others have posited two separate markets with two separate
42 Vijay Mahajan and Robert A. Peterson, Modelsfor Innovation Diffusion, Sage University Papers Series.
Quantitative Applications in the Social Sciences no. 07-048 (Beverly Hills: Sage Publications, 1985).
43 Frank M. Bass, Trichy V. Krishnan, and Dipak C. Jain, "Why the Bass Model Fits Without Decision
Variables," Marketing Science 13, no. 3 (July 1, 1994): 203-223.
424 See Demetrios Vakratsas and Ceren Kolsarici, "A Dual-market Diffusion Model for a New Prescription
Pharmaceutical," International Journal ofResearch in Marketing 25, no. 4 (December 2008): 282-293;
Christophe Van den Bulte and Yogesh V. Joshi, "New Product Diffusion with Influentials and Imitators,"
Marketing Science 26, no. 3 (May 1, 2007): 400-421; Jacob Goldenberg, Barak Libai, and Eitan Muller,
"Riding the Saddle: How Cross-Market Communications Can Create a Major Slump in Sales," Journal of
Marketing 66, no. 2 (April 1, 2002): 1-16.
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market potentials. Complete separation of the adoption populations may be more
appropriate to describe situations when manufacturers receive approval for new
indications for their existing product. The approval occurs discretely in time although off-
label use of the product in non-labeled indications may have preceded formal approval.
There have been multiple theories to describe why a segmentation might exist4 2 5 , and
most of these theories focus on the innovators as risk takers, technology enthusiasts, or
those that seek to send a signal of high social status by adopting new innovations very
early in a product's lifecycle. Many of these theories are appropriate in the context of a
new product that is a durable good, e.g., a new smartphone. However, there are other
theories more appropriate to the context of new medical product adoption.
One theory referred to as information transfer describes the social contagion effect as
being the result of information transfer from influentials who are described as "opinion
leaders." Essentially, the opinion leaders/influentials adopt and develop experience by
prescribing and monitoring the effects of the new medical product, thereby reducing
uncertainties associated with its unknown risks and benefits in a non-clinical trial
population. These opinion leaders/influentials then exhibit contagion behavior among
themselves, and to the "imitator" physician adopters who become more willing to adopt
the product once a body of evidence begins to develop with respect to the medical
product's risks and benefits. Appropriate empirical testing of this theory would require
modeling physician adopter networks, which I do not intend to do here, and others have
done ably.4 2 6 However, it is reasonable to assume that patient populations may be divided
similarly. That is, some patients may be less risk-averse and more willing to try a new
medical product based on its clinical trial profile.
42 See summary in Bulte and Joshi, "New Product Diffusion with Influentials and Imitators."
426 For example models, see Raghuram Iyengar, Christophe Van den Bulte, and Thomas W. Valente,
"Opinion Leadership and Social Contagion in New Product Diffusion," Marketing Science 30, no. 2
(March 1, 2011): 195-212; Mark Paich, Corey Peck, and Jason Valant, "Pharmaceutical Market Dynamics
and Strategic Planning: a System Dynamics Perspective," System Dynamics Review (Wiley) 27, no. I
(March 2011): 47-63; Mary A. Burke, Gary M. Fournier, and Kislaya Prasad, "The Diffusion of a Medical
Innovation: Is Success in the Stars?," Southern Economic Journal 73, no. 3 (January 1, 2007): 588-603;
Christophe Van den Bulte and Gary L. Lilien, "Medical Innovation Revisited: Social Contagion Versus
Marketing Effort," American Journal of Sociology 106, no. 5 (March 1, 2001): 1409-1435; James Samuel
Coleman and University Columbia, Medical Innovation; a Diffision Study (Indianapolis: Bobbs-Merrill
Co, 1966).
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Vakratsas et al. follow up this idea and postulate that this phenomenon may be
particularly true for diseases that encompass varying levels of severity, e.g., diabetes,
obesity, cardiovascular disease.42 They postulate that the early market segment consists
of individuals who are performing poorly on all existing therapies and so are willing to
try new products as soon as they become available due to unmet medical needs. The late
market segment of adopters consists of patients who may be satisfied with their current
therapy, but may be more convinced to switch therapies as more information develops
about the new product's risks and benefits. They completely separate these populations,
i.e. their primary model is not pooled.
9.4.2 Model Fitting
In general, I adopt the functional forms first described by Bass and others cited in this
section and attempt to fit the Mini-Sentinel System incident user data to these forms
using the LSQCURVEFIT and non-linear model fitting functions available in
MATLAB@ (R2012a). The goal is to assess whether these functional forms appropriately
describe the data, and how planners might use these forms to speculate as to the adoption
and utilization patterns for new medical products being evaluated via sequential database
surveillance. Throughout, I do not make use of the "marketing mix" components that
could be present in any of these functional forms since the FDA typically does not have
these data prior to the launch of the product.
As a note, I do not treat the adopter population as a "dynamic adopter population" as
described by others.428 These authors require additional modeling to describe the adopter
population's growth as a natural outgrowth of population, i.e. as a continuous expansion.
For example, as the population ages, there will likely be dynamic adoption of medical
products that treat disease associated with older age like cardiovascular disease. Because
the adoption timeframe that I am considering is relatively short, I omit these dynamics for
simplicity.
Last, I narrowed my original cohort only to those medical products that had enough
exposure that they might be reasonable candidates for sequential database surveillance.
427 Vakratsas and Kolsarici, "A Dual-market Diffusion Model for a New Prescription Pharmaceutical."
428 Vijay Mahajan and Robert A. Peterson, "Innovation Diffusion in a Dynamic Potential Adopter
Population," Management Science 24, no. 15 (November 1, 1978): 1589-1597.
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Therefore, I eliminated new molecular entities in the original cohort that did not have at
least 10,000 incident users over the entire evaluation period. I chose 10,000 users because
it mirrors a setpoint established by Congress in the 2007 Food and Drug Amendments
Act, which requires the FDA to post a safety summary regarding the new product to its
website.42 9 This narrowed my cohort to 22 medical products, and the data that I fit was
the monthly cumulative adopters who I required to be incident users. Incident users were
defined as not having used the medical product in the 120 days preceding the first use,
and only users with continuous drug coverage during that time were included.43
9.4.2.1 Single Market Model Forms
Model Form 1 (MF1) is shown as equation (10). The cumulative adopters (N(t)) is
the market size (M) multiplied by the cumulative density function for the Bass Model, as
shown in equation (8).
N(t) = M * F(t) (10)
9.4.2.2 Dual Market Model Forms: Dual Bass
Model Form 2 (MF2) is a pooled dual-Bass market model. It consists of two Bass
models coupled together with a simple, constant probability (7n) to describe the likelihood
of belonging to the first or second market, and is shown in equation (11). Again the
cumulative density functions (F2 and F2) are shown in equation (8).
N(t) = [inF1 (t) + (1 - 7)F 2 (t)]* M
(11)
Model Form 3 (MF3) is also a pooled dual-Bass market model as shown in equation
(11). However, it uses a different formulation for the probability, a time-dynamic one that
requires the early market to precede the later market and requires the highest probability
429 § 915 of Food and Drug Administration Amendments Act of 2007, Public Law 110-85..."[The Secretary
via the FDA shall provide drug safety information to patients and prescribers by] preparing, by 18 months
after approval of a drug or after use of the drug by 10,000 individuals, whichever is later, a summary
analysis of the adverse drug reaction reports received for the drug, including identification of any new risks
not previously identified, potential new risks, or known risks reported in unusual number;". Codified at 21
U.S.C. § 355(r)(2)(D).
430 A 45-day enrollment gap was allowed.
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of being part of the early market to occur earliest and then fade to zero. This formulation
was first used in Vakratsas et al.'s paper4
e-ot
w(t) = ((1 + e-t) (12)
Model Form 4 (MF4) is a non-pooled version (i.e., note the two M variables) of MF2,
a dual-Bass market model, with a static probability. It is shown in equation (13).
N(t) = [ rM1 F1 (t) + (1 - w)M2 F2 (t)] (13)
Model Form 5 (MF5) is a non-pooled version of MF3 using the dynamic probability.
It is represented as equation (13) with the probability equivalent to equation (12).
9.4.2.3 Dual Market Model Forms: Exponential-Bass Model
Vakratsas et al.'s main dual market models begin by linking together two Bass
models.4 32 However, they hypothesize that the early market is made up only of the
innovator sub-group with no contribution from imitators. Thus, they set q in equation (8)
equal to zero for the early market. The result is an early market described by an
exponential cumulative density function and a later market described by the Bass
cumulative density function. They also reason that the delay in the availability of the new
medical product during the process of licensure creates a pent-up demand for the product
that is well-modeled by an exponential adoption function.
They examine this dual-market combination as both a pooled and non-pooled market
and with both a static and dynamic probability using the same sort of iterations discussed
above. However, to ensure that the early market precedes the later market, their static
probability formulation is slightly more complex. Essentially, they take the dynamic
formulation listed in equation (12) and set time equal to 1. Thus, by constraining 0 to be
positive, the early market must be smaller than the later market.
Model Form 6 (MF6) is a pooled dual market model with static probability as
described above where the first market is exponential and the second market is a Bass
431 Vakratsas and Kolsarici, "A Dual-market Diffusion Model for a New Prescription Pharmaceutical."
43 Ibid.
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model. Model Form 7 (MF7) is a pooled version of this model with a dynamic probability
as formulated in equation (12). Model Form 8 (MF8) is a non-pooled version of MF6.
Model Form 9 (MF9) is a non-pooled version of MF7. Table 15 is a brief summary of
these model forms.
Model Form Description Pooled? Probability? Parameters
MFI Single Bass N/A N/A M, p, q
MF2 Dual Bass Yes Static M, p1, gl, in, p2, q2
MF3 Dual Bass Yes Dynamic M, pl, gl, p2, q2, 0
MF4 Dual Bass No Static M1, M2, p1, g , 7, p2, q2
MF5 Dual Bass No Dynamic M1, M2, pl, gl, p2 , q2, 0
MF6 Exponential-Bass Yes Static M, pI, a, p2, q2
MF7 Exponential-Bass Yes Dynamic M, p1, p2, q2, 0
MF8 Exponential-Bass No Static M1, M2, p1, nr, p2, q2
MF9 Exponential-Bass No Dynamic M1, M2, p1, p2, q2, 0
Table 15. Summary of Model Functional Forms used with Mini-Sentinel System Incident User Data
Abbreviations: MF; Model Form.
9.4.3 Findings
9.4.3.1 Single Market Bass Model (MF1)
First, all uptake patterns could be fit to a Single Market Bass Model. With the
exception of one medical product in the cohort, all parameter estimates were significant
at the 0.05 level and all signs were in the correct direction. As measures of the goodness
of model fit, I list mean squared error (MSE), median absolute deviation from the median
(MAD), and the Bayesian Information Criterion (BIC) in Table 16. These metrics are
consistent with what others have previously reported.m R2 and adjusted R2 are usually
quite high and generally not informative (i.e., nearly all are greater than .995 and some
are 1.)
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433Ibid.
Amitiza 1.55E+06 867.98 983.27
Byetta 8.40E+05 707.491136
Campral
Chantix
Cymbalta 70E0
Enablex 3.36E+05 443.57 1021.9
invega
Januvia 3.02E+061 14.9
Levemir
Lunesta* L2+
Lyrica 1.9E+061 ct h.05 level
Nevanac 4.08E+051 435.17 1018.00
Omacor/Lovaza 7.01E+05 582.82 1036.8
Ranexa
Rozerem 4.34E+05 59425 1021.94
Sanctura1048
Sensipar 9749
Spiriva 5.67E+06 121
Tarceva
Tindlamax 935
Vesicare 4.13E+05 380.56141
Xiaxan 6.14E+05 514.99
*one parameter not significant at the 0.05 level
Table 16. Measures of Model Fit for New Molecular Entity Cohort with Single Market Bass Model
Abbreviations: MSE, Mean Squared Error; MAD, Median Absolute Deviation from the Median; BIC,
Bayesian Information Criterion.
9.4.3.2 Dual Market Bass Models (MF2-MF5)
Generally, the MSE, MAD, and BIC were lower for the dual market Bass models
than for the single market bass models and the results of the dual market Bass models are
shown in Table 17. However, many of the parameters in the various model fits were not
significant at the 0.05 level. Models in which all the parameters were significant are
marked with an asterisk. MF3 (i.e., the pooled, dynamic market model) had a particularly
hard time fitting the 0 parameter (i.e., the dynamic probability of belonging to one market
or the other) and MF4 (the non-pooled static market model) could fit neither of the
market sizes nor the a parameter at a significant level. The signs of all the parameters
were in the right direction but I had to relax the constraint requiring 0 to be positive,
meaning that some models fit better when the early market was larger than the latter
market.
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MSE DvMAD BIC
MF2 | MFS | MF4 I MF5 MF2 I MF3 | MF4 I MF5 MF2 MFS MF4 MF5
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Campa 857.70 853.82 862.08. 796.05
Chatx 14[+6 14E0 .2 921,58 920.68 925.69 9247
Cymbalta
Enalx 56. 46 689 64885.14 893.191 889.501 877
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Nevanac 11E 5|1.01E+05 1,117E+051 6,07E+04 1 682 143.07T 165.5T 4 5 963 937.77 950.56 984
Omacor/Lovaza 2 o1.21E+05| 2.71E+05 1.22Ea dual-arke model 9a4.64 934.78 9tg90 o
Rozerem 858E+04 4sE+05 8 f73E+04 70E4 109.28 927c.6 10Sut.60 931.90 918.41
sureilance is.161 e s 990.70 961.4 997.81
produc. T45A45 45si 94 8 968.73 917.51 f
Tindamax 49.74 92.782.4.3355999
Vesicare* I3.29E+041 SA9E+04[ 3.34E+04 &*011 1531 9,91 1 1.2 92072.851 977.131 977.22 901
Xiaa*6.W 987.601 982.091 1015.88 951
*At least one of the Dual Bass Model Forms had all significant parametars
Table 17. Measures of Model Fit for New Molecular Entity Cohort with Dual Market Bass Model
Forms
Abbreviations: MSE, Mean Squared Error; MAD, Median Absolute Deviation from the Median; BIC,
Bayesian Information Criterion.
The implication that a dual-market model is a better fit than the single market model,
particularly for models in which all parameters are significant, is an important finding
epidemiologically-speaking for sequential database surveillance. Sequential database
surveillance is envisioned as a technique to be used soon after licensure of a new medical
product. Thus, surveillance conclusions would likely be based on an "early market" for
the new medical product. If this early market of users were substantially different than
the later market of users, then there may be less "transportability "a of sequential
database surveillance findings to these later users. Additionally, the dual market model
may indicate the presence of channeling bias. Regulatory action resulting from these
findings likely needs to be more tailored than perhaps originally envisioned. Finally,
because sequential database surveillance may be performed with less covariate control
than a traditional retrospective epidemniologic study, it may be more difficult to identify
characteristics that tend to place a user in the "early" v. "late" markets.
434 Recall that transportability is a preferred term in pharmacoepidemiology but is generally equivalent to
the more familiar, external validity or general izability.
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9.4.3.3 Dual Market Exponential-Bass Models (MF6-MF9)
In general, most of these data visually do not support an early market exponential
model. Consequently, there were significant sign problems associated with fitting the
dual market exponential-Bass model in many fits. Most commonly, p1 was negative,
which essentially creates a single market Bass model. Again, many of the parameters in
the various model fits were not significant at the 0.05 level. In MF8 and MF9, there was
not a single new molecular entity with parameters that were all significant. The results
are shown in Table 18. I show results as "NA" if the model did not have correct signs
since those fits did not really reflect an exponential-Bass model.
MSE MAD BIC
MF6 MF7 MF8 MF9 MF6 MF7 MF8 MF9 MF6 MF7 MF8 MF9
Amitiza 211E406 #N/A 1.20E406 #N/A MN/A 602.25 #N 974.58 #N/A 977.97 #N/A
Byetta 3.06E+05 #N/A 3.10E+05 3.05E+05 #N/A 251.88 1052.51 #N/A 1056.56 1055.38
Campral #N/A #N$A 9 #N/A 6039; 880A9
Chantix #N/A #N996.54 #N/A 1000.63 990.03
Enable .74 #N/A . 2.29E+05 .N/A 1 305.68N 36.867 1N/A 7 
Invega #N/A #N/A
Januvia 9.69E+05 #N/A 9.82E+05 9.48E+05 47AN/A 1 483,7 . 1
Levemir #N/A #N/A 255#N/A #N/A
Lunesta* #N/A #N/A
Lyrica* 1.29E+06 1.66E406 1.914006 7.99E+05 1 .
Nevanac #N/A #N/A 4.30E+05 3.15E+05 6 34 #N/A #N/A 1080.70 1010.85
Omacor/Lovaza #N/A #N/A #N/A 2.3605 N/A A N/A #N/A N/A #N/A 976.99
Ranexa #N/A #N/A MN/A MN/A
Rozerem* 9$A3 905.62 902.681 900A5
Sanctura 990.101 1006.27 994.521 994.51
Sensiper 909.03 978.07 913.49 913.49
Spiriva*
Tarceva #N/A #N/A #N
Tindamax MN/A MN/A N/A MN/AN/A 921.90 #N/A 926.33
Vesicare #N/A #N/A 4.32E+05 MN/A #N/A 380.56 221.19 #N/A N/A 167
XIfaxan 5.09E+05 #N/A 642E+05 4.69E+05 514.99 #N/A 510.30 450.23 #N/A
*lndicates at least one Exponential-Bass Dual Market Model had all significant parameters
Table 18. Measures of Model Fit for New Molecular Entity Cohort with Dual Market Exponential-
Bass Model Forms
Abbreviations: MSE, Mean Squared Error; MAD, Median Absolute Deviation from the Median; BIC,
Bayesian Information Criterion.
In general, regardless of model form, each uptake pattern can be described with one
of the models described above. However, in this retrospective analysis, I have the benefit
of fitting the regression on four years worth of uptake data. In modeling and simulating
future sequential database surveillance on a completely new product, the user may have
little or no data to rely on to speculate about uptake. Thus, it is important to use a model
form that may be fit on very little data. Future work should more thoroughly examine
these model fits in the presence of little data and assess how well they forecast future
utilization.
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Appendix C contains individual figures with the best model fits displayed. The
pattern and the model fits are observable but the cumulative adoption numbers are
deliberately removed because they are not authorized to be shared publicly.
9.5 Summary
In general, there is much work to be done with respect to modeling adoption/uptake
functions, particularly when challenged with a new molecular entity. The main idea of
modeling adoption and utilization is to support the simulation of sequential database
surveillance scenarios, and sensitivity analyses on adoption and utilization functions are
appropriate in these circumstances.
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10 SUMMARY OF FINDINGS AND FUTURE DIRECTIONS
10.1 Summary
This research develops qualitative and quantitative tools to aid the U.S. Food and
Drug Administration (FDA) in evaluating the Mini-Sentinel System's sequential database
surveillance capabilities to support regulatory decision-making. The qualitative tool - the
Mini-Sentinel System Pre-Screening Checklist - is designed to help determine whether
the Mini-Sentinel System is well suited, on itsface, to evaluate a pre-specified exposure-
outcome pair. This checklist does not provide definitive answers but rather is intended to
prompt thoughtful analysis as a first step. Necessary inputs to the Mini-Sentinel System
Pre-screening Checklist are: 1) a tracked safety issue that identifies a particular exposure-
outcome pair of interest; and 2) a regulator's goal with respect to the strength of causal
inference necessary to support regulatory decision-making.
The quantitative tool is a Sequential Database Surveillance Simulator that allows the
user to explore virtually whether sequential database surveillance of a particular
exposure-outcome pair is likely to generate evidence to identify and assess safety risks in
a timely manner to support regulatory decision-making. The simulator is intended to be a
learning tool that allows regulators/investigators to explore the many potential
surveillance scenarios they could face. Specifically, the tool is designed to allow the
regulator/public health investigator to explore the performance limitations and
capabilities of sequential database surveillance virtually and in a low-cost way. That is, in
this planning stage, there is no need to "learn-by-doing" while expending public health
resources. In general, this tool is not intended to be strictly predictive or to forecast
exactly how sequential database surveillance of a particular tracked safety issue will
occur. It is intended to allow regulators to explore possible scenarios they may face in the
hopes that they may learn through experimentation how to more precisely deploy the
evidence generation capabilities of the Mini-Sentinel System, and further refine their
assessments of its sufficiency for evidence generation.
By using a simple vaccine example to illustrate the use of the simulator, this
dissertation also demonstrates the tradeoffs associated with sample size calculations in
sequential statistical analysis, particularly the tradeoff between statistical power and
median sample size. In some circumstances, decreasing statistical power (i.e., increasing
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type II error and the chance of a missed signal) results in faster detection of a signal (i.e.,
smaller median sample sizes). Is this tradeoff worth it? Should a user take on the bigger
risk of missing the signal if it means they can find it faster? These tradeoffs have more
concrete meaning by translating the information time concepts into calendar time. With
an understanding of the time to takes to detect a signal of excess risk in calendar time, it
is possible for the user to estimate the potential public health harm that may occur
depending on the speed and confidence with which a safety signal is detected or ruled
out.
Second, the dissertation demonstrates differences in performance between various
surveillance configurations that are possible when using distributed database systems.
Specifically, I look at the performance of two continuous sequential testing methods in
the Mini-Sentinel System. However, I also address the ability to reconfigure the Mini-
Sentinel System into component configurations, particularly segregating the component
databases by their data types.
Third, the dissertation demonstrates the effects of misclassification error on
sequential database surveillance, and specifically how such errors may be accounted for
in the design of surveillance. I find that imperfect positive predictive value has more
strongly deleterious effects on statistical power whereas imperfect sensitivity can
significantly increase the median and maximum sample sizes required to end
surveillance.
Fourth, this dissertation considers the complexities of modeling new medical product
adoption, and specifically, the existence of a "dual market" phenomenon for these new
medical products. This finding raises a non-trivial generalizability concern regarding
evidence generated via sequential database surveillance when performed immediately
post-licensure.
10.2 Future Work
The current version of the Sequential Database Surveillance Simulator accommodates
two specific sequential statistical models that have been frequently used in prior vaccine
safety surveillance. I began this process using these models because they were well-
established in this still developing field. However, this simulator could be built out to
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accommodate other models, such as the group sequential models reviewed in subsection
5.2.2. An important aspect of future work will be to increase representation of group
sequential models to better under their comparative performance characteristics.
The Mini-Sentinel System is still developing modular programs aimed at better
understanding drug utilization patterns after a drug has been adopted. These data will be
important for modeling continuous exposures. In this dissertation, I have focused on point
exposures as a proof-of-concept. However, the simulator will remain a quite limited tool
without expansion into continuous exposures. Once these modular programs detailing
utilization patterns are complete, the simulator can be extended to support tracked safety
issues with continuous exposures.
Research on modeling adoption patterns has just begun. Important future steps will be
to show the predictive power of various functional forms of adoption that are based on
little or no data. That is, it will be important to segregate adoption patterns into general
categories and then try to understand a priori the contributing factors that led to that
adoption pattern.
Finally, as the FDA considers the larger scope of exposure-outcome pairs that it needs
to evaluate and uses the Sequential Database Surveillance Simulator repeatedly, it will be
possible to establish overall demand for this capability. Understanding the level of
demand for this capability and the others associated with the Mini-Sentinel System is an
important determinant in public policy with respect to its ongoing public funding. That is,
a more reasoned annual budget can be devoted to this piece of infrastructure when it
becomes clear how often and for what purposes it is used.
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12 APPENDIX A - Vaccine Validation Data
12.1 Mini-Sentinel System Vaccine Incident User Data
In sections 7 and 8, I used a simulated vaccine example to illustrate use of the
Sequential Database Surveillance Simulator. To model adoption of a new routine
childhood vaccination, I proposed a linear adoption function coincident with one-year
well-visits for a cohort of 0-1 year olds. Later, data became available with respect to
adoption of new vaccinations in the Mini-Sentinel System and I obtained these data via
execution of a modular program to validate the example that I presented. I requested data
for new childhood vaccinations approved since 2005 as shown in Table 19 below. Data
partners that did not have complete data for the entire evaluation period (i.e., date of
approval-2010) were censored from the analysis. I fit monthly cumulative adopters who I
required to be incident users. Incident users were defined as not having used the medical
product in the 30 days preceding the first use, and only users with continuous drug and
medical coverage during that time were included.43
Trade Name (n=4) Generic Name (n=4) Approval Date
Pentacel Diphtheria and Tetanus Toxoids and
Acellular Pertussis Adsorbed, Inactivated 06-20-2008
Poliovirus and Haemophilus b Conjugate
(Tetanus Toxoid Conjugate) Vaccine
Prevnar- 13 Pneumococcal 13-valent Conjugate Vaccine 02-24-2010[Diphtheria CRM 197 Protein]
Rotateg Rotavirus Vaccine, Live, Oral, Pentavalent 02-03-2006
ProQuad Measles, Mumps, Rubella and Varicella
Virus Vaccine Live Lyophilized preparation 09-06-2005
for subcutaneous injection
Table 19. Vaccine Validation Cohort
In early 2007, Merck, the manufacturer of ProQuad@, reported shortages of the
varicella-zoster virus and its subsequent prioritization of other varicella-containing
vaccinations over ProQuad@.43 6 Therefore, I censored ProQuad® data at the end of 2006.
Later, based on safety risk data developed during sequential database surveillance in the
435 A 45-day enrollment gap was allowed.
436 "Notice to Readers: Update on Supply of Vaccines Containing Varicella-Zoster Virus," JAMA: The
Journal of the American Medical Association 298, no. 7 (August 15, 2007): 736.
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Vaccine Safety Datalink, the Advisory Committee on Immunization Practices changed its
recommendations on the use of ProQuad@, specifically eliminating language that
indicated a preference for the combined vaccine over its separately available components
(i.e., measles, mumps, and rubella vaccination AND varicella vaccination).4 37 In
subsequent years, ProQuad@ has only been intermittently available, reflecting its low
prioritization.
12.2 Model Fits
I used the generalized linear model fitting functions of MATLAB@ (R2012a). I
report the model fits below. Table 20 shows the linear fits when using data from the date
of approval until the end of 2010. Both the intercept and coefficient terms were
significant at the 0.005 level for all four models. Table 21 shows the linear fits when the
first three months of adoption data are excluded, which accounts for uneven uptake
among the different data partners that comprise the Mini-Sentinel System. With this
adjustment, the intercept and coefficient terms were significant at the 0.0005 level for all
four models. The R2 and adjusted R2 values are uniformly higher with these initial
datapoints excluded because the adoption pattern begins to reflect the steady state of new
vaccinations. In conclusion, a linear adoption function is appropriate to model adoption
of new childhood vaccinations.
Trade Name Approval Date RMSE R Adjusted R2
(n=4)
Pentacel 06-20-2008 1.50E4 0.991 0.991
Prevnar-13 02-24-2010 2.88E4 0.983 0.982
Rotateq 02-03-2006 3.43E4 0.983 0.982
ProQuad* 09-06-2005 8.67E3 0.827 0.815
Table 20. Linear Regression Model for the Vaccine Cohort
*ProQuad@ data censored from 2007-2010.
Abbreviations: RMSE, root mean square error.
4 "Update: Recommendations from the Advisory Committee on Immunization Practices (ACIP)
Regarding Administration of Combination MMRV Vaccine," MMWR. Morbidity and Mortality Weekly
Report 57, no. 10 (March 14, 2008): 258-260.
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Table 21. Linear Regression Model for the Vaccine Cohort with
*ProQuad@ data censored from 2007-2010.
Abbreviations: RMSE, root mean square error.
the First Three Months Excluded
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Trade Name Approval Date RMSE R2 Adjusted R2
Pentacel 06-20-2008 6.48E3 0.998 0.998
Prevnar-13 02-24-2010 1.46E4 0.994 0.993
Rotateq 02-03-2006 2.65E4 0.989 0.989
ProQuad* 09-06-2005 6.93E3 0.896 0.886
THIS PAGE INTENTIONALLY LEFT BLANK
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13 APPENDIX B - Medicaid Dispensing Data Simulations
13.1 Common Event Rates
Generic Name Total Exposed Range of Total Exposed Range of
(n=40) Days detectable IRRs Days detectable IRRs
after 8 quarters after 8 quarters after 15 quarters after 15 quarters
New Molecular Entities Approved in 2004
tinidazolea 36,110 5-10 101,133 2.75-10
rifaximinb 206,795 2.25-5 485,250 1.75-2.75
erlotinib 434,685 1.75-2.25 762,915 1.75-2.75
insulin glulisine 446,310 1.75-2.75 1,179,420 1.5-2
injection
lanthanum 1,024,095 1.5-2 1,634,145 1.5-2
trospium 993,940 1.5-2.25 1,758,405 1.5-2.75
acamprosate 1,727,108 1.5-1.75 3,529,605 1.33-1.75
cinacalcet 3,052,635 1.33-1.75 5,006,580 1.33-1.5
omega-3 acid 2,223,360 1.33-1.75 7,896,930 1.2-1.5
ethyl esters
darifenacin 4,007,340 1.33-1.5 8,366,490 1.2-1.33
solifenacin 3,566,535 1.33-1.75 8,982,105 1.2-1.33
eszopiclone 19,705,410 1.2-1.33 33,866,880 1.2
tiotropium 33,532,470 1.2 58,154,685 1.2
pregabalin 39,717,375 1.2 79,711,665 1.2
duloxetine 45,217,020 1.2 92,261,400 1.2
New Molecular Entities Approved in 2005
lenalidomide 73,164 3-10 233,996 2.25-5
sorafenib toylate 78,345 3-10 237,585 2.25-5
tipranavir 300,900 2-3 437,745 1.75-2.75
nepafenacb 393,570 2-2.75 762,075 1.75-2.25
pramlintide 371,190 2-3 903,300 1.75-2.25
acetate
entecavir 272,370 2-5 1,129,140 1.5-2
deferasirox 725,865 1.75-2.25 1,592,055 1.5-2
exenatide 3,341,895 1.33-1.75 8,517,255 1.2-1.33
ramelteon 4,816,590 1.33-1.5 10,779,270 1.2-1.33
insulin detemir 2,437,695 1.33-1.75 12,483,555 1.2-1.33
Table 22. Detectable Incidence Rate Ratios for Common Events using the Poisson MaxSPRT Model
Estimates based on power=.80, alpha=.05. One prescription is assumed to be a 30-day supply unless
otherwise specified. Range is based on sensitivity analyses of doubling and halving the days exposed.
aindicates one prescription was equivalent to a 5-day supply.
bindicates one prescription was equivalent to a 15-day supply.
cindicates one prescription was equivalent to a 28-day supply.dindicates that 10 quarters of data were available.
'indicates one prescription was equivalent to a 14-day supply.
indicates one prescription was equivalent to a 10-day supply.
Abbreviations: IRR, incidence rate ratio; MaxSPRT, Maximized Sequential Probability Ratio Test.
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Total Exposed Range of Total Exposed Range ofGeneric Name Days detectable IRRs Days detectable IRRs
(n=40) after 8 quarters after 8 quarters after 15 quarters after 15 quarters
New Molecular Entities Approved in 2006
vorinostat 6,180 100 11,910 10-100
kunecatechinsd 6,630 100 ** **
biskalcitrate
potassium,
metronidazole 30,100 5-10 59,480 5-10
and tetracycline
hydrochloride'
posaconazolef 32,508 5-10 63,672 5-10
dasatinib 59,820 5-10 143,880 2.5-5
rasagiline 69,060 5-10 170,520 2.25-5
mesylate
sunitinib malate' 80,668 3-10 175,672 2.25-5
telbivudine 164,580 2.5-5 381,330 2-2.75
ranolazine 553,215 1.75-2.5 1,784,115 1.5-1.75
ciclesonided 821,835 1.75-2.25 ** **
darunavir 966,000 1.5-2.25 3,346,500 1.33-1.75
lubiprostone 2,066,100 1.33-1.75 5,995,890 1.2-1.5
sitagliptin 7,960,500 1.2-1.5 20,810,620 1.2-1.33
phosphate
paliperidone 9,789,630 1.2-1.33 23,213,280 1.2
varenicline 17,177,985 1.2-1.33 30,531,405 1.2
Table 22 (Continued). Detectable Incidence
MaxSPRT Model
Rate Ratios for Common Events using the Poisson
Estimates based on power-.80, alpha=.05. One prescription is assumed to be a 30-day supply unless
otherwise specified. Range is based on sensitivity analyses of doubling and halving the days exposed.
aindicates one prescription was equivalent to a 5-day supply.
bindicates one prescription was equivalent to a 15-day supply.
cindicates one prescription was equivalent to a 28-day supply.
dindicates that 10 quarters of data were available.
eindicates one prescription was equivalent to a 14-day supply.
indicates one prescription was equivalent to a 10-day supply.
Abbreviations: IRR, incidence rate ratio; MaxSPRT, Maximized Sequential Probability Ratio Test.
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13.2 Infrequent Event Rates
Generic Name Total Exposed Range of Total Exposed Range ofGneric Days detectable IRRs Days detectable IRRs
(n=40) after 8 quarters after 8 quarters after 15 quarters after 15 quarters
New Molecular Entities Approved in 2004
tinidazolea 36,110 100 101,133 10-100
rifaximinb 206,795 10-100 485,250 5-10
erlotinib 434,685 5-10 762,915 3-10
insulin glulisine 446,310 5-10 1,179,420 2.75-5
injection
lanthanum 1,024,095 2.75-5 1,634,145 2.5-5
trospium 993,940 2.75-10 1,758,405 2.25-5
acamprosate 1,727,108 2.25-5 3,529,605 2-3
cinacalcet 3,052,635 2-3 5,006,580 1.75-2.5
omega-3 acid 2,223,360 2.25-5 7,896,930 1.75-2.25
ethyl esters '
darifenacin 4,007,340 2-2.75 8,366,490 1.75-2.25
solifenacin 3,566,535 2-3 8,982,105 1.75-2.25
eszopiclone 19,705,410 1.5-1.75 33,866,880 1.33-1.75
tiotropium 33,532,470 1.33-1.75 58,154,685 1.2-1.5
pregabalin 39,717,375 1.33-1.5 79,711,665 1.2-1.5
duloxetine 45,217,020 1.33-1.5 92,261,400 1.2-1.33
New Molecular Entities Approved in 2005
lenalidomidec 73,164 10-100 233,996 10-100
sorafenib toylate 78,345 10-100 237,585 10-100
tipranavir 300,900 5-10 437,745 5-10
nepafenacb 393,570 5-10 762,075 3-10
pramlintide 371,190 5-10 903,300 3-10
acetate
entecavir 272,370 5-100 1,129,140 2.75-5
deferasirox 725,865 5-10 1,592,055 2.5-5
exenatide 3,341,895 2-3 8,517,255 1.75-2.25
ramelteon 4,816,590 1.75-2.75 10,779,270 1.5-2
insulin detemir 2,437,695 2.25-5 12,483,555 1.5-2
Table 23. Detectable Incidence Rate Ratios for Infrequent Events using the Poisson MaxSPRT Model
Estimates based on power-.80, alpha=.05. One prescription is assumed to be a 30-day supply unless
otherwise specified. Range is based on sensitivity analyses of doubling and halving the days exposed.
aindicates one prescription was equivalent to a 5-day supply.
bindicates one prescription was equivalent to a 15-day supply.
indicates one prescription was equivalent to a 28-day supply.
dindicates that 10 quarters of data were available.
'indicates one prescription was equivalent to a 14-day supply.
rindicates one prescription was equivalent to a 10-day supply.
Abbreviations: IRR, incidence rate ratio; MaxSPRT, Maximized Sequential Probability Ratio Test.
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Table 23 (Continued). Detectable Incidence Rate Ratios
MaxSPRT Model
for Infrequent Events using the Poisson
Estimates based on power=.80, alpha=.05. One prescription is assumed to be a 30-day supply unless
otherwise specified. Range is based on sensitivity analyses of doubling and halving the days exposed.
aindicates one prescription was equivalent to a 5-day supply.bindicates one prescription was equivalent to a 15-day supply.
'indicates one prescription was equivalent to a 28-day supply.
dindicates that 10 quarters of data were available.
eindicates one prescription was equivalent to a 14-day supply.
findicates one prescription was equivalent to a 10-day supply.
Abbreviations: IRR, incidence rate ratio; MaxSPRT, Maximized Sequential Probability Ratio Test.
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Generic Name Total Exposed Range of Total Exposed Range of
(n=40) Days detectable IRRs Days detectable IRRs
after 8 quarters after 8 quarters after 15 quarters after 15 quarters
New Molecular Entities Approved in 2006
vorinostat 6,180 100-1000 11,910 100-1000
kunecatechinsd 6,630 100-1000 ** **
biskalcitrate
potassium,
metronidazole 30,100 100 59,480 100
and tetracycline
hydrochloridee
posaconazole' 32,508 100 63,672 100
dasatinib 59,820 100 143,880 10-100
rasagiline 69,060 100 170,520 10-100
mesylate__________
sunitinib malatec 80,668 10-100 175,672 10-100
telbivudine 164,580 10-100 381,330 5-10
ranolazine 553,215 5-10 1,784,115 2.25-5
ciclesonided 821,835 3-10 ** **
darunavir 966,000 2.75-10 3,346,500 2-3
lubiprostone 2,066,100 2.25-5 5,995,890 1.75-2.5
sitagliptin
phosphate 7,960,500 1.75-2.25 20,810,620 1.33-1.75
paliperidone 9,789,630 1.5-2.25 23,213,280 1.33-1.75
varenicline 17,177,985 1.5-1.75 30,531,405 1.33-1.75
13.3 Rare Event Rates
Generic Name Total Exposed Range of Total Exposed Range ofGneric Days detectable IRRs Days detectable IRRs
(n=40) after 8 quarters after 8 quarters after 15 quarters after 15 quarters
New Molecular Entities Approved in 2004
tinidazolea 36,110 1000 101,133 100-1000
rifaximinb 206,795 100 485,250 100
erlotinib 434,685 100 762,915 10-100
insulin glulisine 446,310 100 1,179,420 10-100
injection
lanthanum 1,024,095 10-100 1,634,145 10-100
trospium 993,940 10-100 1,758,405 10-100
acamprosate 1,727,108 10-100 3,529,605 5-10
cinacalcet 3,052,635 5-10 5,006,580 5-10
omega-3 acid 2,223,360 10-100 7,896,930 3-10
ethyl esters
darifenacin 4,007,340 5-10 8,366,490 3-10
solifenacin 3,566,535 5-10 8,982,105 3-10
eszopiclone 19,705,410 2.25-5 33,866,880 2-3
tiotropium 33,532,470 2-3 58,154,685 1.75-2.5
pregabalin 39,717,375 2-2.75 79,711,665 1.75-2.25
duloxetine 45,217,020 1.75-2.75 92,261,400 1.5-2.25
New Molecular Entities Approved in 2005
lenalidomidec 73,164 100-1000 233,996 100
sorafenib toylate 78,345 100-1000 237,585 100
tipranavir 300,900 100 437,745 100
nepafenacb 393,570 100 762,075 10-100
pramlintide 371,190 100 903,300 10-100
acetate
entecavir 272,370 100 1,129,140 10-100
deferasirox 725,865 100 1,592,055 10-100
exenatide 3,341,895 5-10 8,517,255 3-10
ramelteon 4,816,590 5-10 10,779,270 2.75-5
insulin detemir 2,437,695 10-100 12,483,555 2.5-5
Table 24. Detectable Incidence Rate Ratios for Rare Events using the Poisson MaxSPRT Model
Estimates based on power=.80, alpha=.05. One prescription is assumed to be a 30-day supply unless
otherwise specified. Range is based on sensitivity analyses of doubling and halving the days exposed.
"indicates one prescription was equivalent to a 5-day supply.
bindicates one prescription was equivalent to a 15-day supply.
cindicates one prescription was equivalent to a 28-day supply.
dindicates that 10 quarters of data were available.
"indicates one prescription was equivalent to a 14-day supply.
findicates one prescription was equivalent to a 10-day supply.
Abbreviations: IRR, incidence rate ratio; MaxSPRT, Maximized Sequential Probability Ratio Test.
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Total Exposed Range of Total Exposed Range ofGeneric Name Days detectable IRRs Days detectable IRRs(n=40) after 8 quarters after 8 quarters after 15 quarters after 15 quarters
New Molecular Entities Approved in 2006
vorinostat 6,180 >=1000 11,910 >=1000
kunecatechinsd 6,630 >=1000 ** **
biskalcitrate 1000 100-1000
potassium,
metronidazole 30,100 59,480
and tetracycline
hydrochloridee
posaconazolef 32,508 1000 63,672 100-1000
dasatinib 59,820 100-1000 143,880 100-1000
rasagiline 69,060 100-1000 170,520 100
mesylate__________
sunitinib 80,668 100-1000 175,672 100
malatec
telbivudine 164,580 100 381,330 100
ranolazine 553,215 100 1,784,115 10-100
ciclesonided 821,835 10-100 ** **
darunavir 966,000 10-100 3,346,500 5-10
lubiprostone 2,066,100 10-100 5,995,890 5-10
sitagliptin7,960,500 3-10 20,810,620 2.25-5
phosphate 7,6,0 
-102,1,2
paliperidone 9,789,630 2.75-10 23,213,280 2.25-5
varenicline 17,177,985 2.25-5 30,531,405 2-3
Table 24 (Continued). Detectable Incidence
Model
Rate Ratios for Rare Events using the Poisson MaxSPRT
Estimates based on power-.80, alpha=.05. One prescription is assumed to be a 30-day supply unless
otherwise specified. Range is based on sensitivity analyses of doubling and halving the days exposed.aindicates one prescription was equivalent to a 5-day supply.
bindicates one prescription was equivalent to a 15-day supply.
eindicates one prescription was equivalent to a 28-day supply.dindicates that 10 quarters of data were available.
eindicates one prescription was equivalent to a 14-day supply.
indicates one prescription was equivalent to a 10-day supply.
Abbreviations: IRR, incidence rate ratio; MaxSPRT, Maximized Sequential Probability Ratio Test.
222
13.4 Very Rare Event Rates
Generic Name Total Exposed Range of Total Exposed Range of
(n=40) Days detectable IRRs Days detectable IRRs
after 8 quarters after 8 quarters after 15 quarters after 15 quarters
New Molecular Entities Approved in 2004
tinidazolea 36,110 >1000 101,133 >=1000
rifaximinb 206,795 1000 485,250 100-1000
erlotinib 434,685 100-1000 762,915 100-1000
insulin
glulisine 446,310 100-1000 1,179,420 100-1000
injection
lanthanum 1,024,095 100-1000 1,634,145 100
trospium 993,940 100-1000 1,758,405 100
acamprosate 1,727,108 100 3,529,605 100
cinacalcet 3,052,635 100 5,006,580 100
omega-3 acid 2,223,360 100 7,896,930 10-100
ethyl esters
darifenacin 4,007,340 100 8,366,490 10-100
solifenacin 3,566,535 100 8,982,105 10-100
eszopiclone 19,705,410 10-100 33,866,880 5-10
tiotropium 33,532,470 5-10 58,154,685 5-10
pregabalin 39,717,375 5-10 79,711,665 3-10
duloxetine 45,217,020 5-10 92,261,400 3-10
New Molecular Entities Approved in 2005
lenalidomide' 73,164 >=1000 233,996 1000
sorafenib 78,345 >=1000 237,585 1000
toylate
tipranavir 300,900 1000 437,745 100-1000
b
nepafenac 393,570 100-1000 762,075 100-1000
pramlintide 371,190 100-1000 903,300 100-1000
acetate
entecavir 272,370 1000 1,129,140 100-1000
deferasirox 725,865 100-1000 1,592,055 100
exenatide 3,341,895 100 8,517,255 10-100
ramelteon 4,816,590 100 10,779,270 10-100
insulin detemir 2,437,695 100 12,483,555 10-100
Table 25. Detectable Incidence Rate Ratios for Very Rare Events using the Poisson MaxSPRT Model
Estimates based on power-.80, alpha=.05. One prescription is assumed to be a 30-day supply unless
otherwise specified. Range is based on sensitivity analyses of doubling and halving the days exposed.
aindicates one prescription was equivalent to a 5-day supply.
bindicates one prescription was equivalent to a 15-day supply.
cindicates one prescription was equivalent to a 28-day supply.
dindicates that 10 quarters of data were available.
eindicates one prescription was equivalent to a 14-day supply.
indicates one prescription was equivalent to a 10-day supply.
Abbreviations: IRR, incidence rate ratio; MaxSPRT, Maximized Sequential Probability Ratio Test.
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New Molecular Entities Approved in 2006
vorinostat 6,180 >1000 11,910 >=1000
kunecatechinsd 6,630 >1000 ** **
biskalcitrate >1000 >=1000
potassium,
metronidazole 30,100 59,480
and tetracycline
hydrochloride*
posaconazolef 32,508 >1000 63,672 >=1000
dasatinib 59,820 >=1000 143,880 >=1000
rasagiline 69,060 >=1000 170,520 1000
mesylate
sunitinib malatec 80,668 >=1000 175,672 1000
telbivudine 164,580 1000 381,330 100-1000
ranolazine 553,215 100-1000 1,784,115 100
ciclesonided 821,835 100-1000 ** **
darunavir 966,000 100-1000 3,346,500 100
lubiprostone 2,066,100 100 5,995,890 100
sitagliptin 7,960,500 10-100 20,810,620 10-100
phosphate
paliperidone 9,789,630 10-100 23,213,280 10-100
varenicline 17,177,985 10-100 30,531,405 5-10
Table 25 (Continued). Detectable Incidence Rate Ratios for Very Rare Events using the Poisson
MaxSPRT Model
Estimates based on power--.80, alpha=.05. One prescription is assumed to be a 30-day supply unless
otherwise specified. Range is based on sensitivity analyses of doubling and halving the days exposed.
aindicates one prescription was equivalent to a 5-day supply.
bindicates one prescription was equivalent to a 15-day supply.
cindicates one prescription was equivalent to a 28-day supply.
dindicates that 10 quarters of data were available.
eindicates one prescription was equivalent to a 14-day supply.
findicates one prescription was equivalent to a 10-day supply.
Abbreviations: IRR, incidence rate ratio; MaxSPRT, Maximized Sequential Probability Ratio Test.
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14 APPENDIX C - New Molecular Entity Cohort Model Fits
This appendix contains individual figures with respect to the subset of new molecular
entities that were examined for uptake patterns in the Mini-Sentinel System. A select
group of the model functional forms are displayed. The pattern and the model fits are
observable, but the cumulative adoptions are deliberately removed because they are not
authorized to be shared publicly. Also, I have a included a brief summary of each drug's
indications, approval dates, and other pieces of information that may have impacted
adoption. These summaries are based on data contained in the Drugs@FDA database and
are not meant to be an exhaustive discussion of the therapeutic in question. Launch dates
were verified with press releases from manufacturers.
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14.1 Amitiza@ (lubiprostone)
Amitiza@ (lubiprostone) was approved January 31, 2006 and became commercially
available in the United States in April 2006. It was a first-in-class chloride channel
activator approved for chronic idiopathic constipation. A competitor, Zelnorm@
(tegaserod) was voluntarily withdrawn from the market on March 30, 2007 due to
cardiovascular risks, and a large increase in utilization of Amitiza@ is observable at that
time. Zelnorm@ was returned to limited use as a treatment investigational new drug, but
was then withdrawn completely on April 2, 2008. Additionally, in April 2008, Amitiza@
received a supplemental approval for the treatment of irritable bowel syndrome with
constipation in women over 18 years old.
Visually, the dual market models are superior to the single market model. In this case,
the existence of two markets may be well-explained by the indication expansion although
there was presumably some level of off-label use for this indication prior to the new
indication approval date. Both the indications that Amitiza@ is approved for are diseases
that exist on a spectrum in severity, which is one theoretical construct hypothesized to
explain the dual market phenomena. All parameters of the single market Bass model were
significant at the 0.05 level.
Cumulative Adoptions AMITIZA/lubiprostone New Adoptions
Data
--- Bass
DB-D
--- PDB-S
--- PDB-D
--- PEB-S
-+- Data
- -- Bass - - - -
- -DB-D
--- PEB-S
0 20 4 60 80 100 0 20 40 60 80 100
Time from Launch in Months Time from Launch In Months
Figure 30. Amitiza@ (lubiprostone) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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14.2 Byetta@ (exenatide)
Byetta@ (exenatide) was approved April 28, 2005 and became commercially available
in the United States in June 2005. It was approved as a first-in-class glucagon-like
peptide-1 agonist to be used an adjunct therapy for type 2 diabetics in conjunction with
other diabetes medications (i.e., metformin and sulfonylurea). On October 16, 2006, a
competitor product - Januvia@ (sitagliptin) - was approved as a monotherapy for type 2
diabetics and as an adjunct therapy. Januvia@ was also a first-in-class therapeutic in a
competing class (i.e., a dipeptidyl peptidase-4 inhibitor). Warnings regarding an
increased risk of acute pancreatitis were added to Byetta@'s label in October 2007. In
November of 2009, Byetta@ was approved as a first-line monotherapy. On January 26,
2010, the second therapeutic glucagon-like peptide-1 agonist was approved, Victoza@
(liraglutide), although as an add-on therapy and with a black box warning for pancreatitis
and thyroid cancer.
Visually, there are not notable differences between the single market model and most
of the dual market models. The only dual market model that fits the first large spike in
adoption is the non-pooled dual Bass model with a dynamic probability. All parameters
of the single market Bass model were significant at the 0.05 level.
Cumulative Adoptions BYETTA/exenatide New Adoptions
-- Data
--- Bass
DB-D
-'- --- PDB-S
--- PDB-D
--- PEB-S
- -Data
--- Bass
-- DB-D - - ---
--- PDB-S
--- PDB-D
--- PEB-S
0 0 40 60 80 100 0 20 4 0 6 0 8 0 100
Time from Launch in Months Time from Launch In Months
Figure 31. Byetta@ (exenatide) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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14.3 Campral@ (acamprosate)
Campral@ (acamprosate) was approved July 29, 2004 and became commercially
available in the United States in 2005. It was approved as a first-in-class gamma-
aminobutyric acid- type A receptors for the supportive treatment for alcoholism recovery.
A competitor in another pharmacologic class, Vivitrol@ (naltrexone injection), was
approved in April 2006.
Visually, all the models are fairly similar although the pooled dual Bass model with a
dynamic probability is predicting a rather large secondary market for this therapeutic. In
general, there seems to be less evidence of a distinction or clear superiority of a dual
market model over a single market model. All parameters of the single market Bass
model were significant at the 0.05 level.
Cumulative Adoptions
0 20 40 60 80
Time from Launch In Months
CAMPRAL/acamprosate
100
New Adoptions
0 20 40 60 80
Time from Launch In Months
Figure 32. Campral@ (acamprosate) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
228
14.4 Chantix@ (varenicline)
Chantix@ (varenicline) was approved May 10, 2006 and became commercially
available in the United States in August 2, 2006. It was approved as a treatment for
smoking cessation and was a first-in-class therapeutic. In November 2007, the FDA
began reviewing a potential risk of suicidal thoughts and aggressive or erratic behavior
associated with Chantix@.
Visually, the dual market Bass models are better fits than the single market Bass
model. The dynamic non-pooled dual Bass model reduces to the single market Bass
model. All parameters of the single market Bass model were significant at the 0.05 level.
Cumulative Adoptions CHA
0 20 40 60
Time from Launch In Months
NTIX/varenicline
30 0
New Adoptions
- Data
- -- Bass/1-O B-D
- - PDB-S
PDB-D
--- PEB-S
Figure 33. Chantix@ (varenicline) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit.
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-- Data
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- DB-D
- PDB-S
--- PDB-D
--- PEB-
14.5 Cymbalta@ (duloxetine)
Cymbalta@ (duloxetine) was approved August 3, 2004 and became commercially
available in the United States immediately post-approval. It is a selective serotonin and
norepinephrine reuptake inhibitor approved as a treatment for depression among adults. It
was not a first-in-class therapeutic. On November 8, 2004, it received a subsequent
approval for use in the management of diabetic peripheral neuropathic pain. In February
2007, it received another approval for generalized anxiety disorder. In December 2007, it
received another approved as a maintenance therapy for major depressive disorder in
adult patients. On March 3, 2008, a competitor drug in the same pharmacologic class,
Pristiq@ (desvenlafaxine), was approved. On June 13, 2008, Cymbalta@ received another
supplemental approval for the treatment of fibromyalgia. This approval happened to
coincide with the generic entry of the first-in-class drug for this class. On November 4,
2010, Cymbalta@ received another supplemental indication approval for the treatment of
chronic musculoskeletal pain.
Visually, only the pooled dual Bass market model with a static probability correctly
identifies the early market. The dynamic dual Bass market model reduces to the single
Bass market model. All parameters of the single market Bass model and the static pooled
exponential-Bass model were significant at the 0.05 level.
Cumulative Adoptions CYMBALTA/duloxetine New Adoptions
-+-Data
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Figure 34. Cymbalta@ (duloxetine) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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14.6 Enablex@ (darifenacin)
Enablex@ (darifenacin) was approved December 22, 2004 and became commercially
available in the United States after February 9, 2005. It was an
antispasmodic/anticholinergic approved as a treatment for overactive bladder and was the
sixth-in-class. Two other drugs in this class - Sanctura@ (trospium) and Vesicare@
(solifenacin) - were also approved in the same year and are a part of this cohort.
Visually, the dual Bass models perform similarly. The dual market models are a
better fit than the single market Bass model. All parameters of the single market Bass
model and the static pooled dual Bass market model were significant at the 0.05 level.
Cumulative Adoptions ENABLEX/darifenacin
20 40 60 80
Time from Launch In Months
100 0 20 40 60 8Time from Launch in Months
Figure 35. Enablex@ (darifenacin) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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New Adoptions
14.7 Invega@ (paliperidone)
Invega@ (paliperidone) was approved December 19, 2006 and became commercially
available in the United States after January 7, 2007. It was approved for acute treatment
of schizophrenia and was not a first-in-class therapeutic. As of April 30, 2007, it was
approved for the maintenance (long-term) treatment of schizophrenia. On August 3,
2009, Invega@ was approved for schizoaffective disorder treatment as either a
monotherapy or adjunctive therapy. At the same time,, an extended-release (i.e., once
monthly) injectable suspension version of the drug was approved. For the purposes of
incident users, I considered the injectable version to be a different drug.
Visually, the dual Bass market models are similar and clearly better than the single
Bass market model. All parameters of the single market Bass model were significant at
the 0.05 level.
Cumulative Adoptions INVEGA/paliperidone New Adoptions
-e-Data
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--- PDB-S
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Figure 36. Invega@ (paliperidone) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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14.8 Januvia@ (sitagliptin phosphate)
Januvia@ (sitagliptin phosphate) was approved October 16, 2006 and became
commercially available in the United States immediately postapproval. It was the first-in-
class dipeptidyl peptidase-4 inhibitor approved as a monotherapy or adjunct therapy for
type 2 diabetics. On October 18, 2007, Januvia received additional approvals as an
adjunct therapy. In August 2009, a competitor in the same class, Onglyza@ (saxagliptin)
was approved. Shortly thereafter, Januvia@'s label was amended to include reports of
acute pancreatitis.
Visually, all the dual market models outperform the single market model. All
parameters of the single market Bass model were significant at the 0.05 level.
Cumulative Adoptions JANUVIA/sitagliptin
0 20 40 60
Time from Launch In Months
80 20 40 60
Time from Launch in Months
Figure 37. Januvia@ (sitagliptin) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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New Adoptions
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14.9 Levemir@ (insulin detemir)
Levemir@ (insulin detemir) was approved June 16, 2005 and became commercially
available in the United States in March 2006. It was approved for the treatment of adult
patients with Type 1 or Type 2 diabetes mellitus who require basal (long-acting) insulin
for the control of hyperglycemia. It was not a first-in-class therapeutic.
Visually, the dual market models outperform the single market models with the
dynamic non-pooled dual Bass market model getting the slight edge. All parameters of
the single market Bass model and the static pooled dual Bass market model were
significant at the 0.05 level.
Cumulative Adoptions
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Time from Launch In Months
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Figure 38. Levemir@ (insulin detemir) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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14.10 Lunesta@ (eszopiclone)
Lunesta@ (eszopiclone) was approved December 16, 2004 and became commercially
available in the United States after April 3, 2005. It was a non-benzodiazepine hypnotic
agent approved for the treatment of insomnia and is a scheduled drug. A non-scheduled
competitor drug, Rozerem@ (ramelteon), was approved later that year.
Visually, this is one of the instances when the dual market models all outperform the
single market model, but also one when the exponential-Bass dual market model does
well. All parameters in the dynamic non-pooled dual Bass model and in the static pooled
exponential-Bass were significant.
Cumulative Adoptions LUNESTA/eszopiclone
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Figure 39. Lunesta@ (eszopiclone) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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New Adoptions
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14.11 Lyrica@ (pregabalin)
Lyrica@ (pregabalin) was approved December 31, 2004 and became commercially
available in the United States after September 22, 2005. It was approved for the
management of neuropathic pain associated with diabetic peripheral neuropathy and post-
herpetic neuralgia. It is not a first-in-class therapeutic. On June 14, 2005, it received an
additional approval as an adjunct treatment for partial seizures. It was also designated as
a controlled substance. As of June 22, 2007, Lyrica@ was additionally approved for the
management of fibromyalgia.
Visually, only the dynamic non-pooled dual Bass market model identifies the early
market closely whereas the static pooled dual Bass market model performs better on the
latter market peak. All parameters of the single market Bass model and the pooled static
exponential-Bass dual market model are significant at the 0.05 level.
Cumulative Adoptions LYRICA/pregaballn New Adoptions
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Figure 40. Lyrica® (pregabalin) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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14.12 Nevanac@ (nepafanac)
Nevanac@ (nepafanac) was approved August 19, 2005 and became commercially
available in the United States in September 2005. It was approved for the treatment of
pain and inflammation associated with cataract surgery and is the first-in-class
ophthalmic non-steroidal anti-inflammatory drug.
All the models I fit had trouble with this therapeutic because the market appears to be
continually strongly growing whereas all these models are expecting saturation effects to
begin to takeover. This therapeutic is perhaps better modeled with a dynamic adopter
population that accounts for age dynamics and the trends in cataract surgery.
All parameters of the single market Bass model are significant at the 0.05 level.
Cumulative Adoptions NEVANAC/nepafenac New Adoptions
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Figure 41. Nevanac@ (nepafanac) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit.
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14.13 Omacor@/Lovaza@ (omega-3 acid ethyl ester)
Omacor@ (omega-3 acid ethyl ester) was approved November 10, 2004 and became
commercially available in the United States after October 5, 2005. It was approved as an
adjunct to diet to reduce very high triglyceride levels (greater than or equal to 500
mg/dL) in adult patients. As of October 22, 2007, at the FDA's request, the therapeutic's
name was changed from Omacor@ to Lovaza@ as a result of reports of prescribing errors
between Omacor@ and Amicar@.
Visually, it is difficult to distinguish whether a true dual market exists or a single
market Bass model adequately explains the adoption pattern. All parameters of the single
market Bass model are significant at the 0.05 level.
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Figure 42. Omacor@ /Lovaza@ (omega-3 acid ethyl ester) Adoption Patterns and Nonlinear
Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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14.14 Ranexa@ (ranolazine)
Ranexa@ (ranolazine) was approved January 27, 2006 and became commercially
available in the United States after March 24, 2006. It was approved for the reduction of
chest pain (i.e., angina) in patients who have failed to respond adequately to older anti-
angina drugs and was a first-in-class therapeutic. As of November 5, 2008, an extended
release version of Ranexa@ was approved and it also received a new indication as a first-
line treatment for chronic angina.
Visually, it appears a dual market model is superior to a single market model that may
line up well with the additional indication Ranexa@ received. Additionally, chronic
angina is a disease with a spectrum in severity, which is one theoretical construct
hypothesized to explain the dual market phenomena. All parameters of the single market
Bass model and pooled static dual Bass market model were significant at the 0.05 level.
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Figure 43. Ranexa@ (ranolazine) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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14.15 Rozerem@ (ramelteon)
Rozerem@ (ramelteon) was approved July 22, 2005 and became commercially
available in the United States in September 2005. It was approved as a non-scheduled
treatment for insomnia and was a first-in-class therapeutic. The market leader for
insomnia treatments became available generically around the same time Rozerem@ was
approved.
Visually, there does not seem to be clear evidence of a dual market, and there are not
supplemental indications for this product. All parameters of the single market Bass model
and pooled static exponential-Bass dual market model were significant at the 0.05 level.
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Figure 44. Rozerem@ (ramelteon) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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14.16 Sanctura@ (trospium)
Sanctura@ (trospium) was approved May 28, 2004 and became commercially available
in the United States after August 23, 2004. Sanctura@ was approved for the treatment of
overactive bladder and was the fourth-in-class. Two competitor drugs in class were
approved later in 2004: Vesicare@ (solifenacin) and Enablex@ (darifenacin). As of
August 7, 2007, an extended release version of Sanctura@ was approved.
Despite a singular indication, there are clearly multiple markets. All parameters of the
pooled static dual market model, the pooled dynamic dual market model, and the non-
pooled dynamic dual market model were significant at the 0.05 level.
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Figure 45. Sanctura@ (trospium) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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14.17 Sensipar@ (cinacalcet)
Sensipar@ (cinacalcet) was approved March 8, 2004 and became commercially
available in the United States in April 2004. It was approved as a first-in-class oral
calcimimetic, and was indicated for the treatment of secondary hyperparathyroidism in
chronic kidney disease patients on dialysis, and the treatment of elevated calcium levels
in patients with parathyroid carcinoma. It was approved with an orphan drug designation.
Sensipar@ appears to have at least two markets which were best identified by the
pooled static dual Bass market model and the non-pooled dynamic dual Bass market
model. All parameters of the single market Bass model were significant at the 0.05 level.
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Figure 46. Sensipar@ (cinacalcet) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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New Adoptions
14.18 Spiriva@ (tiotropium oral inhalation)
Spiriva@ (tiotropium oral inhalation) was approved June 30, 2004 and became
commercially available in the United States after May 25, 2004. It was approved for the
treatment of chronic obstructive pulmonary disease. In October 2006, a competitor was
approved for the maintenance therapy of chronic obstructive pulmonary disease,
Brovana@ (arformoterol inhalation). Another competitor was approved in March 2009.
Despite a single indication, there are clearly two markets for this product. All
parameters of the pooled dynamic dual Bass market model, the pooled static exponential-
Bass model, and the single market Bass model were significant at the 0.05 level.
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Figure 47. Spiriva@ (tiotropium oral inhalation) Adoption Patterns and Nonlinear Regression Model
Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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14.19 Tarceva@ (erlotinib)
Tarceva@ (erlotinib) was approved November 18, 2004 and became commercially
available in the United States later that month. It was approved for the treatment of non-
small cell lung cancer for patients that have already failed one treatment. In May 2005, a
competitor drug, Iressa@ (gefitinib) was voluntarily withdrawn from the market. On
November 3, 2005, Tarceva@ received an a supplemental indication for first-line
treatment of pancreatic cancer.
Visually, only the non-pooled dynamic dual Bass model seemed to identify a small
second market. It is unclear why a dual market model would be superior to the single
market model in this case. All parameters of the single market Bass model were
significant at the 0.05 level.
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Figure 48. Tarceva@ (erlotinib) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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New Adoptions
14.20 Tindamax@ (tinidazole)
Tindamax@ (tinidazole) was approved May 17, 2004 and became commercially
available in the United States in July 2004. It was approved for the treatment of
trichomoniasis, a sexually-transmitted disease. On May 27, 2007, Tindamax@ received a
supplemental approval for the treatment of bacterial vaginosis.
In terms of model fit, all the models are very similar. There is not strong evidence to
suggest the superiority of a dual market model over a single market model despite the
two indications. All parameters of the single market Bass model were significant at the
0.05 level.
Cumulative Adoptions
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Figure 49. Tindamax® (tinidazole) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit.
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New Adoptions
14.21 Vesicare@ (solifenacin)
Vesicare@ (solifenacin) was approved November 19, 2004 and became commercially
available in the United States after January 21, 2005. It was approved for the treatment of
overactive bladder and was the fifth-in-class. It was preceded by the approval of the
fourth-in-class, Sanctura@ (trospium), and followed shortly by approval of the sixth-in-
class, Enablex@ (darifenacin).
With regard to model fits, both the single market model and the dual market models
are similar. Compared to the patterns of the two other overactive bladder drugs that both
suggest a dual market phenomena, this therapeutic is unusual. Notably, it also emerged as
the market leader among the three. All parameters of the single market Bass model and
the pooled static dual Bass market model were significant at the 0.05 level.
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Figure 50. Vesicare@ (solifenacin) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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14.22 Xifaxan@ (rifaximin)
Xifaxan@ (rifaximin) was approved May 25, 2004 and became commercially
available in the United States in July 2005. It was approved as a treatment for traveller's
diarrhea for patients 12 and older. On March 3, 2010, the FDA approved a supplemental
indication for Xifaxan@ for the reduction in risk of overt hepatic encephalopathy
recurrence in patients aged 18 years or older. The dosage for the two indications is quite
different.
The presence of two markets is pronounced and explainable due to the indication
expansion. All the dual Bass models tend to perform similarly. The pooled exponential-
Bass model with a static probability reduced to the single market Bass model. All
parameters of the single market Bass model, the pooled dynamic dual market Bass
model, the static pooled dual market Bass model, and the dynamic non-pooled dual
market Bass model were significant at the 0.05 level.
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Figure 51. Xifaxan@ (rifaximin) Adoption Patterns and Nonlinear Regression Model Fits
Abbreviations: Bass, Single Bass Model Fit; DB-D, Non-pooled Dual Bass-Dynamic Probability Fit; PDB-
S, Pooled Dual Bass-Static Probability Fit; PDB-D, Pooled Dual Bass-Dynamic Probability Fit; PEB-S;
Pooled Exponential-Bass-Static Probability Fit
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15 APPENDIX D - Glossary of Terms
This is a glossary of terms to aid the reader. All these terms are explained in the footnotes
when they are referenced in the text and are repeated here. Quotations indicate that the
definition is from another source, which is cited in the text. Italics indicate that the
definition is a legal one, derived from the 2007 Food and Drug Administration
Amendments Act.
Adjudication - Procedures that are performed to validate the data, i.e. to ensure that the
electronic record actually reflects patient experiences. It often involves medical chart
abstraction and confirmation of the exposures, outcomes, and covariates of interest.
Adverse drug experience - "Any adverse event associated with the use of a drug in
humans, whether or not considered drug related, including-(A) an adverse event
occurring in the course of the use of the drug in professional practice; (B) an adverse
event occurring from an overdose of the drug, whether accidental or intentional;(C)
an adverse event occurring from abuse of the drug; (D) an adverse event occurring
from withdrawal of the drug; and (E) any failure of expected pharmacological action
of the drug."
Association - "A statistically significant inference regarding a population."
Comparison window - In self-controlled designs, a time period when a person
contributes "unexposed" time to surveillance.
Effect size - The quantitative strength of an association, which is usually a point estimate
of the effect.
Epidemiologic design - The way the population of interest and the comparison
population are sampled for statistical inference.
Exposure - "In epidemiology, it is customary to refer to potential causal characteristics as
exposures. Thus, exposure can refer to a behavior (e.g., needle sharing), a treatment
or other intervention (e.g., an educational program about hazards of needle sharing), a
trait (e.g., a genotype), an exposure in the ordinary sense (e.g., an injection of
contaminated blood), or even a disease (e.g., diabetes as the cause of death)."
Exposure-outcome pair - A hypothesized relationship between the exposure and outcome
of interest, e.g., oral anti-diabetic medications and acute myocardial infarctions.
Induction period /latency period- The time period after a person has been exposed to a
medical product but before the person is "at risk" for experiencing the outcome of
interest.
Meta-analysis - "The statistical analysis of a collection of analytic results for the purpose
of integrating the findings."
Near real-time data - Data on clinical experiences that arrive with a variable delay from
when the experience occurred. There are two sources of delay. First, there is a
processing delay, which is the time that elapses between when the experience occurs,
and when it is recorded and available for analysis. Second, there is a refresh delay,
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which is associated with the frequency with which an originating data source renews
their dataset and makes it available for analysis.
New safety information - "Information derived from a clinical trial, an adverse event
report, a postapproval study (including a study under section 505(o)(3)), or peer-
reviewed biomedical literature; data derived from the postmarket risk identification
and analysis system under section 505(k); or other scientific data deemed appropriate
by the Secretary about- (A) a serious risk or an unexpected serious risk associated
with use of the drug that the Secretary has become aware of (that may be based on a
new analysis of existing information) since the drug was approved, since the risk
evaluation and mitigation strategy was required, or since the last assessment of the
approved risk evaluation and mitigation strategy for the drug; or (B) the effectiveness
of the approved risk evaluation and mitigation strategy for the drug obtained since the
last assessment of such strategy."
Outcomes - Health outcomes of interest.
Positive predictive value - The number of true positive cases/(true positive cases + false
positive cases).
Postmarket - The period after licensure of a product by the U.S. Food and Drug
Administration.
Postmarketing requirement - A mandate from the U.S. Food and Drug Administration to
the manufacturer/sponsor of a particular product to perform a study.
Precision - The inverse of the variance of the measurements or estimates that a statistical
process produces.
Processing delay time - Also known as the claims lag time, is the time that elapses
between when an exposure or outcome occurs, and when it is recorded and available
for analysis.
Rare event rate - Events that occur with a frequency greater than 1 event per 10,000
person-years , but less than 1 event per 1,000 person years.
Refresh delay time - The frequency with which a participating data partner renews their
dataset and makes it available for analysis.
Risk window - The time period when a person is "at risk" of experiencing an outcome of
interest following some exposure of interest.
Sensitivity - The number of true positive cases/(true positive cases + false negative
cases).
Serious adverse drug experience - "An adverse drug experience that (A) results in-(i)
death; (ii) an adverse drug experience that places the patient at immediate risk of
death[.. .];(iii) inpatient hospitalization or prolongation of existing hospitalization;
(iv) a persistent or significant incapacity or substantial disruption of the ability to
conduct normal life functions; or (v) a congenital anomaly or birth defect; or (B)
based on appropriate medical judgment, may jeopardize the patient and may require a
medical or surgical intervention to prevent an outcome described under subparagraph
(A)."
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Serious risk - "The risk of a serious adverse drug experience."
Signal - 1) "Information that arises from one or multiple sources (including observations
and experiments) which suggests a new potentially causal association, or a new
aspect of a known association, between an intervention and an event or set of related
events, either adverse or beneficial, that is judged to be of sufficient likelihood to
justify verificatory action." 2) "Reported information on a possible causal relationship
between an adverse event and a drug, the relationship being unknown or incompletely
documented previously. Usually more than a single report is required to generate a
signal, depending upon the seriousness of the event and the quality of the
information."
Signal evaluation - "Consists of the implementation of a full epidemiological analysis to
more thoroughly evaluate the causal relationship between exposure to the medical
product and the adverse outcome of interest."
Signal generation/detection - "An approach that uses statistical methods to identify
medical product-adverse outcome associations that may be safety signals; no
particular medical product exposure or adverse outcome is pre-specified."
Signal of a serious risk - "Information related to a serious adverse drug experience
associated with use of a drug."
Signal refinement - "A process by which an identified potential safety signal is further
investigated to determine whether evidence exists to support a relationship between
the medical product exposure and the outcome."
Specificity - The number of true negative cases/(false positive cases + true negative
cases).
Tracked safety issue - An operational term that formalizes the evaluation of a medical
product safety signal because it has the potential to lead to regulatory action.
Transportability - An alternative term for what is commonly referred to as external
validity or generalizability.
Type I error - The false positive rate or the incorrect rejection of the null hypothesis
when it should have failed to be rejected.
Type II error - The false negative rate or the failure to reject the null hypothesis when it
should have been rejected.
Unexpected Serious Risk - "A serious adverse drug experience that is not listed in the
labeling of a drug, or that may be symptomatically and pathophysiologically related
to an adverse drug experience identified in the labeling, but differs from such adverse
drug experience because of greater severity, specificity, or prevalence."
Very Rare event rate - Events that occur with a frequency greater than 1 event per
100,000 person-years, but less than 1 event per 10,000 person years.
Washout period - In self-controlled designs, a time period when a person contributes no
information to surveillance as they are considered neither exposed nor unexposed.
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